

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **ABALOPARATIDE**

---

**Products Affected**

- TYMLOS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 MONTHS
<b>Other Criteria</b>	OSTEOPOROSIS: HAS NOT RECEIVED A TOTAL OF 24 MONTHS CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **ABATACEPT IV**

---

**Products Affected**

- ORENCIA INTRAVENOUS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST.
<b>Coverage Duration</b>	RA, PJIA, PSA: INITIAL: 6 MOS, RENEWAL: 12 MOS. ACUTE GRAFT VERSUS HOST DISEASE (AGVHD): 1 MO.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## ABATACEPT SQ

**Products Affected**

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **ABEMACICLIB**

---

**Products Affected**

- VERZENIO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## ABIRATERONE

### Products Affected

- *abiraterone acetate*
- *abirtega*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC), METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **ABIRATERONE SUBMICRONIZED**

---

**Products Affected**

- YONSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **ACALABRUTINIB**

---

**Products Affected**

- CALQUENCE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **ADAGRASIB**

---

**Products Affected**

- KRAZATI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## ADALIMUMAB

### Products Affected

- HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML
- HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PED<40KG CROHNS STARTER
- HUMIRA-PED>=40KG CROHNS START
- HUMIRA-PED>=40KG UC STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PS/UV/ADOL HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PSORIASIS/UEVIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST
Coverage Duration	INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.

Y0135\_PA25\_C

Formulary ID: 25261

Last Updated: 11/26/2025

Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
Other Criteria	<p>INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED.</p> <p>POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. HS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR HS. UVEITIS: NO ISOLATED ANTERIOR UVEITIS. RENEWAL: RA, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND</p>

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## ADALIMUMAB-AATY

### Products Affected

- YUFLYMA (1 PEN)
- YUFLYMA (2 SYRINGE)
- YUFLYMA-CD/UC/HS STARTER

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST
Coverage Duration	INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4

Y0135\_PA25\_C

Formulary ID: 25261

Last Updated: 11/26/2025

Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	<p>INHIBITOR) FOR PJIA. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. HS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR HS. UVEITIS: NO ISOLATED ANTERIOR UVEITIS. RENEWAL: RA, HS, UVEITIS: CONTINUES TO BENEFIT FROM MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.</p>

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **ADALIMUMAB-ADB**

**Products Affected**

- CYLTEZO (2 PEN)
- CYLTEZO (2 SYRINGE)
- CYLTEZO-CD/UC/HS STARTER
- CYLTEZO-PSORIASIS/UV STARTER

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST
<b>Coverage Duration</b>	INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	<p>TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. HS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR HS. UVEITIS: NO ISOLATED ANTERIOR UVEITIS. RENEWAL: RA, HS, UVEITIS: CONTINUES TO BENEFIT FROM MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH</p>

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **AFATINIB**

---

**Products Affected**

- GILOTRIF

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **ALECTINIB**

---

**Products Affected**

- ALECENSA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **ALPELISIB-PIQRAY**

---

**Products Affected**

- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **AMIKACIN LIPOSOMAL INH**

---

**Products Affected**

- ARIKAYCE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE: RENEWAL: 1) NO POSITIVE MAC SPUTUM CULTURE AFTER CONSECUTIVE NEGATIVE CULTURES, AND 2) IMPROVEMENT IN SYMPTOMS. ADDITIONALLY, FOR FIRST RENEWAL, APPROVAL REQUIRES AT LEAST ONE NEGATIVE SPUTUM CULTURE FOR MAC BY SIX MONTHS OF ARIKAYCE TREATMENT. FOR SECOND AND SUBSEQUENT RENEWALS, APPROVAL REQUIRES AT LEAST THREE NEGATIVE SPUTUM CULTURES FOR MAC BY 12 MONTHS OF ARIKAYCE TREATMENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	MAC LUNG DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR INFECTIOUS DISEASE SPECIALIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 6 MONTHS.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **AMIVANTAMAB-VMJW**

---

**Products Affected**

- RYBREVANT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## ANAKINRA

### Products Affected

- KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS.
<b>Required Medical Information</b>	INITIAL: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE NLRP3 GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR, SERUM AMYLOID A PROTEIN (SAA) OR S100 PROTEINS), AND 2) TWO OF THE FOLLOWING: URTICARIAL-LIKE RASH (NEUTROPHILIC DERMATITIS), COLD-TRIGGERED EPISODES, SENSORINEURAL HEARING LOSS, MUSCULOSKELETAL SYMPTOMS, CHRONIC ASEPTIC MENINGITIS, SKELETAL ABNORMALITIES. DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE IL1RN GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR), AND 2) ONE OF THE FOLLOWING: PUSTULAR PSORIASIS-LIKE RASHES, OSTEOMYELITIS, ABSENCE OF BACTERIAL OSTEOMYELITIS, ONYCHOMADESIS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	RA: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. CAPS, DIRA: LIFETIME.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. CAPS, DIRA: NO CONCURRENT USE WITH OTHER IL-1

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	INHIBITORS. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## APALUTAMIDE

### Products Affected

- ERLEADA ORAL TABLET 240 MG, 60 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): HIGH RISK PROSTATE CANCER (I.E., RAPIDLY INCREASING PROSTATE SPECIFIC ANTIGEN [PSA] LEVELS). NMCRPC, METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. RENEWAL: NMCRPC, MCSPC: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GNRH ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **APOMORPHINE - ONAPGO**

---

**Products Affected**

- ONAPGO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PARKINSONS DISEASE (PD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PD: RENEWAL: IMPROVEMENT IN MOTOR SYMPTOMS WHILE ON THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **APOMORPHINE - SL**

**Products Affected**

- KYNMOBI
- KYNMOBI TITRATION KIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	PARKINSONS DISEASE (PD): INITIAL: 18 YEARS OF AGE OR OLDER.
<b>Prescriber Restrictions</b>	PD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	PD: RENEWAL: IMPROVEMENT WITH MOTOR FLUCTUATIONS DURING OFF EPISODES WITH THE USE OF THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## APREMILAST

### Products Affected

- OTEZLA
- OTEZLA XR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: MILD PLAQUE PSORIASIS (PSO): 1) PSORIASIS COVERING 2 PERCENT OF BODY SURFACE AREA (BSA), 2) STATIC PHYSICIAN GLOBAL ASSESSMENT (SPGA) SCORE OF 2, OR 3) PSORIASIS AREA AND SEVERITY INDEX (PASI) SCORE OF 2 TO 9. MODERATE TO SEVERE PSO: PSORIASIS COVERING 3 PERCENT OR MORE OF BSA, OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. BEHCETS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. MILD PSO: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL SYSTEMIC THERAPY (E.G., METHOTREXATE, ACITRETIN, CYCLOSPORINE) OR ONE CONVENTIONAL TOPICAL THERAPY (E.G., PUVA [PHOTOTHERAPY], UVB [ULTRAVIOLET LIGHT B], TOPICAL CORTICOSTEROIDS). MODERATE TO SEVERE PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	<p>ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR MODERATE TO SEVERE PSO. BEHCETS DISEASE: 1) HAS ORAL ULCERS OR A HISTORY OF RECURRENT ORAL ULCERS BASED ON CLINICAL SYMPTOMS, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OR MORE CONSERVATIVE TREATMENTS (E.G., COLCHICINE, TOPICAL CORTICOSTEROID, ORAL CORTICOSTEROID). RENEWAL: MILD PSO, BEHCETS DISEASE: CONTINUES TO BENEFIT FROM THE MEDICATION. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. MODERATE TO SEVERE PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR MODERATE TO SEVERE PSO.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## ARIMOCLOMOL

---

**Products Affected**

- MIPLYFFA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	NIEMANN-PICK DISEASE TYPE C (NPC): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH NEUROLOGIST OR GENETICIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	NPC: RENEWAL: IMPROVEMENT OR SLOWING OF DISEASE PROGRESSION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## ASCIMINIB

---

**Products Affected**

- SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PREVIOUSLY TREATED OR T315I MUTATION PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML); MUTATIONAL ANALYSIS PRIOR TO INITIATION AND SCEMBLIX IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## ASFOTASE ALFA

### Products Affected

- STRENSIQ

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HYPOPHOSPHATASIA (HPP): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST, GENETICIST, OR METABOLIC SPECIALIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PERINATAL/INFANTILE-ONSET HPP: 1) 6 MONTHS OF AGE OR YOUNGER AT ONSET OF HPP, AND 2) POSITIVE FOR A TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE (TNSALP) (ALPL) GENE MUTATION AS CONFIRMED BY GENETIC TESTING OR TWO OF THE FOLLOWING: (A) SERUM ALKALINE PHOSPHATASE (ALP) LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE, (B) ELEVATED SERUM PYRIDOXAL-5'-PHOSPHATE (PLP) LEVELS AND NO VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK, (C) URINE PHOSPHOETHANOLAMINE (PEA) LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE, (D) RADIOGRAPHIC EVIDENCE OF HPP, (E) AT LEAST TWO OF THE FOLLOWING: (I) RACHITIC CHEST DEFORMITY, (II) CRANIOSYNOSTOSIS, (III) DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, (IV) HISTORY OF VITAMIN B6 DEPENDENT SEIZURES, (V) NEPHROCALCINOSIS OR HISTORY OF ELEVATED SERUM CALCIUM, (VI) HISTORY OR PRESENCE

Y0135\_PA25\_C

Formulary ID: 25261

Last Updated: 11/26/2025

Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	<p>OF NON-TRAUMATIC POSTNATAL FRACTURE AND DELAYED FRACTURE HEALING. JUVENILE-ONSET HPP: 1) 18 YEARS OF AGE OR YOUNGER AT ONSET OF HPP, AND 2) POSITIVE FOR A TNSALP ALPL GENE MUTATION AS CONFIRMED BY GENETIC TESTING OR TWO OF THE FOLLOWING: (A) SERUM ALP LEVEL BELOW THAT OF NORMAL RANGE FOR PATIENT AGE, (B) ELEVATED SERUM PLP LEVELS AND NO VITAMIN B6 SUPPLEMENTATION IN THE PREVIOUS WEEK, (C) URINE PEA LEVEL ABOVE THAT OF NORMAL RANGE FOR PATIENT AGE, (D) RADIOGRAPHIC EVIDENCE OF HPP, (E) AT LEAST TWO OF THE FOLLOWING: (I) RACHITIC DEFORMITIES, (II) PREMATURE LOSS OF PRIMARY TEETH PRIOR TO 5 YEARS OF AGE, (III) DELAY IN SKELETAL GROWTH RESULTING IN DELAY OF MOTOR DEVELOPMENT, (IV) HISTORY OR PRESENCE OF NON-TRAUMATIC FRACTURES OR DELAYED FRACTURE HEALING. ALL INDICATIONS: 1) NOT CURRENTLY RECEIVING TREATMENT WITH A BISPHOSPHONATE, 2) CALCIUM OR PHOSPHATE LEVELS ARE NOT BELOW THE NORMAL RANGE, 3) NOT HAVE A TREATABLE FORM OF RICKETS. RENEWAL: ALL INDICATIONS: 1) IMPROVEMENT IN THE SKELETAL CHARACTERISTICS OF HPP, AND 2) NOT CURRENTLY RECEIVING TREATMENT WITH A BISPHOSPHONATE.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## ATOGEPANT

---

**Products Affected**

- QULIPTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## AVACOPAN

### Products Affected

- TAVNEOS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODY (ANCA)-ASSOCIATED VASCULITIS: INITIAL: ANCA SEROPOSITIVE (ANTI-PR3 OR ANTI-MPO).
Age Restrictions	
Prescriber Restrictions	ANCA-ASSOCIATED VASCULITIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST.
Coverage Duration	INITIAL/RENEWAL: 6 MONTHS.
Other Criteria	ANCA-ASSOCIATED VASCULITIS: RENEWAL: CONTINUES TO BENEFIT FROM THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **AVAPRITINIB**

---

**Products Affected**

- AYVAKIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **AVUTOMETINIB-DEFACTINIB**

---

**Products Affected**

- AVMAPKI FAKZYNJA CO-PACK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **AXATILIMAB-CSFR**

---

**Products Affected**

- NIKTIMVO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **AXITINIB**

---

**Products Affected**

- INLYTA ORAL TABLET 1 MG, 5 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## AZACITIDINE

---

**Products Affected**

- ONUREG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **AZTREONAM INHALED**

---

**Products Affected**

- CAYSTON

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	7 YEARS OF AGE OR OLDER
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **BEDAQUILINE**

---

**Products Affected**

- SIRTURO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 WEEKS
<b>Other Criteria</b>	PULMONARY TUBERCULOSIS (TB): USE IN COMBINATION WITH 3 OTHER ANTIBIOTICS
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **BELIMUMAB**

### **Products Affected**

- BENLYSTA SUBCUTANEOUS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. LUPUS NEPHRITIS (LN): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: SLE: CURRENTLY TAKING CORTICOSTEROIDS, ANTIMALARIALS, NSAIDS, OR IMMUNOSUPPRESSIVE AGENTS. RENEWAL: SLE: PATIENT HAD CLINICAL IMPROVEMENT. LN: IMPROVEMENT IN RENAL RESPONSE FROM BASELINE LABORATORY VALUES (I.E., EGFR OR PROTEINURIA) AND/OR CLINICAL PARAMETERS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **BELUMOSUDIL**

---

**Products Affected**

- REZUROCK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **BELZUTIFAN**

---

**Products Affected**

- WELIREG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **BENDAMUSTINE**

---

**Products Affected**

- BENDAMUSTINE HCL  
INTRA VENOUS SOLUTION
- *bendamustine hcl intravenous solution  
reconstituted*
- BENDEKA
- VIVIMUSTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **BENRALIZUMAB**

### **Products Affected**

- FASENRA
- FASENRA PEN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	ASTHMA: INITIAL: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	ASTHMA: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE, OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS, OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA, AND 3) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. EOSINOPHILIC

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	<p>GRANULOMATOSIS WITH POLYANGIITIS (EGPA): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-2 INHIBITOR) FOR EGPA. RENEWAL: ASTHMA: 1) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA, 2) CONTINUED USE OF ICS AND ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, OR (D) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS. EGPA: 1) REDUCTION IN EGPA SYMPTOMS COMPARED TO BASELINE OR ABILITY TO REDUCE/ELIMINATE CORTICOSTEROID USE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR EGPA</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## BETAINE

---

**Products Affected**

- *betaine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **BEVACIZUMAB-ADCD**

---

**Products Affected**

- VEGZELMA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **BEVACIZUMAB-AWWB**

---

**Products Affected**

- MVASI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **BEVACIZUMAB-BVZR**

---

**Products Affected**

- ZIRABEV

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **BEXAROTENE**

---

**Products Affected**

- *bexarotene*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **BINIMETINIB**

---

**Products Affected**

- MEKTOVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **BORTEZOMIB**

---

**Products Affected**

- *bortezomib injection*
- BORUZU

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## BOSENTAN

### Products Affected

- bosentan oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
Age Restrictions	
Prescriber Restrictions	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	PAH: INITIAL: 1) DOES NOT HAVE ELEVATED LIVER ENZYMES (ALT, AST) MORE THAN 3 TIMES UPPER LIMIT OF NORMAL (ULN) OR INCREASE IN BILIRUBIN BY 2 OR MORE TIMES ULN, AND 2) NO CONCURRENT USE WITH CYCLOSPORINE A OR GLYBURIDE. RENEWAL: NO CONCURRENT USE WITH CYCLOSPORINE A OR GLYBURIDE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **BOSUTINIB**

### **Products Affected**

- BOSULIF ORAL CAPSULE 100 MG, 50 MG
- BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND BOSULIF IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **BRIGATINIB**

---

**Products Affected**

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLET THERAPY PACK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **C1 ESTERASE INHIBITOR-HAEGARDA**

### **Products Affected**

- HAEGARDA SUBCUTANEOUS  
 SOLUTION RECONSTITUTED 2000  
 UNIT, 3000 UNIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	HEREDITARY ANGIOEDEMA (HAE): INITIAL: DIAGNOSIS CONFIRMED BY ONE OF THE FOLLOWING COMPLEMENT TESTING: C1INH PROTEIN LEVELS, C4 PROTEIN LEVELS, C1-INH FUNCTIONAL LEVELS, C1Q.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HAE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, IMMUNOLOGIST, ALLERGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	HAE: INITIAL: NOT ON CONCURRENT TREATMENT WITH ALTERNATIVE PROPHYLACTIC AGENT FOR HAE ATTACKS. RENEWAL: 1) IMPROVEMENT COMPARED TO BASELINE IN HAE ATTACKS (I.E., REDUCTIONS IN ATTACK FREQUENCY OR ATTACK SEVERITY), AND 2) NOT ON CONCURRENT TREATMENT WITH ALTERNATIVE PROPHYLACTIC AGENT FOR HAE ATTACKS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **CABOZANTINIB CAPSULE**

---

**Products Affected**

- COMETRIQ (100 MG DAILY DOSE)  
ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE)  
ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **CABOZANTINIB TABLET**

---

**Products Affected**

- CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## CANNABIDIOL

**Products Affected**

- EPIDIOLEX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	DRAVET SYNDROME (DS), LENNOX-GASTAUT SYNDROME (LGS), TUBEROUS SCLEROSIS COMPLEX (TSC): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: LENNOX-GASTAUT SYNDROME (LGS): TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING ANTIEPILEPTIC MEDICATIONS: RUFINAMIDE, FELBAMATE, CLOBAZAM, TOPIRAMATE, LAMOTRIGINE, CLONAZEPAM.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## CAPIVASERTIB

---

**Products Affected**

- TRUQAP ORAL TABLET
- TRUQAP TABLET THERAPY PACK  
160 MG ORAL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **CAPMATINIB**

---

**Products Affected**

- TABRECTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## CARGLUMIC ACID

### Products Affected

- carglumic acid oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: ACUTE OR CHRONIC HYPERAMMONEMIA (HA) DUE TO N ACETYLGUTAMATE SYNTHASE (NAGS) DEFICIENCY: NAGS GENE MUTATION IS CONFIRMED BY BIOCHEMICAL OR GENETIC TESTING. ACUTE HA DUE TO PROPIONIC ACIDEMIA (PA): 1) CONFIRMED BY ELEVATED METHYLCITRIC ACID AND NORMAL METHYLMALONIC ACID, OR 2) GENETIC TESTING CONFIRMS MUTATION IN THE PCCA OR PCCB GENE. ACUTE HA DUE TO METHYLMALONIC ACIDEMIA (MMA): 1) CONFIRMED BY ELEVATED METHYLMALONIC ACID, METHYLCITRIC ACID, OR 2) GENETIC TESTING CONFIRMS MUTATION IN THE MMUT, MMA, MMAB OR MMADHC GENES.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ACUTE HA DUE TO NAGS/PA/MMA: 7 DAYS. CHRONIC HA DUE TO NAGS: INITIAL: 6 MOS, RENEWAL: 12 MOS.
Other Criteria	RENEWAL: CHRONIC HA DUE TO NAGS: PATIENT HAS SHOWN CLINICAL IMPROVEMENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **CERITINIB**

---

**Products Affected**

- ZYKADIA ORAL TABLET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## CERTOLIZUMAB PEGOL

### Products Affected

- CIMZIA (2 SYRINGE)
- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PSA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA/CYLTEZO/YUFLYMA, STELARA/SELARSDI/YESINTEK,

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

PA Criteria	Criteria Details
	<p>XELJANZ, RINVOQ, SKYRIZI, TREMFYA, ORENCIA, OTEZLA. PSO: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA/CYLTEZO/YUFLYMA, STELARA/SELARSDI/YESINTEK, SKYRIZI, TREMFYA, OTEZLA. AS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ. CD: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: STELARA/SELARSDI/YESINTEK, HUMIRA/CYLTEZO/YUFLYMA, RINVOQ, SKYRIZI, TREMFYA. NR-AXSPA: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, ORENCIA, RINVOQ. INITIAL FOR RA, PSA, PSO, AS, CD, PJIA: TRIAL OF OR CONTRAINDICATION TO THE STEP AGENTS IS NOT REQUIRED IF THE PATIENT IS PREGNANT, BREASTFEEDING, OR TRYING TO BECOME PREGNANT. INITIAL/RENEWAL FOR PSA, PSO, AS, CD, NR-AXSPA, PJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR SAME INDICATION. RENEWAL FOR RA, PSA, AS, PSO, NR-AXSPA, PJIA: CONTINUES TO BENEFIT FROM MEDICATION.</p>
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **CETUXIMAB**

---

**Products Affected**

- ERBITUX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated:11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## CLADRIBINE

### Products Affected

- MAVENCLAD (10 TABS)
- MAVENCLAD (4 TABS)
- MAVENCLAD (5 TABS)
- MAVENCLAD (6 TABS)
- MAVENCLAD (7 TABS)
- MAVENCLAD (8 TABS)
- MAVENCLAD (9 TABS)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	48 WEEKS.
Other Criteria	RELAPSING FORM OF MULTIPLE SCLEROSIS (MS): HAS NOT RECEIVED A TOTAL OF TWO YEARS OF MAVENCLAD TREATMENT (I.E., TWO YEARLY TREATMENT COURSES OF TWO CYCLES IN EACH).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **CLOBAZAM-SYMPAZAN**

### **Products Affected**

- SYMPAZAN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: LENNOX-GASTAUT SYNDROME (LGS): THERAPY IS PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS
<b>Other Criteria</b>	LGS: INITIAL: CONTRAINDICATION TO OR UNABLE TO SWALLOW CLOBAZAM TABLETS OR SUSPENSION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **COBIMETINIB**

---

**Products Affected**

- COTELLIC

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## CORTICOTROPIN

### Products Affected

- ACTHAR
- ACTHAR GEL SUBCUTANEOUS PEN-INJECTOR 40 UNIT/0.5ML, 80 UNIT/ML
- CORTROPHIN

PA Criteria	Criteria Details
Exclusion Criteria	INITIAL: NOT APPROVED FOR DIAGNOSTIC PURPOSES.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS AND MULTIPLE SCLEROSIS (MS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, ALLERGIST/IMMUNOLOGIST, OPHTHALMOLOGIST, PULMONOLOGIST OR NEPHROLOGIST.
Coverage Duration	INFANTILE SPASMS AND MS: 28 DAYS. ALL OTHER FDA APPROVED INDICATIONS: INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS: TRIAL OF OR CONTRAINDICATION TO INTRAVENOUS (IV) CORTICOSTEROIDS. RENEWAL: ALL FDA APPROVED INDICATIONS EXCEPT INFANTILE SPASMS AND MS: DEMONSTRATED CLINICAL BENEFIT WHILE ON THERAPY AS INDICATED BY SYMPTOM RESOLUTION AND/OR NORMALIZATION OF LABORATORY TESTS. PART B BEFORE PART D STEP THERAPY, APPLIES ONLY TO BENEFICIARIES IN AN MA-PD PLAN.
Indications	All FDA-approved Indications.
Off Label Uses	

Y0135\_PA25\_C

Formulary ID: 25261

Last Updated: 11/26/2025

Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	Yes

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **CRIZOTINIB CAPSULE**

---

**Products Affected**

- XALKORI ORAL CAPSULE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **CRIZOTINIB PELLETS**

---

**Products Affected**

- XALKORI ORAL CAPSULE SPRINKLE  
150 MG, 20 MG, 50 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	NON-SMALL CELL LUNG CANCER (NSCLC), ANAPLASTIC LARGE CELL LYMPHOMA (ALCL), INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT): UNABLE TO SWALLOW CAPSULES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **DABRAFENIB CAPSULES**

---

**Products Affected**

- TAFINLAR ORAL CAPSULE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **DABRAFENIB SUSPENSION**

---

**Products Affected**

- TAFINLAR ORAL TABLET SOLUBLE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	UNABLE TO SWALLOW TAFINLAR CAPSULES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **DACOMITINIB**

### **Products Affected**

- VIZIMPRO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE-INHIBITOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **DALFAMPRIDINE**

### **Products Affected**

- *dalfampridine er*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	MULTIPLE SCLEROSIS (MS): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	MS: INITIAL: HAS SYMPTOMS OF A WALKING DISABILITY SUCH AS MILD TO MODERATE BILATERAL LOWER EXTREMITY WEAKNESS OR UNILATERAL WEAKNESS PLUS LOWER EXTREMITY OR TRUNCAL ATAXIA. RENEWAL: IMPROVEMENT IN WALKING ABILITY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## DAROLUTAMIDE

### Products Affected

- NUBEQA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	INITIAL: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): HIGH RISK PROSTATE CANCER (I.E., RAPIDLY INCREASING PROSTATE SPECIFIC ANTIGEN [PSA] LEVELS). NMCRPC, METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. RENEWAL: NMCRPC, MCSPC: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GNRH ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## DASATINIB

### Products Affected

- dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND DASATINIB IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **DATOPOTAMAB DERUXTECAN-DLNK**

---

**Products Affected**

- DATROWAY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## DECITABINE/CEDAZURIDINE

---

**Products Affected**

- INQOVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## DEFERASIROX

### Products Affected

- *deferasirox granules*
- *deferasirox oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 1000 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS). CHRONIC IRON OVERLOAD IN NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT): 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS), AND 2) LIVER IRON CONCENTRATION (LIC) OF 5 MG FE/G OF DRY LIVER WEIGHT OR GREATER. RENEWAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 500 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS). NTDT: 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS) OR 2) LIC OF 3 MG FE/G OF DRY LIVER WEIGHT OR GREATER.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL (CHRONIC IRON OVERLOAD): PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR HEMATOLOGIST/ONCOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL (CHRONIC IRON OVERLOAD): DEFERASIROX SPRINKLE PACKETS: TRIAL OF OR CONTRAINDICATION TO GENERIC DEFERASIROX ORAL TABLET OR TABLET FOR ORAL SUSPENSION.

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **DENOSUMAB-BMWO - OSENVELT**

---

**Products Affected**

- OSENVELT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **DENOSUMAB-XGEVA**

---

**Products Affected**

- XGEVA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## DEUTETRABENAZINE

### Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG
- AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG
- AUSTEDO XR PATIENT TITRATION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HUNTINGTON DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST. TARDIVE DYSKINESIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST.
Coverage Duration	12 MONTHS
Other Criteria	TARDIVE DYSKINESIA: HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **DICLOFENAC TOPICAL SOLUTION**

---

**Products Affected**

- *diclofenac sodium external solution 2 %*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 MONTHS
<b>Other Criteria</b>	OSTEOARTHRITIS OF THE KNEE: TRIAL OF OR CONTRAINDICATION TO A FORMULARY VERSION OF DICLOFENAC SODIUM 1% TOPICAL GEL AND A FORMULARY VERSION OF DICLOFENAC SODIUM 1.5% TOPICAL DROPS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **DICLOFENAC-FLECTOR**

---

**Products Affected**

- *diclofenac epolamine external*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **DIMETHYL FUMARATE**

**Products Affected**

- *dimethyl fumarate oral capsule delayed release 120 mg, 240 mg*
- *dimethyl fumarate starter pack oral capsule delayed release therapy pack*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **DIROXIMEL FUMARATE**

---

**Products Affected**

- VUMERITY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **DORDAVIPRONE**

---

**Products Affected**

- MODEYSO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **DOSTARLIMAB-GXLY**

---

**Products Affected**

- JEMPERLI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **DRONABINOL CAPSULE**

---

**Products Affected**

- *dronabinol*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	6 MONTHS
<b>Other Criteria</b>	NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY: TRIAL OF OR CONTRAINDICATION TO ONE ANTIEMETIC THERAPY. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D FOR THE INDICATION OF NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **DROXIDOPA**

### **Products Affected**

- *droxidopa*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	NEUROGENIC ORTHOSTATIC HYPOTENSION (NOH): INITIAL: 1) BASELINE BLOOD PRESSURE READINGS WHILE THE PATIENT IS SITTING AND ALSO WITHIN 3 MINUTES OF STANDING FROM A SUPINE POSITION. 2) A DECREASE OF AT LEAST 20 MMHG IN SYSTOLIC BLOOD PRESSURE OR 10 MMHG DIASTOLIC BLOOD PRESSURE WITHIN THREE MINUTES AFTER STANDING FROM A SITTING POSITION.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	NOH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR CARDIOLOGIST.
<b>Coverage Duration</b>	INITIAL: 3 MONTHS RENEWAL: 12 MONTHS
<b>Other Criteria</b>	NOH: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## DUPILUMAB

### Products Affected

- DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: EOSINOPHILIC ASTHMA: BLOOD EOSINOPHIL LEVEL OF 150 TO 1500 CELLS/MCL WITHIN THE PAST 12 MONTHS. EOSINOPHILIC ESOPHAGITIS (EOE): DIAGNOSIS CONFIRMED BY ESOPHAGOGASTRODUODENOSCOPY (EGD) WITH BIOPSY. ATOPIC DERMATITIS (AD): AD COVERING AT LEAST 10 PERCENT OF BODY SURFACE AREA OR AD AFFECTING THE FACE, HEAD, NECK, HANDS, FEET, GROIN, OR INTERTRIGINOUS AREAS.
Age Restrictions	
Prescriber Restrictions	INITIAL: AD, PRURIGO NODULARIS (PN): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE. CRSWNP: PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. EOE: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, ALLERGIST, OR IMMUNOLOGIST. EOSINOPHILIC COPD: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST.
Coverage Duration	BP: 12 MO. AD/CRSWNP/EOE/PN/CSU: INITIAL/RENEWAL: 6 MO/12 MO. ASTHMA/COPD: INITIAL/RENEWAL: 12 MO.
Other Criteria	INITIAL/RENEWAL: AD: NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGICS OR JAK INHIBITORS FOR AD. ASTHMA: NO CONCURRENT USE WITH XOLAIR, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. CRSWNP: NO

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	<p>CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION.</p> <p>EOSINOPHILIC COPD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. INITIAL: AD: 1) INTRACTABLE PRURITUS OR CRACKING/OOZING/BLEEDING OF AFFECTED SKIN, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE TOPICAL (CORTICOSTEROID, CALCINEURIN INHIBITOR, PDE4 INHIBITOR, OR JAK INHIBITOR). ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY-TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS, OR ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA. CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID. PRURIGO NODULARIS (PN): CHRONIC PRURITUS (ITCH MORE THAN 6 WEEKS), MULTIPLE PRURIGINOUS LESIONS, AND HISTORY OR SIGN OF A PROLONGED SCRATCHING BEHAVIOR. EOSINOPHILIC COPD: USED IN COMBINATION WITH A LAMA/LABA/ICS. CHRONIC SPONTANEOUS URTICARIA (CSU): 1) TRIAL OF AND MAINTAINED ON, OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE AND 2) STILL EXPERIENCES HIVES OR ANGIOEDEMA MOST DAYS OF THE WEEK FOR AT LEAST 6 WEEKS. RENEWAL: AD, CRSWNP, EOE: IMPROVEMENT WHILE ON THERAPY. ASTHMA: 1) CONTINUED USE OF ICS AND ONE OTHER MAINTENANCE MEDICATION, AND 2) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED</p>

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	UTILIZATION OF RESCUE MEDICATIONS, (C) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, OR (D) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS. PN: IMPROVEMENT OR REDUCTION OF PRURITUS OR PRURIGINOUS LESIONS. EOSINOPHILIC COPD: 1) USED IN COMBINATION WITH A LAMA/LABA/ICS, AND 2) CLINICAL RESPONSE AS EVIDENCED BY (A) REDUCTION IN COPD EXACERBATIONS FROM BASELINE, (B) REDUCTION IN SEVERITY OR FREQUENCY OF COPD-RELATED SYMPTOMS, OR (C) INCREASE IN FEV1 OF AT LEAST 5 PERCENT FROM PRETREATMENT BASELINE. CSU: MAINTAINED ON OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **DUVELISIB**

---

**Products Affected**

- COPIKTRA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **EFLORNITHINE**

---

**Products Affected**

- IWILFIN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## ELACESTRANT

---

**Products Affected**

- ORSERDU ORAL TABLET 345 MG, 86 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## ELAGOLIX

### Products Affected

- ORILISSA ORAL TABLET 150 MG, 200 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.
Age Restrictions	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: 18 YEARS OF AGE OR OLDER.
Prescriber Restrictions	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS
Other Criteria	MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS: INITIAL: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, AND 2) TRIAL OF OR CONTRAINDICATION TO AN NSAID AND A PROGESTIN-CONTAINING PREPARATION. RENEWAL: 1) IMPROVEMENT IN PAIN ASSOCIATED WITH ENDOMETRIOSIS WHILE ON THERAPY, AND 2) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT
Indications	All FDA-approved Indications.
Off Label Uses	

Y0135\_PA25\_C

Formulary ID: 25261

Last Updated: 11/26/2025

Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **ELRANATAMAB-BCMM**

### **Products Affected**

- ELREXFIO SUBCUTANEOUS  
SOLUTION 44 MG/1.1ML, 76  
MG/1.9ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	RELAPSED OR REFRACTORY MULTIPLE MYELOMA: RENEWAL: 1) HAS RECEIVED AT LEAST 24 WEEKS OF TREATMENT WITH ELREXFIO, AND 2) HAS RESPONDED TO TREATMENT (PARTIAL RESPONSE OR BETTER), AND HAS MAINTAINED THIS RESPONSE FOR AT LEAST 2 MONTHS. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **ELTROMBOPAG - ALVAIZ**

### **Products Affected**

- ALVAIZ

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): INITIAL: 1) PLATELET COUNT IS LESS THAN $30 \times 10^9/L$ , OR 2) PLATELET COUNT IS LESS THAN $50 \times 10^9/L$ AND HAD A PRIOR BLEEDING EVENT.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: ITP: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST.
<b>Coverage Duration</b>	ITP: INITIAL: 6 MO, RENEWAL: 12 MO. HEPATITIS C, SEVERE APLASTIC ANEMIA: 12 MO.
<b>Other Criteria</b>	INITIAL: ITP: 1) TRIAL OF OR CONTRAINDICATION TO ONE CORTICOSTEROID OR IMMUNOGLOBULIN, OR AN INSUFFICIENT RESPONSE TO SPLENECTOMY, AND 2) NO CONCURRENT USE WITH OTHER THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS). RENEWAL: ITP: 1) IMPROVEMENT IN PLATELET COUNT FROM BASELINE OR REDUCTION IN BLEEDING EVENTS, AND 2) NO CONCURRENT USE WITH OTHER TPO-RAS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## ELTROMBOPAG - PROMACTA

### Products Affected

- *eltrombopag olamine oral packet 12.5 mg, 25 mg*
- *eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): INITIAL: 1) PLATELET COUNT OF LESS THAN 30 X 10 <sup>9</sup> /L, OR 2) PLATELET COUNT OF LESS THAN 50 X 10 <sup>9</sup> /L AND A PRIOR BLEEDING EVENT.
Age Restrictions	
Prescriber Restrictions	INITIAL: ITP: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST.
Coverage Duration	ITP: INITIAL: 6 MO, RENEWAL: 12 MO. HEPATITIS C, SEVERE APLASTIC ANEMIA: 12 MO.
Other Criteria	INITIAL: ITP: 1) TRIAL OF OR CONTRAINDICATION TO ONE CORTICOSTEROID OR IMMUNOGLOBULIN, OR HAD AN INSUFFICIENT RESPONSE TO SPLENECTOMY, AND 2) NO CONCURRENT USE WITH OTHER THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS). ALL INDICATIONS: APPROVAL FOR ELTROMBOPAG ORAL SUSPENSION PACKETS REQUIRES A TRIAL OF A FORMULARY VERSION OF ELTROMBOPAG TABLET OR PATIENT IS UNABLE TOLERATE TABLET FORMULATION. RENEWAL: ITP: 1) IMPROVEMENT IN PLATELET COUNTS FROM BASELINE OR REDUCTION IN BLEEDING EVENTS, AND 2) NO CONCURRENT USE WITH OTHER TPO-RAS.
Indications	All FDA-approved Indications.
Off Label Uses	

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **ENASIDENIB**

---

**Products Affected**

- IDHIFA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **ENCORAFENIB**

---

**Products Affected**

- BRAFTOVI ORAL CAPSULE 75 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **ENTRECTINIB CAPSULES**

---

**Products Affected**

- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **ENTRECTINIB PELLETS**

---

**Products Affected**

- ROZLYTREK ORAL PACKET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), SOLID TUMORS: 1) TRIAL OF OR CONTRAINDICATION TO ROZLYTREK CAPSULES MADE INTO AN ORAL SUSPENSION, AND 2) DIFFICULTY OR UNABLE TO SWALLOW CAPSULES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## ENZALUTAMIDE

**Products Affected**

- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: ALL INDICATIONS: 12 MONTHS. RENEWAL: MCRPC, NMCRPC, MCSPC: 12 MONTHS.
Other Criteria	INITIAL: NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC): HIGH RISK PROSTATE CANCER (I.E. RAPIDLY INCREASING PROSTATE SPECIFIC ANTIGEN [PSA] LEVELS). NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC): HIGH RISK FOR METASTASIS (I.E. PSA DOUBLING TIME OF 9 MONTHS OR LESS). METASTATIC CRPC (MCRPC), NMCRPC, METASTATIC CSPC (MCSPC), NMCSPC : 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. RENEWAL: MCRPC, NMCRPC, MCSPC: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GNRH ANALOG.
Indications	All FDA-approved Indications.

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **EPCORITAMAB-BYSP**

---

**Products Affected**

- EPKINLY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **EPOETIN ALFA-EPBX**

### **Products Affected**

- RETACRIT INJECTION SOLUTION                      UNIT/ML, 4000 UNIT/ML, 40000  
     10000 UNIT/ML, 10000 UNIT/ML(1ML),      UNIT/ML  
     2000 UNIT/ML, 20000 UNIT/ML, 3000

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: CHRONIC KIDNEY DISEASE (CKD), ANEMIA RELATED TO ZIDOVUDINE, OR CANCER CHEMOTHERAPY: HEMOGLOBIN LEVEL IS LESS THAN 10G/DL. ELECTIVE, NON-CARDIAC, NON-VASCULAR SURGERY: HEMOGLOBIN LEVEL IS LESS THAN 13G/DL. RENEWAL: 1) CKD IN ADULTS NOT ON DIALYSIS: (A) HEMOGLOBIN LEVEL IS LESS THAN 10G/DL, OR (B) HEMOGLOBIN LEVEL HAS REACHED 10G/DL AND THE DOSE IS BEING OR HAS BEEN REDUCED/INTERRUPTED TO DECREASE THE NEED FOR BLOOD TRANSFUSIONS. 2) CKD IN PEDIATRIC PATIENTS: (A) HEMOGLOBIN LEVEL IS LESS THAN 10G/DL, OR (B) HEMOGLOBIN LEVEL HAS APPROACHED OR EXCEEDS 12G/DL AND THE DOSE IS BEING OR HAS BEEN REDUCED/INTERRUPTED TO DECREASE THE NEED FOR BLOOD TRANSFUSIONS. 3) ANEMIA RELATED TO ZIDOVUDINE: HEMOGLOBIN LEVEL BETWEEN 10G/DL AND 12G/DL. 4) CANCER CHEMOTHERAPY: (A) HEMOGLOBIN LEVEL IS LESS THAN 10 G/DL, OR (B) HEMOGLOBIN LEVEL DOES NOT EXCEED A LEVEL NEEDED TO AVOID RBC TRANSFUSION.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	ANEMIA FROM CHEMO/CKD WITHOUT DIALYSIS/ZIDOVUDINE: INITIAL/RENEWAL: 12 MONTHS. SURGERY: 1 MONTH.
<b>Other Criteria</b>	RENEWAL: CKD: NOT RECEIVING DIALYSIS TREATMENT. THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **ERDAFITINIB**

---

**Products Affected**

- BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **ERENUMAB-AOOE**

### **Products Affected**

- AIMOVIG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## ERLOTINIB

### Products Affected

- erlotinib hcl oral tablet 100 mg, 150 mg, 25 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## ESKETAMINE

**Products Affected**

- SPRAVATO (56 MG DOSE)
- SPRAVATO (84 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: TREATMENT-RESISTANT DEPRESSION (TRD), MAJOR DEPRESSIVE DISORDER (MDD): PRESCRIBED BY OR IN CONSULTATION WITH A PSYCHIATRIST.
Coverage Duration	INITIAL: TRD: 3 MONTHS. MDD: 4 WEEKS. RENEWAL: TRD, MDD: 12 MONTHS.
Other Criteria	INITIAL: TRD, MDD: 1) NON-PSYCHOTIC, UNIPOLAR DEPRESSION, AND 2) NO ACTIVE SUBSTANCE ABUSE. RENEWAL: TRD, MDD: DEMONSTRATED CLINICAL BENEFIT (IMPROVEMENT IN DEPRESSION) COMPARED TO BASELINE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## ETANERCEPT

### Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. PSA: NO CONCURRENT

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	<p>USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **EVEROLIMUS-AFINITOR**

---

**Products Affected**

- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **EVEROLIMUS-AFINITOR DISPERZ**

---

**Products Affected**

- *everolimus oral tablet soluble*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **FECAL MICROBIOTA CAPSULE**

### **Products Affected**

- VOWST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	30 DAYS
<b>Other Criteria</b>	CLOSTRIDIODES DIFFICILE INFECTION (CDI): 1) HAS NOT PREVIOUSLY RECEIVED VOWST: COMPLETION OF ANTIBIOTIC TREATMENT FOR RECURRENT CDI (AT LEAST 3 CDI EPISODES), OR 2) PREVIOUSLY RECEIVED VOWST: (A) TREATMENT FAILURE (DEFINED AS THE PRESENCE OF CDI DIARRHEA WITHIN 8 WEEKS OF FIRST DOSE OF VOWST AND A POSITIVE STOOL TEST FOR C. DIFFICILE), AND (B) HAS NOT RECEIVED MORE THAN ONE TREATMENT COURSE OF VOWST WHICH WAS AT LEAST 12 DAYS AND NOT MORE THAN 8 WEEKS PRIOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **FEDRATINIB**

---

**Products Affected**

- INREBIC

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	MYELOFIBROSIS: INITIAL: TRIAL OF OR CONTRAINDICATION TO JAKAFI (RUXOLITINIB). RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **FENFLURAMINE**

---

**Products Affected**

- FINTEPLA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: DRAVET SYNDROME, LENNOX-GASTAUT SYNDROME (LGS): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: LGS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING ANTIEPILEPTIC MEDICATIONS: RUFINAMIDE, FELBAMATE, CLOBAZAM, TOPIRAMATE, LAMOTRIGINE, CLONAZEPAM.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## FENTANYL CITRATE

### Products Affected

- *fentanyl citrate buccal lozenge on a handle*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	CANCER RELATED PAIN: 1) CURRENTLY ON A MAINTENANCE DOSE OF CONTROLLED-RELEASE OPIOID PAIN MEDICATION, AND 2) TRIAL OF OR CONTRAINDICATION TO AT LEAST ONE IMMEDIATE-RELEASE ORAL OPIOID PAIN AGENT OR PATIENT HAS DIFFICULTY SWALLOWING TABLETS/CAPSULES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## FEZOLINETANT

### Products Affected

- VEOZAH

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	MENOPAUSAL VASOMOTOR SYMPTOMS (VMS): INITIAL: 1) EXPERIENCES 7 OR MORE HOT FLASHES PER DAY, AND 2) TRIAL OF OR CONTRAINDICATION TO HORMONAL THERAPY (E.G., ESTRADIOL TRANSDERMAL PATCH, ORAL CONJUGATED ESTROGENS). RENEWAL: 1) CONTINUED NEED FOR VMS TREATMENT (I.E., PERSISTENT HOT FLASHES), AND 2) REDUCTION IN VMS FREQUENCY OR SEVERITY DUE TO VEOZAH TREATMENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **FILGRASTIM-AAFI**

---

**Products Affected**

- NIVESTYM

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **FINERENONE**

**Products Affected**

- KERENDIA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: HEART FAILURE (HF): 1) NEW YORK HEART ASSOCIATION (NYHA) CLASS II-IV, AND 2) LEFT VENTRICULAR EJECTION FRACTION OF AT LEAST 40 PERCENT NOT DUE TO AN UNDERLYING CAUSE (E.G., INFILTRATIVE CARDIOMYOPATHY, HYPERTROPHIC CARDIOMYOPATHY, VALVULAR DISEASE, PERICARDIAL DISEASE, HIGH-OUTPUT HEART FAILURE).
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: HF: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST.
<b>Coverage Duration</b>	CHRONIC KIDNEY DISEASE ASSOCIATED WITH TYPE 2 DIABETES: 12 MOS. INITIAL/RENEWAL: HF: 12 MOS
<b>Other Criteria</b>	INITIAL/RENEWAL: HF: NO CONCURRENT USE WITH ANOTHER MINERALOCORTICOID (ALDOSTERONE) RECEPTOR ANTAGONIST.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## FINGOLIMOD

---

**Products Affected**

- *fingolimod hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **FOSCARBIDOPA-FOSLEVODOPA**

### **Products Affected**

- VYALEV SUBCUTANEOUS  
SOLUTION 12-240 MG/ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PARKINSONS DISEASE (PD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
<b>Coverage Duration</b>	INITIAL: 3 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PD: INITIAL: 1) RESPONSIVE TO LEVODOPA, 2) CURRENT REGIMEN INCLUDES AT LEAST 400 MG/DAY OF LEVODOPA, AND 3) MOTOR SYMPTOMS ARE CURRENTLY UNCONTROLLED (DEFINED AS AN AVERAGE OFF TIME OF AT LEAST 2.5 HOURS/DAY OVER 3 CONSECUTIVE DAYS WITH A MINIMUM OF 2 HOURS EACH DAY). RENEWAL: IMPROVEMENT IN MOTOR SYMPTOMS WHILE ON THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **FREMANEZUMAB-VFRM**

---

**Products Affected**

- AJOVY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **FRUQUINTINIB**

---

**Products Affected**

- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **FUTIBATINIB**

### **Products Affected**

- LYTGOBI (12 MG DAILY DOSE)
- LYTGOBI (16 MG DAILY DOSE)
- LYTGOBI (20 MG DAILY DOSE)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INTRAHEPATIC CHOLANGIOCARCINOMA (ICCA): COMPLETE A COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), PRIOR TO THE INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **GALCANEZUMAB-GNLM**

**Products Affected**

- EMGALITY
- EMGALITY (300 MG DOSE)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: MIGRAINE PREVENTION: 6 MOS. EPISODIC CLUSTER HEADACHE: 3 MOS. RENEWAL (ALL): 12 MOS.
<b>Other Criteria</b>	MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY. EPISODIC CLUSTER HEADACHE: RENEWAL: IMPROVEMENT IN EPISODIC CLUSTER HEADACHE FREQUENCY AS COMPARED TO BASELINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## GANAXOLONE

---

**Products Affected**

- ZTALMY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **GEFITINIB**

---

**Products Affected**

- *gefitinib*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **GILTERITINIB**

---

**Products Affected**

- XOSPATA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **GLASDEGIB**

---

**Products Affected**

- DAURISMO ORAL TABLET 100 MG,  
25 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## GLATIRAMER

---

**Products Affected**

- *glatiramer acetate subcutaneous solution*      • *glatopa subcutaneous solution prefilled*  
*prefilled syringe 20 mg/ml, 40 mg/ml*                      *syringe 20 mg/ml, 40 mg/ml*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## GLECAPREVIR/PIBRENTASVIR

**Products Affected**

- MAVYRET ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
Other Criteria	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) ONE OF THE FOLLOWING, WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSA GUIDANCE: (A) SHORT TRIAL OF A PREFERRED FORMULARY AGENT: HARVONI OR EPCLUSA, OR (B) CONTRAINDICATION TO BOTH OF THE PREFERRED FORMULARY AGENTS: HARVONI AND EPCLUSA, 3) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: CARBAMAZEPINE, RIFAMPIN, ETHINYL ESTRADIOL-CONTAINING MEDICATION, ATAZANAVIR, DARUNAVIR, LOPINAVIR, RITONAVIR, EFAVIRENZ, ATORVASTATIN, LOVASTATIN, SIMVASTATIN, ROSUVASTATIN AT DOSES GREATER THAN 10MG, CYCLOSPORINE AT DOSES GREATER THAN 100MG PER DAY, EPCLUSA, HARVONI, VOSEVI, OR ZEPATIER, AND 4) DOES NOT HAVE MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD PUGH B OR C).
Indications	All FDA-approved Indications.

Y0135\_PA25\_C

Formulary ID: 25261

Last Updated: 11/26/2025

Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **GLP1-DULAGLUTIDE**

---

**Products Affected**

- TRULICITY SUBCUTANEOUS  
SOLUTION AUTO-INJECTOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## GLP1-SEMAGLUTIDE

---

**Products Affected**

- OZEMPIC (0.25 OR 0.5 MG/DOSE)
- OZEMPIC (1 MG/DOSE)
- OZEMPIC (2 MG/DOSE)
- RYBELSUS
- RYBELSUS (FORMULATION R2)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated:11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **GLP1-TIRZEPATIDE**

---

**Products Affected**

- MOUNJARO SUBCUTANEOUS  
SOLUTION AUTO-INJECTOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS.
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## GOSERELIN

### Products Affected

- ZOLADEX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	ENDOMETRIOSIS: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.
Age Restrictions	
Prescriber Restrictions	ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.
Coverage Duration	STAGE B2-C PROSTATIC CARCINOMA: 4 MOS. ENDOMETRIOSIS: 6 MOS PER LIFETIME. ALL OTHERS: 12 MONTHS.
Other Criteria	ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 6 MONTHS OF TREATMENT PER LIFETIME. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **GUSELKUMAB**

### **Products Affected**

- TREMFYA CROHNS INDUCTION
- TREMFYA INTRAVENOUS
- TREMFYA ONE-PRESS SOLUTION PEN-INJECTOR 100 MG/ML SUBCUTANEOUS
- TREMFYA ONE-PRESS SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- TREMFYA PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/2ML
- TREMFYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- TREMFYA-CD/UC INDUCTION SOLUTION AUTO-INJECTOR 200 MG/2ML SUBCUTANEOUS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. ULCERATIVE COLITIS (UC), CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY)

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	<p>FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. RENEWAL: PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **IBRUTINIB**

---

**Products Affected**

- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL SUSPENSION
- IMBRUVICA ORAL TABLET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## ICATIBANT

---

**Products Affected**

- *icatibant acetate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HEREDITARY ANGIOEDEMA (HAE): DIAGNOSIS CONFIRMED BY COMPLEMENT TESTING.
Age Restrictions	
Prescriber Restrictions	HAE: PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, IMMUNOLOGIST, OR HEMATOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	HAE: NO CONCURRENT USE WITH OTHER MEDICATIONS FOR TREATMENT OF ACUTE HAE ATTACKS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **IDELALISIB**

---

**Products Affected**

- ZYDELIG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## IMATINIB

### Products Affected

- *imatinib mesylate oral tablet 100 mg, 400 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ADJUVANT GASTROINTESTINAL STROMAL TUMOR TREATMENT: 36 MONTHS. ALL OTHER DIAGNOSES: 12 MONTHS.
Other Criteria	PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA: PATIENT HAS NOT RECEIVED A PREVIOUS TREATMENT WITH ANOTHER TYROSINE KINASE INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## IMATINIB SOLUTION

### Products Affected

- IMKELDI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ADJUVANT GASTROINTESTINAL STROMAL TUMOR TREATMENT: 36 MONTHS. ALL OTHER DIAGNOSES: 12 MONTHS.
Other Criteria	PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA: PATIENT HAS NOT RECEIVED A PREVIOUS TREATMENT WITH ANOTHER TYROSINE KINASE INHIBITOR. ALL INDICATIONS: UNABLE TO SWALLOW GENERIC IMATINIB TABLETS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## IMETELSTAT

---

**Products Affected**

- RYTELO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **IMLUNESTRANT**

---

**Products Affected**

- INLURIYO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## INAVOLISIB

---

**Products Affected**

- ITOVEBI ORAL TABLET 3 MG, 9 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## INFLIXIMAB

### Products Affected

- infliximab*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP, OR FACE.
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PSA: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA/CYLTEZO/YUFLYMA, STELARA/SELARSDI/YESINTEK, XELJANZ, RINVOQ, SKYRIZI, TREMFYA, ORENCIA, OTEZLA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	<p>PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA/CYLTEZO/YUFLYMA, STELARA/SELARSDI/YESINTEK, SKYRIZI, TREMFYA, OTEZLA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. AS: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. MODERATE TO SEVERE CD: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS, WHERE AGES ALIGN: STELARA/SELARSDI/YESINTEK, HUMIRA/CYLTEZO/YUFLYMA, RINVOQ, SKYRIZI, TREMFYA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS, WHERE AGES ALIGN: STELARA/SELARSDI/YESINTEK, XELJANZ, HUMIRA/CYLTEZO/YUFLYMA, RINVOQ, SKYRIZI, TREMFYA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. AS: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. MODERATE TO SEVERE CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.</p>
<b>Indications</b>	All FDA-approved Indications.

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **INSULIN SUPPLIES PAYMENT DETERMINATION**

---

### **Products Affected**

- ABOUTTIME PEN NEEDLE 30G X 8 MM
- ABOUTTIME PEN NEEDLE 31G X 5 MM
- ABOUTTIME PEN NEEDLE 31G X 8 MM
- ABOUTTIME PEN NEEDLE 32G X 4 MM
- ADVOCATE INSULIN PEN NEEDLE 32G X 4 MM
- ADVOCATE INSULIN PEN NEEDLES 29G X 12.7MM
- ADVOCATE INSULIN PEN NEEDLES 31G X 5 MM
- ADVOCATE INSULIN PEN NEEDLES 31G X 8 MM
- ADVOCATE INSULIN PEN NEEDLES 33G X 4 MM
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 1 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 1 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 1 ML
- ALCOHOL PREP PAD
- ALCOHOL PREP PAD 70 %
- ALCOHOL PREP PADS PAD 70 %
- ALCOHOL SWABS PAD
- ALCOHOL SWABS PAD 70 %
- AQ INSULIN SYRINGE 31G X 5/16" 1 ML
- AQINJECT PEN NEEDLE 31G X 5 MM
- AQINJECT PEN NEEDLE 32G X 4 MM
- ASSURE ID DUO PRO PEN NEEDLES 31G X 5 MM
- ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 1 ML
- ASSURE ID INSULIN SAFETY SYR 31G X 15/64" 0.5 ML
- ASSURE ID INSULIN SAFETY SYR 31G X 15/64" 1 ML
- ASSURE ID PRO PEN NEEDLES 30G X 5 MM
- AUM ALCOHOL PREP PADS PAD 70 %
- AUM INSULIN SAFETY PEN NEEDLE 31G X 4 MM
- AUM INSULIN SAFETY PEN NEEDLE 31G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 4 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 6 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 8 MM

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

- AUM MINI INSULIN PEN NEEDLE 33G X 4 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 6 MM
- AUM PEN NEEDLE 32G X 4 MM
- AUM PEN NEEDLE 32G X 5 MM
- AUM PEN NEEDLE 32G X 6 MM
- AUM PEN NEEDLE 33G X 4 MM
- AUM PEN NEEDLE 33G X 5 MM
- AUM PEN NEEDLE 33G X 6 MM
- AUM READYGARD DUO PEN NEEDLE 32G X 4 MM
- AUM SAFETY PEN NEEDLE 31G X 4 MM
- BD AUTOSHIELD DUO 30G X 5 MM
- BD ECLIPSE SYRINGE 30G X 1/2" 1 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 0.3 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 0.5 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 1 ML
- BD INSULIN SYRINGE 27.5G X 5/8" 2 ML
- BD INSULIN SYRINGE 25G X 1" 1 ML
- BD INSULIN SYRINGE 25G X 5/8" 1 ML
- BD INSULIN SYRINGE 26G X 1/2" 1 ML
- BD INSULIN SYRINGE 27G X 1/2" 1 ML
- BD INSULIN SYRINGE 29G X 1/2" 0.5 ML (OTC)
- BD INSULIN SYRINGE 29G X 1/2" 0.5 ML (RX)
- BD INSULIN SYRINGE 29G X 1/2" 1 ML (OTC)
- BD INSULIN SYRINGE 29G X 1/2" 1 ML (RX)
- BD INSULIN SYRINGE HALF-UNIT 31G X 5/16" 0.3 ML
- BD INSULIN SYRINGE MICROFINE 27G X 5/8" 1 ML
- BD INSULIN SYRINGE MICROFINE 28G X 1/2" 1 ML (OTC)
- BD INSULIN SYRINGE MICROFINE 28G X 1/2" 1 ML (RX)
- BD INSULIN SYRINGE U-100 1 ML
- BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 0.3 ML
- BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 0.5 ML
- BD INSULIN SYRINGE ULTRAFINE 30G X 1/2" 0.3 ML
- BD INSULIN SYRINGE ULTRAFINE 30G X 1/2" 0.5 ML
- BD PEN NEEDLE MICRO ULTRAFINE 32G X 6 MM
- BD PEN NEEDLE MINI U/F 31G X 5 MM
- BD PEN NEEDLE MINI ULTRAFINE 31G X 5 MM
- BD PEN NEEDLE NANO 2ND GEN 32G X 4 MM
- BD PEN NEEDLE NANO ULTRAFINE 32G X 4 MM
- BD PEN NEEDLE ORIG ULTRAFINE 29G X 12.7MM
- BD PEN NEEDLE SHORT ULTRAFINE 31G X 8 MM
- BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- BD SAFETYGLIDE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 0.3 ML

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**



## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 0.5 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 1 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- BD SAFETYGLIDE SYRINGE/NEEDLE 27G X 5/8" 1 ML
- BD SWAB SINGLE USE REGULAR PAD
- BD SWABS SINGLE USE BUTTERFLY PAD
- BD VEO INSULIN SYR U/F 1/2UNIT 31G X 15/64" 0.3 ML
- BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 0.3 ML
- BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 0.5 ML
- BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 1 ML
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.3 ML
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.5 ML
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 1 ML
- CAREFINE PEN NEEDLES 29G X 12MM
- CAREFINE PEN NEEDLES 30G X 8 MM
- CAREFINE PEN NEEDLES 31G X 6 MM
- CAREFINE PEN NEEDLES 31G X 8 MM
- CAREFINE PEN NEEDLES 32G X 4 MM
- CAREFINE PEN NEEDLES 32G X 5 MM
- CAREFINE PEN NEEDLES 32G X 6 MM
- CAREONE INSULIN SYRINGE 30G X 1/2" 0.3 ML
- CAREONE INSULIN SYRINGE 30G X 1/2" 0.5 ML
- CAREONE INSULIN SYRINGE 30G X 1/2" 1 ML
- CAREONE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- CAREONE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- CAREONE INSULIN SYRINGE 31G X 5/16" 1 ML
- CARETOUCH ALCOHOL PREP PAD 70 %
- CARETOUCH INSULIN SYRINGE 28G X 5/16" 1 ML
- CARETOUCH INSULIN SYRINGE 29G X 5/16" 1 ML
- CARETOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML
- CARETOUCH INSULIN SYRINGE 30G X 5/16" 1 ML
- CARETOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML
- CARETOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML
- CARETOUCH INSULIN SYRINGE 31G X 5/16" 1 ML
- CARETOUCH PEN NEEDLES 29G X 12MM
- CARETOUCH PEN NEEDLES 31G X 5 MM
- CARETOUCH PEN NEEDLES 31G X 6 MM
- CARETOUCH PEN NEEDLES 31G X 8 MM
- CARETOUCH PEN NEEDLES 32G X 4 MM
- CARETOUCH PEN NEEDLES 32G X 5 MM

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

- CARETOUCH PEN NEEDLES 33G X 4 MM
- CLEVER CHOICE COMFORT EZ 29G X 12MM
- CLEVER CHOICE COMFORT EZ 33G X 4 MM
- CLICKFINE PEN NEEDLES 31G X 8 MM
- CLICKFINE PEN NEEDLES 32G X 4 MM
- COMFORT ASSIST INSULIN SYRINGE 29G X 1/2" 1 ML
- COMFORT ASSIST INSULIN SYRINGE 31G X 5/16" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 28G X 1/2" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 28G X 1/2" 1 ML
- COMFORT EZ INSULIN SYRINGE 29G X 1/2" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 29G X 1/2" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 29G X 1/2" 1 ML
- COMFORT EZ INSULIN SYRINGE 30G X 1/2" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 30G X 1/2" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 30G X 1/2" 1 ML
- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 1 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 1 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 1 ML
- COMFORT EZ PEN NEEDLES 31G X 5 MM
- COMFORT EZ PEN NEEDLES 31G X 6 MM
- COMFORT EZ PEN NEEDLES 31G X 8 MM
- COMFORT EZ PEN NEEDLES 32G X 4 MM
- COMFORT EZ PEN NEEDLES 32G X 5 MM
- COMFORT EZ PEN NEEDLES 32G X 6 MM
- COMFORT EZ PEN NEEDLES 32G X 8 MM
- COMFORT EZ PEN NEEDLES 33G X 4 MM
- COMFORT EZ PEN NEEDLES 33G X 5 MM
- COMFORT EZ PEN NEEDLES 33G X 6 MM
- COMFORT EZ PEN NEEDLES 33G X 8 MM
- COMFORT EZ PRO PEN NEEDLES 30G X 8 MM
- COMFORT EZ PRO PEN NEEDLES 31G X 4 MM
- COMFORT EZ PRO PEN NEEDLES 31G X 5 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 4 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 5 MM

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

- COMFORT TOUCH INSULIN PEN  
NEED 31G X 6 MM
- COMFORT TOUCH INSULIN PEN  
NEED 31G X 8 MM
- COMFORT TOUCH INSULIN PEN  
NEED 32G X 4 MM
- COMFORT TOUCH INSULIN PEN  
NEED 32G X 5 MM
- COMFORT TOUCH INSULIN PEN  
NEED 32G X 6 MM
- COMFORT TOUCH INSULIN PEN  
NEED 32G X 8 MM
- CURITY ALCOHOL PREPS PAD 70 %
- CURITY ALL PURPOSE SPONGES  
PAD 2"X2"
- CURITY GAUZE PAD 2"X2"
- CURITY GAUZE SPONGE PAD 2"X2"
- CURITY SPONGES PAD 2"X2"
- CVS GAUZE PAD 2"X2"
- CVS GAUZE STERILE PAD 2"X2"
- CVS ISOPROPYL ALCOHOL WIPES
- DERMACEA GAUZE SPONGE PAD  
2"X2"
- DERMACEA IV DRAIN SPONGES  
PAD 2"X2"
- DERMACEA NON-WOVEN SPONGES  
PAD 2"X2"
- DERMACEA TYPE VII GAUZE PAD  
2"X2"
- DIATHRIVE PEN NEEDLE 31G X 5  
MM
- DIATHRIVE PEN NEEDLE 31G X 6  
MM
- DIATHRIVE PEN NEEDLE 31G X 8  
MM
- DIATHRIVE PEN NEEDLE 32G X 4  
MM
- DROPLET INSULIN SYRINGE 29G X  
1/2" 0.3 ML
- DROPLET INSULIN SYRINGE 29G X  
1/2" 0.5 ML
- DROPLET INSULIN SYRINGE 29G X  
1/2" 1 ML
- DROPLET INSULIN SYRINGE 30G X  
1/2" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X  
1/2" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X  
1/2" 1 ML
- DROPLET INSULIN SYRINGE 30G X  
15/64" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X  
15/64" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X  
15/64" 1 ML
- DROPLET INSULIN SYRINGE 30G X  
5/16" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X  
5/16" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X  
5/16" 1 ML
- DROPLET INSULIN SYRINGE 31G X  
15/64" 0.3 ML
- DROPLET INSULIN SYRINGE 31G X  
15/64" 0.5 ML
- DROPLET INSULIN SYRINGE 31G X  
15/64" 1 ML
- DROPLET INSULIN SYRINGE 31G X  
5/16" 0.3 ML
- DROPLET INSULIN SYRINGE 31G X  
5/16" 0.5 ML
- DROPLET INSULIN SYRINGE 31G X  
5/16" 1 ML
- DROPLET MICRON 34G X 3.5 MM
- DROPLET PEN NEEDLES 29G X  
10MM
- DROPLET PEN NEEDLES 29G X  
12MM
- DROPLET PEN NEEDLES 30G X 8 MM
- DROPLET PEN NEEDLES 31G X 5 MM
- DROPLET PEN NEEDLES 31G X 6 MM
- DROPLET PEN NEEDLES 31G X 8 MM

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

- |  |   |
|--|---|
| • DROPLET PEN NEEDLES 32G X 4 MM                     | • EASY COMFORT INSULIN SYRINGE 29G X 5/16" 0.5 ML |
| • DROPLET PEN NEEDLES 32G X 5 MM                     | • EASY COMFORT INSULIN SYRINGE 29G X 5/16" 1 ML   |
| • DROPLET PEN NEEDLES 32G X 6 MM                     | • EASY COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML  |
| • DROPLET PEN NEEDLES 32G X 8 MM                     | • EASY COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML    |
| • DROPSAFE ALCOHOL PREP PAD 70 %                     | • EASY COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML |
| • DROPSAFE SAFETY PEN NEEDLES 31G X 5 MM             | • EASY COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML   |
| • DROPSAFE SAFETY PEN NEEDLES 31G X 6 MM             | • EASY COMFORT INSULIN SYRINGE 31G X 1/2" 0.3 ML  |
| • DROPSAFE SAFETY PEN NEEDLES 31G X 8 MM             | • EASY COMFORT INSULIN SYRINGE 31G X 5/16" 0.3 ML |
| • DROPSAFE SAFETY SYRINGE/NEEDLE 29G X 1/2" 1 ML     | • EASY COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML |
| • DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 0.3 ML | • EASY COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML   |
| • DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 0.5 ML | • EASY COMFORT INSULIN SYRINGE 32G X 5/16" 0.5 ML |
| • DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 1 ML   | • EASY COMFORT INSULIN SYRINGE 32G X 5/16" 1 ML   |
| • DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 0.3 ML  | • EASY COMFORT PEN NEEDLES 29G X 4MM              |
| • DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 0.5 ML  | • EASY COMFORT PEN NEEDLES 29G X 5MM              |
| • DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 1 ML    | • EASY COMFORT PEN NEEDLES 31G X 5 MM             |
| • DRUG MART ULTRA COMFORT SYR 29G X 1/2" 0.3 ML      | • EASY COMFORT PEN NEEDLES 31G X 6 MM             |
| • DRUG MART ULTRA COMFORT SYR 29G X 1/2" 1 ML        | • EASY COMFORT PEN NEEDLES 31G X 8 MM             |
| • DRUG MART ULTRA COMFORT SYR 30G X 5/16" 0.5 ML     | • EASY COMFORT PEN NEEDLES 32G X 4 MM             |
| • DRUG MART ULTRA COMFORT SYR 30G X 5/16" 1 ML       | • EASY COMFORT PEN NEEDLES 33G X 4 MM             |
| • DRUG MART UNIFINE PENTIPS 31G X 5 MM               | • EASY COMFORT PEN NEEDLES 33G X 5 MM             |
| • EASY COMFORT ALCOHOL PADS PAD                      |   |

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

## Provider Partners Health Plan

### 2025 Formulary – Prior Authorization Criteria

- EASY COMFORT PEN NEEDLES 33G X 6 MM
- EASY GLIDE PEN NEEDLES 33G X 4 MM
- EASY TOUCH ALCOHOL PREP MEDIUM PAD 70 %
- EASY TOUCH FLIPLOCK INSULIN SY 29G X 1/2" 1 ML
- EASY TOUCH FLIPLOCK INSULIN SY 30G X 1/2" 1 ML
- EASY TOUCH FLIPLOCK INSULIN SY 30G X 5/16" 1 ML
- EASY TOUCH FLIPLOCK INSULIN SY 31G X 5/16" 1 ML
- EASY TOUCH FLIPLOCK SAFETY SYR 27G X 1/2" 1 ML
- EASY TOUCH INSULIN BARRELS U-100 1 ML
- EASY TOUCH INSULIN SAFETY SYR 29G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SAFETY SYR 29G X 1/2" 1 ML
- EASY TOUCH INSULIN SAFETY SYR 30G X 1/2" 1 ML
- EASY TOUCH INSULIN SAFETY SYR 30G X 5/16" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 27G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 27G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 27G X 5/8" 1 ML
- EASY TOUCH INSULIN SYRINGE 28G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 28G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 29G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 30G X 1/2" 1 ML
- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 30G X 5/16" 1 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML
- EASY TOUCH INSULIN SYRINGE 31G X 5/16" 1 ML
- EASY TOUCH PEN NEEDLES 29G X 12MM
- EASY TOUCH PEN NEEDLES 30G X 5 MM
- EASY TOUCH PEN NEEDLES 30G X 6 MM
- EASY TOUCH PEN NEEDLES 30G X 8 MM
- EASY TOUCH PEN NEEDLES 31G X 5 MM
- EASY TOUCH PEN NEEDLES 31G X 6 MM
- EASY TOUCH PEN NEEDLES 31G X 8 MM
- EASY TOUCH PEN NEEDLES 32G X 4 MM
- EASY TOUCH PEN NEEDLES 32G X 5 MM
- EASY TOUCH PEN NEEDLES 32G X 6 MM
- EASY TOUCH SAFETY PEN NEEDLES 29G X 5MM

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

- EASY TOUCH SAFETY PEN NEEDLES 29G X 8MM
- EASY TOUCH SAFETY PEN NEEDLES 30G X 8 MM
- EASY TOUCH SHEATHLOCK SYRINGE 29G X 1/2" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 30G X 1/2" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 30G X 5/16" 1 ML
- EASY TOUCH SHEATHLOCK SYRINGE 31G X 5/16" 1 ML
- EMBECTA AUTOSHIELD DUO 30G X 5 MM
- EMBECTA INS SYR U/F 1/2 UNIT 31G X 15/64" 0.3 ML
- EMBECTA INS SYR U/F 1/2 UNIT 31G X 5/16" 0.3 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 0.3 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 0.5 ML
- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 1 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 15/64" 0.5 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 15/64" 1 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16" 0.3 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16" 0.5 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16" 1 ML
- EMBECTA INSULIN SYRINGE 28G X 1/2" 0.5 ML
- EMBECTA INSULIN SYRINGE U-100 27G X 5/8" 1 ML
- EMBECTA INSULIN SYRINGE U-100 28G X 1/2" 1 ML
- EMBECTA INSULIN SYRINGE U-500
- EMBECTA PEN NEEDLE NANO 2 GEN 32G X 4 MM
- EMBECTA PEN NEEDLE NANO 32G X 4 MM
- EMBECTA PEN NEEDLE ULTRAFINE 29G X 12.7MM
- EMBECTA PEN NEEDLE ULTRAFINE 31G X 5 MM
- EMBECTA PEN NEEDLE ULTRAFINE 31G X 8 MM
- EMBECTA PEN NEEDLE ULTRAFINE 32G X 6 MM
- EMBRACE PEN NEEDLES 29G X 12MM
- EMBRACE PEN NEEDLES 30G X 5 MM
- EMBRACE PEN NEEDLES 30G X 8 MM
- EMBRACE PEN NEEDLES 31G X 5 MM
- EMBRACE PEN NEEDLES 31G X 6 MM
- EMBRACE PEN NEEDLES 31G X 8 MM
- EMBRACE PEN NEEDLES 32G X 4 MM
- EQL ALCOHOL SWABS PAD 70 %
- EQL GAUZE PAD 2"X2"
- EQL INSULIN SYRINGE 29G X 1/2" 0.5 ML
- EQL INSULIN SYRINGE 30G X 5/16" 0.5 ML
- EXEL COMFORT POINT INSULIN SYR 29G X 1/2" 0.3 ML
- EXEL COMFORT POINT INSULIN SYR 30G X 5/16" 0.3 ML
- EXEL COMFORT POINT PEN NEEDLE 29G X 12MM
- FREESTYLE PRECISION INS SYR 30G X 5/16" 0.5 ML

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

- FREESTYLE PRECISION INS SYR 30G X 5/16" 1 ML
- FREESTYLE PRECISION INS SYR 31G X 5/16" 0.5 ML
- FREESTYLE PRECISION INS SYR 31G X 5/16" 1 ML
- GAUZE PADS PAD 2"X2"
- GAUZE TYPE VII MEDI-PAK PAD 2"X2"
- GLOBAL ALCOHOL PREP EASE
- GLOBAL EASE INJECT PEN NEEDLES 29G X 12MM
- GLOBAL EASE INJECT PEN NEEDLES 31G X 5 MM
- GLOBAL EASE INJECT PEN NEEDLES 31G X 8 MM
- GLOBAL EASE INJECT PEN NEEDLES 32G X 4 MM
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 0.3 ML
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 0.5 ML
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 1/2" 1 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 1 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 1 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 1 ML
- GNP ALCOHOL SWABS PAD
- GNP CLICKFINE PEN NEEDLES 31G X 6 MM
- GNP CLICKFINE PEN NEEDLES 31G X 8 MM
- GNP INSULIN SYRINGE 28G X 1/2" 1 ML
- GNP INSULIN SYRINGE 29G X 1/2" 1 ML
- GNP INSULIN SYRINGE 30G X 5/16" 0.3 ML
- GNP INSULIN SYRINGE 30G X 5/16" 0.5 ML
- GNP INSULIN SYRINGES 29GX1/2" 29G X 1/2" 0.5 ML
- GNP INSULIN SYRINGES 29GX1/2" 29G X 1/2" 1 ML
- GNP INSULIN SYRINGES 30G X 5/16" 1 ML
- GNP INSULIN SYRINGES 30GX5/16" 30G X 5/16" 0.3 ML
- GNP INSULIN SYRINGES 31GX5/16" 31G X 5/16" 0.3 ML
- GNP PEN NEEDLES 32G X 4 MM
- GNP STERILE GAUZE PAD 2"X2"
- GNP ULTRA COM INSULIN SYRINGE 29G X 1/2" 0.5 ML
- GNP ULTRA COM INSULIN SYRINGE 30G X 5/16" 1 ML
- GOODSENSE ALCOHOL SWABS PAD 70 %
- GOODSENSE CLICKFINE PEN NEEDLE 31G X 5 MM
- GOODSENSE PEN NEEDLE PENFINE 31G X 5 MM
- GOODSENSE PEN NEEDLE PENFINE 31G X 8 MM

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

## Provider Partners Health Plan

### 2025 Formulary – Prior Authorization Criteria

- GOODSENSE PEN NEEDLE PENFINE 32G X 4 MM
- GOODSENSE PEN NEEDLE PENFINE 32G X 6 MM
- H-E-B INCONTROL ALCOHOL PAD
- H-E-B INCONTROL PEN NEEDLES 29G X 12MM
- H-E-B INCONTROL PEN NEEDLES 31G X 5 MM
- H-E-B INCONTROL PEN NEEDLES 31G X 6 MM
- H-E-B INCONTROL PEN NEEDLES 31G X 8 MM
- H-E-B INCONTROL PEN NEEDLES 32G X 4 MM
- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 0.3 ML
- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 0.5 ML
- HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 1 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 0.3 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 0.5 ML
- HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 1 ML
- HEALTHWISE MICRON PEN NEEDLES 32G X 4 MM
- HEALTHWISE SHORT PEN NEEDLES 31G X 5 MM
- HEALTHWISE SHORT PEN NEEDLES 31G X 8 MM
- HEALTHY ACCENTS UNIFINE PENTIP 29G X 12MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 5 MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 6 MM
- HEALTHY ACCENTS UNIFINE PENTIP 31G X 8 MM
- HEALTHY ACCENTS UNIFINE PENTIP 32G X 4 MM
- HM STERILE ALCOHOL PREP PAD
- HM STERILE PADS PAD 2"X2"
- HM ULTICARE INSULIN SYRINGE 30G X 1/2" 1 ML
- HM ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- HM ULTICARE SHORT PEN NEEDLES 31G X 8 MM
- INCONTROL ULTICARE PEN NEEDLES 31G X 6 MM
- INCONTROL ULTICARE PEN NEEDLES 31G X 8 MM
- INCONTROL ULTICARE PEN NEEDLES 32G X 4 MM
- INSULIN SYRINGE 29G X 1/2" 0.3 ML
- INSULIN SYRINGE 29G X 1/2" 1 ML
- INSULIN SYRINGE 30G X 5/16" 1 ML
- INSULIN SYRINGE 31G X 5/16" 0.3 ML
- INSULIN SYRINGE 31G X 5/16" 0.5 ML
- INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 0.5 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 1 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 0.5 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 1 ML (RX)
- INSULIN SYRINGE-NEEDLE U-100 30G X 5/16" 1 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 0.3 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 0.5 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 1/4" 1 ML
- INSULIN SYRINGE-NEEDLE U-100 31G X 5/16" 0.5 ML (OTC)

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**



## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

- INSULIN SYRINGE/NEEDLE 27G X 1/2" 0.5 ML
- INSULIN SYRINGE/NEEDLE 28G X 1/2" 0.5 ML
- INSULIN SYRINGE/NEEDLE 28G X 1/2" 1 ML
- INSUPEN PEN NEEDLES 31G X 5 MM
- INSUPEN PEN NEEDLES 31G X 8 MM
- INSUPEN PEN NEEDLES 32G X 4 MM
- INSUPEN PEN NEEDLES 33G X 4 MM
- INSUPEN SENSITIVE 32G X 6 MM
- INSUPEN SENSITIVE 32G X 8 MM
- INSUPEN ULTRAFIN 29G X 12MM
- INSUPEN ULTRAFIN 30G X 8 MM
- INSUPEN ULTRAFIN 31G X 6 MM
- INSUPEN ULTRAFIN 31G X 8 MM
- INSUPEN32G EXTR3ME 32G X 6 MM
- J & J GAUZE PAD 2"X2"
- KENDALL HYDROPHILIC FOAM DRESS PAD 2"X2"
- KENDALL HYDROPHILIC FOAM PLUS PAD 2"X2"
- KINRAY INSULIN SYRINGE 29G X 1/2" 0.5 ML
- KMART VALU INSULIN SYRINGE 29G U-100 1 ML
- KMART VALU INSULIN SYRINGE 30G U-100 0.3 ML
- KMART VALU INSULIN SYRINGE 30G U-100 1 ML
- KROGER INSULIN SYRINGE 30G X 5/16" 0.5 ML
- KROGER PEN NEEDLES 29G X 12MM
- KROGER PEN NEEDLES 31G X 6 MM
- LEADER INSULIN SYRINGE 28G X 1/2" 0.5 ML
- LEADER INSULIN SYRINGE 28G X 1/2" 1 ML
- LEADER UNIFINE PENTIPS 31G X 5 MM
- LEADER UNIFINE PENTIPS 32G X 4 MM
- LEADER UNIFINE PENTIPS PLUS 31G X 5 MM
- LEADER UNIFINE PENTIPS PLUS 31G X 8 MM
- LITETOUCH INSULIN SYRINGE 28G X 1/2" 0.5 ML
- LITETOUCH INSULIN SYRINGE 28G X 1/2" 1 ML
- LITETOUCH INSULIN SYRINGE 29G X 1/2" 0.3 ML
- LITETOUCH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- LITETOUCH INSULIN SYRINGE 29G X 1/2" 1 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 0.3 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML
- LITETOUCH INSULIN SYRINGE 30G X 5/16" 1 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML
- LITETOUCH INSULIN SYRINGE 31G X 5/16" 1 ML
- LITETOUCH PEN NEEDLES 29G X 12.7MM
- LITETOUCH PEN NEEDLES 31G X 5 MM
- LITETOUCH PEN NEEDLES 31G X 6 MM
- LITETOUCH PEN NEEDLES 31G X 8 MM
- LITETOUCH PEN NEEDLES 32G X 4 MM
- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 0.3 ML

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 0.5 ML
- MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 1 ML
- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 0.3 ML
- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 0.5 ML
- MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 1 ML
- MAXI-COMFORT INSULIN SYRINGE 28G X 1/2" 0.5 ML
- MAXI-COMFORT INSULIN SYRINGE 28G X 1/2" 1 ML
- MAXI-COMFORT SAFETY PEN NEEDLE 29G X 5MM
- MAXI-COMFORT SAFETY PEN NEEDLE 29G X 8MM
- MAXICOMFORT II PEN NEEDLE 31G X 6 MM
- MAXICOMFORT SYR 27G X 1/2" 27G X 1/2" 0.5 ML
- MAXICOMFORT SYR 27G X 1/2" 27G X 1/2" 1 ML
- MEDIC INSULIN SYRINGE 30G X 5/16" 0.3 ML
- MEDIC INSULIN SYRINGE 30G X 5/16" 0.5 ML
- MEDICINE SHOPPE PEN NEEDLES 29G X 12MM
- MEDICINE SHOPPE PEN NEEDLES 31G X 8 MM
- MEDPURA ALCOHOL PADS 70 % EXTERNAL
- MEIJER ALCOHOL SWABS PAD 70 %
- MEIJER PEN NEEDLES 29G X 12MM
- MEIJER PEN NEEDLES 31G X 6 MM
- MEIJER PEN NEEDLES 31G X 8 MM
- MICRODOT PEN NEEDLE 31G X 6 MM
- MICRODOT PEN NEEDLE 32G X 4 MM
- MICRODOT PEN NEEDLE 33G X 4 MM
- MIRASORB SPONGES 2"X2"
- MM PEN NEEDLES 31G X 6 MM
- MM PEN NEEDLES 32G X 4 MM
- MONOJECT INSULIN SYRINGE 25G X 5/8" 1 ML
- MONOJECT INSULIN SYRINGE 27G X 1/2" 1 ML (OTC)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 0.5 ML (RX)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 1 ML (OTC)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 29G X 1/2" 0.3 ML
- MONOJECT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- MONOJECT INSULIN SYRINGE 29G X 1/2" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- MONOJECT INSULIN SYRINGE 30G X 5/16" 0.5 ML (RX)
- MONOJECT INSULIN SYRINGE 30G X 5/16" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 31G X 5/16" 1 ML
- MONOJECT INSULIN SYRINGE U-100 1 ML
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 0.5 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 0.5 ML (RX)
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 1 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2" 0.5 ML

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

- MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2" 1 ML
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.3 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.3 ML (RX)
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.5 ML (RX)
- MS INSULIN SYRINGE 30G X 5/16" 0.3 ML
- MS INSULIN SYRINGE 31G X 5/16" 0.3 ML
- MS INSULIN SYRINGE 31G X 5/16" 0.5 ML
- MS INSULIN SYRINGE 31G X 5/16" 1 ML
- NOVOFINE AUTOCOVER 30G X 8 MM
- NOVOFINE PEN NEEDLE 32G X 6 MM
- NOVOFINE PLUS PEN NEEDLE 32G X 4 MM
- NOVOTWIST PEN NEEDLE 32G X 5 MM
- PC UNIFINE PENTIPS 31G X 5 MM
- PC UNIFINE PENTIPS 31G X 6 MM
- PC UNIFINE PENTIPS 31G X 8 MM
- PEN NEEDLE/5-BEVEL TIP 31G X 8 MM
- PEN NEEDLE/5-BEVEL TIP 32G X 4 MM
- PEN NEEDLES 30G X 5 MM (OTC)
- PEN NEEDLES 30G X 8 MM
- PEN NEEDLES 32G X 5 MM
- PENTIPS 29G X 12MM (RX)
- PENTIPS 31G X 5 MM (RX)
- PENTIPS 31G X 8 MM (RX)
- PENTIPS 32G X 4 MM (RX)
- PENTIPS GENERIC PEN NEEDLES 29G X 12MM
- PENTIPS GENERIC PEN NEEDLES 31G X 6 MM
- PENTIPS GENERIC PEN NEEDLES 32G X 6 MM
- PIP PEN NEEDLES 31G X 5MM 31G X 5 MM
- PIP PEN NEEDLES 32G X 4MM 32G X 4 MM
- PRECISION SURE-DOSE SYRINGE 28G X 1/2" 0.5 ML
- PRECISION SURE-DOSE SYRINGE 28G X 1/2" 1 ML
- PRECISION SURE-DOSE SYRINGE 29G X 1/2" 0.5 ML
- PRECISION SURE-DOSE SYRINGE 30G X 3/8" 0.5 ML
- PRECISION SURE-DOSE SYRINGE 30G X 5/16" 0.3 ML
- PRECISION SUREDOSE PLUS SYR 29G X 1/2" 0.3 ML
- PRECISION SUREDOSE PLUS SYR 29G X 1/2" 1 ML
- PREFERRED PLUS INSULIN SYRINGE 28G X 1/2" 0.5 ML
- PREFERRED PLUS INSULIN SYRINGE 29G X 1/2" 0.5 ML
- PREFERRED PLUS INSULIN SYRINGE 29G X 1/2" 1 ML
- PREFERRED PLUS INSULIN SYRINGE 30G X 5/16" 1 ML
- PREFERRED PLUS UNIFINE PENTIPS 29G X 12MM
- PREVENT DROPSAFE PEN NEEDLES 31G X 6 MM
- PREVENT DROPSAFE PEN NEEDLES 31G X 8 MM
- PREVENT SAFETY PEN NEEDLES 31G X 6 MM
- PREVENT SAFETY PEN NEEDLES 31G X 8 MM
- PRO COMFORT ALCOHOL PAD 70 %
- PRO COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

- |   |  |
|---|--|
| • PRO COMFORT INSULIN SYRINGE<br>30G X 1/2" 1 ML    | • PX SHORTLENGTH PEN NEEDLES<br>31G X 8 MM       |
| • PRO COMFORT INSULIN SYRINGE<br>30G X 5/16" 0.5 ML | • QC ALCOHOL                                     |
| • PRO COMFORT INSULIN SYRINGE<br>30G X 5/16" 1 ML   | • QC ALCOHOL SWABS PAD 70 %                      |
| • PRO COMFORT INSULIN SYRINGE<br>31G X 5/16" 0.5 ML | • QC BORDER ISLAND GAUZE PAD<br>2"X2"            |
| • PRO COMFORT INSULIN SYRINGE<br>31G X 5/16" 1 ML   | • QUICK TOUCH INSULIN PEN<br>NEEDLE 29G X 12.7MM |
| • PRO COMFORT PEN NEEDLES 32G X<br>4 MM             | • QUICK TOUCH INSULIN PEN<br>NEEDLE 31G X 4 MM   |
| • PRO COMFORT PEN NEEDLES 32G X<br>5 MM             | • QUICK TOUCH INSULIN PEN<br>NEEDLE 31G X 5 MM   |
| • PRO COMFORT PEN NEEDLES 32G X<br>6 MM             | • QUICK TOUCH INSULIN PEN<br>NEEDLE 31G X 6 MM   |
| • PRO COMFORT PEN NEEDLES 32G X<br>8 MM             | • QUICK TOUCH INSULIN PEN<br>NEEDLE 31G X 8 MM   |
| • PRODIGY INSULIN SYRINGE 28G X<br>1/2" 1 ML        | • QUICK TOUCH INSULIN PEN<br>NEEDLE 32G X 4 MM   |
| • PRODIGY INSULIN SYRINGE 31G X<br>5/16" 0.3 ML     | • QUICK TOUCH INSULIN PEN<br>NEEDLE 32G X 5 MM   |
| • PRODIGY INSULIN SYRINGE 31G X<br>5/16" 0.5 ML     | • QUICK TOUCH INSULIN PEN<br>NEEDLE 32G X 6 MM   |
| • PURE COMFORT ALCOHOL PREP<br>PAD                  | • QUICK TOUCH INSULIN PEN<br>NEEDLE 32G X 8 MM   |
| • PURE COMFORT PEN NEEDLE 32G X<br>4 MM             | • QUICK TOUCH INSULIN PEN<br>NEEDLE 33G X 4 MM   |
| • PURE COMFORT PEN NEEDLE 32G X<br>5 MM             | • QUICK TOUCH INSULIN PEN<br>NEEDLE 33G X 5 MM   |
| • PURE COMFORT PEN NEEDLE 32G X<br>6 MM             | • QUICK TOUCH INSULIN PEN<br>NEEDLE 33G X 6 MM   |
| • PURE COMFORT PEN NEEDLE 32G X<br>8 MM             | • QUICK TOUCH INSULIN PEN<br>NEEDLE 33G X 8 MM   |
| • PURE COMFORT SAFETY PEN<br>NEEDLE 31G X 5 MM      | • RA ALCOHOL SWABS PAD 70 %                      |
| • PURE COMFORT SAFETY PEN<br>NEEDLE 31G X 6 MM      | • RA INSULIN SYRINGE 29G X 1/2" 0.5<br>ML        |
| • PURE COMFORT SAFETY PEN<br>NEEDLE 32G X 4 MM      | • RA INSULIN SYRINGE 29G X 1/2" 1<br>ML          |
|   | • RA INSULIN SYRINGE 30G X 5/16" 0.5<br>ML       |
|   | • RA INSULIN SYRINGE 30G X 5/16" 1<br>ML         |

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

## Provider Partners Health Plan

### 2025 Formulary – Prior Authorization Criteria

- *ra isopropyl alcohol wipes*
- RA PEN NEEDLES 31G X 5 MM
- RA PEN NEEDLES 31G X 8 MM
- RA STERILE PAD 2"X2"
- RAYA SURE PEN NEEDLE 29G X 12MM
- RAYA SURE PEN NEEDLE 31G X 4 MM
- RAYA SURE PEN NEEDLE 31G X 5 MM
- RAYA SURE PEN NEEDLE 31G X 6 MM
- REALITY INSULIN SYRINGE 28G X 1/2" 0.5 ML
- REALITY INSULIN SYRINGE 28G X 1/2" 1 ML
- REALITY INSULIN SYRINGE 29G X 1/2" 0.5 ML
- REALITY INSULIN SYRINGE 29G X 1/2" 1 ML
- REALITY SWABS PAD
- RELI-ON INSULIN SYRINGE 29G 0.3 ML
- RELI-ON INSULIN SYRINGE 29G X 1/2" 1 ML
- RELION ALCOHOL SWABS PAD
- RELION INSULIN SYRINGE 31G X 15/64" 0.3 ML
- RELION INSULIN SYRINGE 31G X 15/64" 0.5 ML
- RELION INSULIN SYRINGE 31G X 15/64" 1 ML
- RELION MINI PEN NEEDLES 31G X 6 MM
- RELION PEN NEEDLES 29G X 12MM
- RELION PEN NEEDLES 31G X 6 MM
- RELION PEN NEEDLES 31G X 8 MM
- RESTORE CONTACT LAYER PAD 2"X2"
- SAFETY INSULIN SYRINGES 29G X 1/2" 0.5 ML
- SAFETY INSULIN SYRINGES 29G X 1/2" 1 ML
- SAFETY INSULIN SYRINGES 30G X 1/2" 1 ML
- SAFETY INSULIN SYRINGES 30G X 5/16" 0.5 ML
- SAFETY PEN NEEDLES 30G X 5 MM
- SAFETY PEN NEEDLES 30G X 8 MM
- SB ALCOHOL PREP PAD 70 %
- SB INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SB INSULIN SYRINGE 29G X 1/2" 1 ML
- SB INSULIN SYRINGE 30G X 5/16" 0.5 ML
- SB INSULIN SYRINGE 30G X 5/16" 1 ML
- SB INSULIN SYRINGE 31G X 5/16" 1 ML
- SECURESAFE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SECURESAFE INSULIN SYRINGE 29G X 1/2" 1 ML
- SECURESAFE SAFETY PEN NEEDLES 30G X 8 MM
- SM ALCOHOL PREP PAD
- SM ALCOHOL PREP PAD 6-70 % EXTERNAL
- SM ALCOHOL PREP PAD 70 %
- SM GAUZE PAD 2"X2"
- STERILE GAUZE PAD 2"X2"
- STERILE PAD 2"X2"
- SURE COMFORT ALCOHOL PREP PAD 70 %
- SURE COMFORT INSULIN SYRINGE 28G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 28G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 0.3 ML

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 1 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- SURE COMFORT PEN NEEDLES 29G X 12.7MM
- SURE COMFORT PEN NEEDLES 30G X 8 MM
- SURE COMFORT PEN NEEDLES 31G X 5 MM
- SURE COMFORT PEN NEEDLES 31G X 6 MM
- SURE COMFORT PEN NEEDLES 31G X 8 MM
- SURE COMFORT PEN NEEDLES 32G X 4 MM (OTC)
- SURE COMFORT PEN NEEDLES 32G X 4 MM (RX)
- SURE COMFORT PEN NEEDLES 32G X 6 MM
- SURE-JECT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- SURE-JECT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- SURE-JECT INSULIN SYRINGE 31G X 5/16" 1 ML
- SURE-PREP ALCOHOL PREP PAD 70 %
- SURGICAL GAUZE SPONGE PAD 2"X2"
- TECHLITE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- TECHLITE PEN NEEDLES 32G X 4 MM
- THERAGAUZE PAD 2"X2"
- TODAYS HEALTH PEN NEEDLES 29G X 12MM
- TODAYS HEALTH SHORT PEN NEEDLE 31G X 8 MM
- TOPCARE CLICKFINE PEN NEEDLES 31G X 6 MM
- TOPCARE CLICKFINE PEN NEEDLES 31G X 8 MM
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 1 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 1 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 0.3 ML

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

## Provider Partners Health Plan

### 2025 Formulary – Prior Authorization Criteria

- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 1 ML
- TRUE COMFORT ALCOHOL PREP PADS PAD 70 %
- TRUE COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- TRUE COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- TRUE COMFORT INSULIN SYRINGE 32G X 5/16" 1 ML
- TRUE COMFORT PEN NEEDLES 31G X 5 MM
- TRUE COMFORT PEN NEEDLES 31G X 6 MM
- TRUE COMFORT PEN NEEDLES 32G X 4 MM
- TRUE COMFORT PRO ALCOHOL PREP PAD 70 %
- TRUE COMFORT PRO INSULIN SYR 30G X 1/2" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 1/2" 1 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 30G X 5/16" 1 ML
- TRUE COMFORT PRO INSULIN SYR 31G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 31G X 5/16" 1 ML
- TRUE COMFORT PRO INSULIN SYR 32G X 5/16" 0.5 ML
- TRUE COMFORT PRO INSULIN SYR 32G X 5/16" 1 ML
- TRUE COMFORT PRO PEN NEEDLES 31G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 31G X 6 MM
- TRUE COMFORT PRO PEN NEEDLES 31G X 8 MM
- TRUE COMFORT PRO PEN NEEDLES 32G X 4 MM
- TRUE COMFORT PRO PEN NEEDLES 32G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 32G X 6 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 4 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 5 MM
- TRUE COMFORT PRO PEN NEEDLES 33G X 6 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 29G X 12.7MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 5 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 6 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 8 MM
- TRUEPLUS 5-BEVEL PEN NEEDLES 32G X 4 MM
- TRUEPLUS INSULIN SYRINGE 28G X 1/2" 0.5 ML
- TRUEPLUS INSULIN SYRINGE 28G X 1/2" 1 ML
- TRUEPLUS INSULIN SYRINGE 29G X 1/2" 0.3 ML
- TRUEPLUS INSULIN SYRINGE 29G X 1/2" 0.5 ML

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

- |   |   |
|---|---|
| • TRUEPLUS INSULIN SYRINGE 29G X 1/2" 1 ML      | • ULTICARE INSULIN SYRINGE 30G X 1/2" 0.5 ML        |
| • TRUEPLUS INSULIN SYRINGE 30G X 5/16" 0.3 ML   | • ULTICARE INSULIN SYRINGE 30G X 1/2" 1 ML          |
| • TRUEPLUS INSULIN SYRINGE 30G X 5/16" 0.5 ML   | • ULTICARE INSULIN SYRINGE 30G X 5/16" 0.3 ML       |
| • TRUEPLUS INSULIN SYRINGE 30G X 5/16" 1 ML     | • ULTICARE INSULIN SYRINGE 30G X 5/16" 0.5 ML (OTC) |
| • TRUEPLUS INSULIN SYRINGE 31G X 5/16" 0.3 ML   | • ULTICARE INSULIN SYRINGE 30G X 5/16" 0.5 ML (RX)  |
| • TRUEPLUS INSULIN SYRINGE 31G X 5/16" 0.5 ML   | • ULTICARE INSULIN SYRINGE 30G X 5/16" 1 ML         |
| • TRUEPLUS INSULIN SYRINGE 31G X 5/16" 1 ML     | • ULTICARE INSULIN SYRINGE 31G X 1/4" 0.3 ML        |
| • TRUEPLUS PEN NEEDLES 29G X 12MM               | • ULTICARE INSULIN SYRINGE 31G X 1/4" 0.5 ML        |
| • TRUEPLUS PEN NEEDLES 31G X 5 MM               | • ULTICARE INSULIN SYRINGE 31G X 1/4" 1 ML          |
| • TRUEPLUS PEN NEEDLES 31G X 6 MM               | • ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML (OTC) |
| • TRUEPLUS PEN NEEDLES 31G X 8 MM               | • ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML (RX)  |
| • TRUEPLUS PEN NEEDLES 32G X 4 MM               | • ULTICARE INSULIN SYRINGE 31G X 5/16" 0.5 ML (OTC) |
| • ULTICARE INSULIN SAFETY SYR 29G X 1/2" 0.5 ML | • ULTICARE INSULIN SYRINGE 31G X 5/16" 0.5 ML (RX)  |
| • ULTICARE INSULIN SAFETY SYR 29G X 1/2" 1 ML   | • ULTICARE INSULIN SYRINGE 31G X 5/16" 1 ML         |
| • ULTICARE INSULIN SYRINGE 28G X 1/2" 0.5 ML    | • ULTICARE MICRO PEN NEEDLES 32G X 4 MM             |
| • ULTICARE INSULIN SYRINGE 28G X 1/2" 1 ML      | • ULTICARE MINI PEN NEEDLES 30G X 5 MM              |
| • ULTICARE INSULIN SYRINGE 29G X 1/2" 0.3 ML    | • ULTICARE MINI PEN NEEDLES 31G X 6 MM              |
| • ULTICARE INSULIN SYRINGE 29G X 1/2" 0.5 ML    | • ULTICARE MINI PEN NEEDLES 32G X 6 MM              |
| • ULTICARE INSULIN SYRINGE 29G X 1/2" 1 ML      | • ULTICARE PEN NEEDLES 29G X 12.7MM (OTC)           |
| • ULTICARE INSULIN SYRINGE 30G X 1/2" 0.3 ML    | • ULTICARE PEN NEEDLES 29G X 12.7MM (RX)            |

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**



## Provider Partners Health Plan

### 2025 Formulary – Prior Authorization Criteria

- ULTICARE PEN NEEDLES 31G X 5 MM
- ULTICARE SHORT PEN NEEDLES 30G X 8 MM
- ULTICARE SHORT PEN NEEDLES 31G X 8 MM (OTC)
- ULTICARE SHORT PEN NEEDLES 31G X 8 MM (RX)
- ULTIGUARD SAFEPAK PEN NEEDLE 29G X 12.7MM
- ULTIGUARD SAFEPAK PEN NEEDLE 31G X 5 MM
- ULTIGUARD SAFEPAK PEN NEEDLE 31G X 6 MM
- ULTIGUARD SAFEPAK PEN NEEDLE 31G X 8 MM
- ULTIGUARD SAFEPAK PEN NEEDLE 32G X 4 MM
- ULTIGUARD SAFEPAK PEN NEEDLE 32G X 6 MM
- ULTIGUARD SAFEPAK SYR/NEEDLE 30G X 1/2" 0.3 ML
- ULTIGUARD SAFEPAK SYR/NEEDLE 30G X 1/2" 0.5 ML
- ULTIGUARD SAFEPAK SYR/NEEDLE 30G X 1/2" 1 ML
- ULTIGUARD SAFEPAK SYR/NEEDLE 31G X 5/16" 0.3 ML
- ULTIGUARD SAFEPAK SYR/NEEDLE 31G X 5/16" 0.5 ML
- ULTIGUARD SAFEPAK SYR/NEEDLE 31G X 5/16" 1 ML
- ULTILET ALCOHOL SWABS PAD
- ULTILET PEN NEEDLE 29G X 12.7MM
- ULTILET PEN NEEDLE 31G X 5 MM
- ULTILET PEN NEEDLE 31G X 8 MM
- ULTILET PEN NEEDLE 32G X 4 MM
- ULTRA COMFORT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN PEN NEEDLES 29G X 12MM
- ULTRA FLO INSULIN PEN NEEDLES 31G X 8 MM
- ULTRA FLO INSULIN PEN NEEDLES 32G X 4 MM
- ULTRA FLO INSULIN PEN NEEDLES 33G X 4 MM
- ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYR 1/2 UNIT 31G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTRA THIN PEN NEEDLES 32G X 4 MM
- ULTRA-COMFORT INSULIN SYRINGE 29G X 1/2" 0.5 ML

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 0.3 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 1 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 0.3 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 1 ML
- ULTRA-THIN II INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA-THIN II INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTRA-THIN II MINI PEN NEEDLE 31G X 5 MM
- ULTRA-THIN II PEN NEEDLE SHORT 31G X 8 MM
- ULTRA-THIN II PEN NEEDLES 29G X 12.7MM
- ULTRACARE INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTRACARE INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTRACARE PEN NEEDLES 31G X 5 MM
- ULTRACARE PEN NEEDLES 31G X 6 MM
- ULTRACARE PEN NEEDLES 31G X 8 MM
- ULTRACARE PEN NEEDLES 32G X 4 MM
- ULTRACARE PEN NEEDLES 32G X 5 MM
- ULTRACARE PEN NEEDLES 32G X 6 MM
- ULTRACARE PEN NEEDLES 33G X 4 MM
- UNIFINE OTC PEN NEEDLES 31G X 5 MM
- UNIFINE OTC PEN NEEDLES 32G X 4 MM
- UNIFINE PEN NEEDLES 32G X 4 MM
- UNIFINE PENTIPS 29G X 12MM
- UNIFINE PENTIPS 31G X 6 MM
- UNIFINE PENTIPS 31G X 8 MM
- UNIFINE PENTIPS 32G X 4 MM
- UNIFINE PENTIPS PLUS 29G X 12MM
- UNIFINE PENTIPS PLUS 31G X 6 MM
- UNIFINE PENTIPS PLUS 32G X 4 MM
- UNIFINE PROTECT PEN NEEDLE 30G X 5 MM
- UNIFINE PROTECT PEN NEEDLE 30G X 8 MM
- UNIFINE PROTECT PEN NEEDLE 32G X 4 MM
- UNIFINE SAFECONTROL PEN NEEDLE 30G X 5 MM
- UNIFINE SAFECONTROL PEN NEEDLE 30G X 8 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 5 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 6 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 8 MM

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

- UNIFINE SAFECONTROL PEN NEEDLE 32G X 4 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 5 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 6 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 8 MM
- UNIFINE ULTRA PEN NEEDLE 32G X 4 MM
- VALUE HEALTH INSULIN SYRINGE 29G X 1/2" 0.5 ML
- VALUE HEALTH INSULIN SYRINGE 29G X 1/2" 1 ML
- VANISHPOINT INSULIN SYRINGE 29G X 5/16" 1 ML
- VANISHPOINT INSULIN SYRINGE 30G X 3/16" 0.5 ML
- VANISHPOINT INSULIN SYRINGE 30G X 3/16" 1 ML
- VANISHPOINT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- VANISHPOINT INSULIN SYRINGE 30G X 5/16" 1 ML
- VERIFINE INSULIN PEN NEEDLE 29G X 12MM
- VERIFINE INSULIN PEN NEEDLE 31G X 5 MM
- VERIFINE INSULIN PEN NEEDLE 32G X 6 MM
- VERIFINE INSULIN SYRINGE 28G X 1/2" 1 ML
- VERIFINE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- VERIFINE INSULIN SYRINGE 29G X 1/2" 1 ML
- VERIFINE INSULIN SYRINGE 30G X 1/2" 1 ML
- VERIFINE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- VERIFINE INSULIN SYRINGE 30G X 5/16" 1 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- VERIFINE INSULIN SYRINGE 31G X 5/16" 1 ML
- VERIFINE PLUS PEN NEEDLE 31G X 5 MM
- VERIFINE PLUS PEN NEEDLE 31G X 8 MM
- VERIFINE PLUS PEN NEEDLE 32G X 4 MM
- VP INSULIN SYRINGE 29G X 1/2" 0.3 ML
- WEBCOL ALCOHOL PREP LARGE PAD 70 %
- WEGMANS UNIFINE PENTIPS PLUS 31G X 8 MM
- ZEVRX STERILE ALCOHOL PREP PAD 70 %

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	LIFETIME
<b>Other Criteria</b>	ONLY COVERED UNDER PART D WHEN USED CONCURRENTLY WITH INSULIN.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated:11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **INTERFERON FOR MS-AVONEX**

---

**Products Affected**

- AVONEX PEN INTRAMUSCULAR  
  AUTO-INJECTOR KIT
- AVONEX PREFILLED  
  INTRAMUSCULAR PREFILLED  
  SYRINGE KIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **INTERFERON FOR MS-BETASERON**

---

**Products Affected**

- BETASERON SUBCUTANEOUS KIT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **INTERFERON FOR MS-PLEGRIDY**

---

**Products Affected**

- PLEGRIDY STARTER PACK  
SUBCUTANEOUS SOLUTION AUTO-  
INJECTOR
- PLEGRIDY STARTER PACK  
SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE
- PLEGRIDY SUBCUTANEOUS  
SOLUTION AUTO-INJECTOR
- PLEGRIDY SUBCUTANEOUS  
SOLUTION PREFILLED SYRINGE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **INTERFERON GAMMA-1B**

**Products Affected**

- ACTIMMUNE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: CHRONIC GRANULOMATOUS DISEASE (CGD): PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, INFECTIOUS DISEASE SPECIALIST, OR IMMUNOLOGIST. SEVERE MALIGNANT OSTEOPECTOSIS (SMO): PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST OR HEMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	RENEWAL: CGD, SMO: 1) DEMONSTRATED CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) HAS NOT RECEIVED HEMATOPOIETIC CELL TRANSPLANTATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## IPILIMUMAB

### Products Affected

- YERVOY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: UNRESECT/MET MEL: 4MO, RCC/CRC/HCC: 3MO, ALL OTHERS: 12MO. INITIAL/RENEWAL: CUTAN MEL: 6MO
Other Criteria	RENEWAL: ADJUVANT CUTANEOUS MELANOMA: NO EVIDENCE OF DISEASE RECURRENCE (DEFINED AS THE APPEARANCE OF ONE OR MORE NEW MELANOMA LESIONS: LOCAL, REGIONAL OR DISTANT METASTASIS). THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## ISAVUCONAZONIUM

---

**Products Affected**

- CRESEMBA ORAL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INVASIVE ASPERGILLOSIS, INVASIVE MUCORMYCOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN INFECTIOUS DISEASE SPECIALIST.
Coverage Duration	6 MONTHS
Other Criteria	INVASIVE ASPERGILLOSIS: TRIAL OF OR CONTRAINDICATION TO VORICONAZOLE. CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE REQUIRES NO EXTRA CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **IVACAFTOR**

---

**Products Affected**

- KALYDECO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	CYSTIC FIBROSIS (CF): INITIAL: CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CYSTIC FIBROSIS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT
<b>Coverage Duration</b>	INITIAL: 12 MONTHS. RENEWAL: LIFETIME
<b>Other Criteria</b>	CF: INITIAL: NOT HOMOZYGOUS FOR F508DEL MUTATION IN CFTR GENE. RENEWAL: IMPROVEMENT IN CLINICAL STATUS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **IVOSIDENIB**

---

**Products Affected**

- TIBSOVO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **IXAZOMIB**

---

**Products Affected**

- NINLARO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## LANREOTIDE

### Products Affected

- LANREOTIDE ACETATE
- SOMATULINE DEPOT  
SUBCUTANEOUS SOLUTION 60  
MG/0.2ML, 90 MG/0.3ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	ACROMEGALY: INITIAL: THERAPY IS PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	ACROMEGALY: INITIAL: 3 MOS, RENEWAL: 12 MOS.GEP-NETS, CARCINOID SYNDROME: 12 MOS.
Other Criteria	ACROMEGALY: INITIAL: TRIAL OF OR CONTRAINDICATION TO ONE GENERIC OCTREOTIDE INJECTION. RENEWAL: 1) REDUCTION, NORMALIZATION, OR MAINTENANCE OF IGF-1 LEVELS BASED ON AGE AND GENDER, AND 2) IMPROVEMENT OR SUSTAINED REMISSION OF CLINICAL SYMPTOMS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated:11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## LAPATINIB

---

**Products Affected**

- *lapatinib ditosylate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## LAROTRECTINIB

**Products Affected**

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	VITRAKVI ORAL SOLUTION: 1) TRIAL OF VITRAKVI CAPSULES, OR 2) UNABLE TO TAKE CAPSULE FORMULATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **LAZERTINIB**

---

**Products Affected**

- LAZCLUZE ORAL TABLET 240 MG,  
80 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## LEDIPASVIR-SOFOSBUVIR

### Products Affected

- HARVONI ORAL PACKET 33.75-150 MG, 45-200 MG
- HARVONI ORAL TABLET
- *ledipasvir-sofosbuvir*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
Other Criteria	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, AND 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING: CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, ROSUVASTATIN, TIPRANAVIR/RITONAVIR, SOFOSBUVIR (AS A SINGLE AGENT), EPCLUSA, ZEPATIER, MAVYRET, OR VOSEVI.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## LENALIDOMIDE

---

**Products Affected**

- *lenalidomide*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## LENVATINIB

### Products Affected

- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## LETERMOVIR

### Products Affected

- PREVYMIS ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	HSCT: NOT AT RISK FOR LATE CMV: 4 MOS, AT RISK FOR LATE CMV: 7 MOS. KIDNEY TRANSPLANT: 7 MOS.
Other Criteria	HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): 1) THERAPY WILL BE INITIATED BETWEEN DAY 0 AND DAY 28 POST TRANSPLANT, AND 2) WILL NOT RECEIVE THE MEDICATION BEYOND 100 DAYS POST TRANSPLANT IF NOT AT RISK FOR LATE CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE, OR BEYOND 200 DAYS POST TRANSPLANT IF AT RISK FOR LATE CMV INFECTION AND DISEASE. KIDNEY TRANSPLANT: 1) THERAPY WILL BE INITIATED BETWEEN DAY 0 AND DAY 7 POST TRANSPLANT, AND 2) WILL NOT RECEIVE THE MEDICATION BEYOND 200 DAYS POST TRANSPLANT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## LEUPROLIDE

---

**Products Affected**

- *leuprolide acetate injection*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	PROSTATE CANCER: 12 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## LEUPROLIDE DEPOT

---

**Products Affected**

- LEUPROLIDE ACETATE (3 MONTH)
- LUTRATE DEPOT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **LEUPROLIDE-ELIGARD**

---

**Products Affected**

- ELIGARD

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## LEUPROLIDE-LUPRON DEPOT

### Products Affected

- LUPRON DEPOT (1-MONTH)
- LUPRON DEPOT (3-MONTH)
- LUPRON DEPOT (4-MONTH)
- LUPRON DEPOT (6-MONTH)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: ENDOMETRIOSIS: DIAGNOSIS IS CONFIRMED VIA SURGICAL OR DIRECT VISUALIZATION (E.G., PELVIC ULTRASOUND) OR HISTOPATHOLOGICAL CONFIRMATION (E.G., LAPAROSCOPY OR LAPAROTOMY) IN THE LAST 10 YEARS.
Age Restrictions	
Prescriber Restrictions	INITIAL: ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.
Coverage Duration	PROSTATE CA: 12 MOS. UTERINE FIBROIDS: 3 MOS. ENDOMETRIOSIS: INITIAL/RENEWAL: 6 MOS.
Other Criteria	INITIAL: ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME. RENEWAL: ENDOMETRIOSIS: 1) IMPROVEMENT OF PAIN RELATED TO ENDOMETRIOSIS WHILE ON THERAPY, 2) RECEIVING CONCOMITANT ADD-BACK THERAPY (I.E., COMBINATION ESTROGEN-PROGESTIN OR PROGESTIN-ONLY CONTRACEPTIVE PREPARATION), 3) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, AND 4) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## LEUPROLIDE-LUPRON DEPOT-PED

**Products Affected**

- LUPRON DEPOT-PED (3-MONTH)
- LUPRON DEPOT-PED (6-MONTH)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	CENTRAL PRECOCIOUS PUBERTY (CPP): INITIAL: FEMALES: ELEVATED LEVELS OF FOLLICLE-STIMULATING HORMONE (FSH) GREATER THAN 4.0 MIU/ML AND LUTEINIZING HORMONE (LH) LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS. MALES: ELEVATED LEVELS OF FSH GREATER THAN 5.0 MIU/ML AND LH LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS.
Age Restrictions	
Prescriber Restrictions	CPP: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	CPP: INITIAL: FEMALES: 1) YOUNGER THAN 8 YEARS OF AGE AT ONSET OF CPP, AND 2) AT TANNER STAGE 2 OR ABOVE FOR BREAST DEVELOPMENT AND PUBIC HAIR GROWTH. MALES: 1) YOUNGER THAN 9 YEARS OF AGE AT ONSET OF CPP, AND 2) AT TANNER STAGE 2 OR ABOVE FOR GENITAL DEVELOPMENT AND PUBIC HAIR GROWTH. RENEWAL: 1) TANNER STAGING AT INITIAL DIAGNOSIS HAS STABILIZED OR REGRESSED DURING THREE SEPARATE MEDICAL VISITS IN THE PREVIOUS YEAR, AND 2) HAS NOT REACHED ACTUAL AGE WHICH CORRESPONDS TO CURRENT PUBERTAL AGE. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## L-GLUTAMINE

### Products Affected

- *l-glutamine oral packet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	SICKLE CELL DISEASE(SCD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST
Coverage Duration	INITIAL: 12 MONTHS. RENEWAL: LIFETIME.
Other Criteria	SCD: INITIAL: AGES 18 YEARS OR OLDER: 1) AT LEAST 2 SICKLE CELL CRISES IN THE PAST YEAR, 2) SICKLE-CELL ASSOCIATED SYMPTOMS WHICH ARE INTERFERING WITH ACTIVITIES OF DAILY LIVING, OR 3) HISTORY OF OR HAS RECURRENT ACUTE CHEST SYNDROME. AGES 5 TO 17 YEARS: APPROVED WITHOUT ADDITIONAL CRITERIA. RENEWAL: MAINTAINED OR EXPERIENCED A REDUCTION IN ACUTE COMPLICATIONS OF SCD.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **LIDOCAINE OINTMENT**

---

**Products Affected**

- *lidocaine external ointment 5 %*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **LIDOCAINE PATCH**

---

**Products Affected**

- *lidocaine external patch 5 %*
- *lidocan*
- ZTLIDO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	1) PAIN ASSOCIATED WITH POST-HERPETIC NEURALGIA, 2) NEUROPATHY DUE TO DIABETES MELLITUS, 3) CHRONIC BACK PAIN, OR 4) OSTEOARTHRITIS OF THE KNEE OR HIP.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **LIDOCAINE PRILOCAINE**

---

**Products Affected**

- *lidocaine-prilocaine external cream*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES. INFORMATION MAY NEED TO BE SUBMITTED DESCRIBING THE USE AND SETTING OF THE DRUG TO MAKE THE DETERMINATION.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **LINVOSELTAMAB-GCPT**

---

**Products Affected**

- LYNOZYFIC INTRAVENOUS  
SOLUTION 200 MG/10ML, 5 MG/2.5ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **LONCASTUXIMAB TESIRINE-LPYL**

---

**Products Affected**

- ZYNLONTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **LORLATINIB**

---

**Products Affected**

- LORBRENA ORAL TABLET 100 MG,  
25 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## LOTILANER

---

**Products Affected**

- XDEMVY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	DEMODEX BLEPHARITIS: 18 YEARS OF AGE OR OLDER
Prescriber Restrictions	
Coverage Duration	6 WEEKS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **LUMACAFITOR-IVACAFITOR**

---

**Products Affected**

- ORKAMBI ORAL TABLET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: CYSTIC FIBROSIS (CF): CONFIRMED MUTATION IN CFTR GENE ACCEPTABLE FOR THE TREATMENT OF CF.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CF EXPERT.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS, RENEWAL: LIFETIME.
<b>Other Criteria</b>	CF: RENEWAL: IMPROVEMENT IN CLINICAL STATUS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## MACITENTAN

**Products Affected**

- OPSUMIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
Age Restrictions	
Prescriber Restrictions	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## MARGETUXIMAB-CMKB

---

**Products Affected**

- MARGENZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## MARIBAVIR

---

**Products Affected**

- LIVTENCITY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## MAVACAMTEN

### Products Affected

- CAMZYOS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY(HCM): INITIAL: LEFT VENTRICULAR OUTFLOW TRACK (LVOT) GRADIENT OF 50 MMHG OR HIGHER
Age Restrictions	
Prescriber Restrictions	OBSTRUCTIVE HCM: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST
Coverage Duration	INITIAL: 4 MONTHS, RENEWAL: 12 MONTHS.
Other Criteria	OBSTRUCTIVE HCM: INITIAL: TRIAL OF OR CONTRAINDICATION TO A BETA-BLOCKER OR A NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER. RENEWAL: CONTINUED CLINICAL BENEFIT (E.G., REDUCTION OF SYMPTOMS, NYHA CLASSIFICATION IMPROVEMENT)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## MECASERMIN

### Products Affected

- INCRELEX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST OR NEPHROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF WRIST AND HAND. RENEWAL: IMPROVEMENT WHILE ON THERAPY (I.E., INCREASE IN HEIGHT OR INCREASE IN HEIGHT VELOCITY).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **MECHLORETHAMINE**

---

**Products Affected**

- VALCHLOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## MEPOLIZUMAB

### Products Affected

- NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 40 MG/0.4ML
- NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: ASTHMA: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.
Age Restrictions	
Prescriber Restrictions	INITIAL: ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN PULMONARY OR ALLERGY MEDICINE. CRSWNP: PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. EOSINOPHILIC COPD: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST.
Coverage Duration	INITIAL: ASTHMA, COPD: 12 MO. CRSWNP: 6 MO. OTHERS: 12 MO. RENEWAL: CRSWNP, ASTHMA, COPD: 12 MO.
Other Criteria	INITIAL: ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, 2) ONE OF THE FOLLOWING: (A) AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	<p>THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA, AND 3) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. CRSWNP: 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. EOSINOPHILIC COPD: 1) USED IN COMBINATION WITH A LAMA/LABA/ICS, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. RENEWAL: ASTHMA: 1) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA, 2) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. CRSWNP: 1) CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. EOSINOPHILIC COPD: 1) USED IN COMBINATION WITH A LAMA/LABA/ICS, 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY (A) REDUCTION IN COPD EXACERBATIONS FROM BASELINE, (B) REDUCTION IN SEVERITY OR FREQUENCY OF COPD-RELATED SYMPTOMS, OR (C) INCREASE IN FEV1 OF AT LEAST 5 PERCENT FROM PRETREATMENT BASELINE.</p>
Indications	All FDA-approved Indications.

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## MIDOSTAURIN

---

**Products Affected**

- RYDAPT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ACUTE MYELOID LEUKEMIA: 6 MONTHS. ADVANCED SYSTEMIC MASTOCYTOSIS: 12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## MIFEPRISTONE

### Products Affected

- mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	CUSHINGS SYNDROME (CS): INITIAL: DIAGNOSIS CONFIRMED BY: 1) 24-HR URINE FREE CORTISOL (2 OR MORE TESTS TO CONFIRM), 2) OVERNIGHT 1MG DEXAMETHASONE TEST, OR 3) LATE NIGHT SALIVARY CORTISOL (2 OR MORE TESTS TO CONFIRM).
Age Restrictions	
Prescriber Restrictions	CS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	CS: INITIAL: HYPERCORTISOLISM IS NOT A RESULT OF CHRONIC GLUCOCORTICOIDS. RENEWAL: 1) CONTINUES TO HAVE IMPROVEMENT OF GLUCOSE TOLERANCE OR STABLE GLUCOSE TOLERANCE (E.G., REDUCED A1C, IMPROVED FASTING GLUCOSE, ETC.), 2) CONTINUES TO HAVE TOLERABILITY TO THERAPY, AND 3) CONTINUES TO NOT BE A CANDIDATE FOR SURGICAL TREATMENT OR HAS FAILED SURGERY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## MILTEFOSINE

---

**Products Affected**

- IMPAVIDO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **MIRDAMETINIB**

**Products Affected**

- GOMEKLI ORAL CAPSULE 1 MG, 2 MG
- GOMEKLI ORAL TABLET SOLUBLE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## MIRVETUXIMAB SORAVTANSINE-GYNX

**Products Affected**

- ELAHERE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER: AN OPHTHALMIC EXAM, INCLUDING VISUAL ACUITY AND SLIT LAMP EXAM, WILL BE COMPLETED PRIOR TO THE INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **MOMELOTINIB**

---

**Products Affected**

- OJJAARA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **MOSUNETUZUMAB-AXGB**

### **Products Affected**

- LUNSUMIO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: INITIAL: 6 MONTHS. RENEWAL: 7 MONTHS.
<b>Other Criteria</b>	RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: RENEWAL: 1) HAS ACHIEVED A PARTIAL RESPONSE TO TREATMENT, AND 2) HAS NOT PREVIOUSLY RECEIVED MORE THAN 17 CYCLES OF TREATMENT. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## NARCOLEPSY AGENTS

---

**Products Affected**

- *armodafinil*
- *modafinil oral tablet 100 mg, 200 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **NAXITAMAB-GQGK**

---

**Products Affected**

- DANYELZA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## NERATINIB

---

**Products Affected**

- NERLYNX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	EARLY-STAGE (STAGE I-III) BREAST CANCER: MEDICATION IS BEING REQUESTED WITHIN 2 YEARS OF COMPLETING THE LAST TRASTUZUMAB DOSE. ALL OTHER FDA APPROVED INDICATIONS ARE COVERED WITHOUT ADDITIONAL CRITERIA, EXCEPT THOSE CRITERIA IN THE FDA APPROVED LABEL.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## NILOTINIB

### Products Affected

- TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND REQUESTED MEDICATION IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **NILOTINIB-DANZITEN**

**Products Affected**

- DANZITEN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): 1) PERFORMED MUTATIONAL ANALYSIS PRIOR TO INITIATION OF THERAPY, AND 2) THERAPY IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## NINTEDANIB

### Products Affected

- OFEV

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: IDIOPATHIC PULMONARY FIBROSIS (IPF): 1) A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT, AND 2) BASELINE FORCED VITAL CAPACITY (FVC) AT LEAST 50% OF PREDICTED VALUE. SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): 1) AT LEAST 10% FIBROSIS ON A CHEST HRCT, AND 2) BASELINE FVC AT LEAST 40% OF PREDICTED VALUE. CHRONIC FIBROSING INTERSTITIAL LUNG DISEASE WITH A PROGRESSIVE PHENOTYPE (PF-ILD): 1) AT LEAST 10% FIBROSIS ON A CHEST HRCT, AND 2) BASELINE FVC AT LEAST 45% OF PREDICTED VALUE.
Age Restrictions	
Prescriber Restrictions	INITIAL: IPF: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST. SSC-ILD, PF-ILD: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR RHEUMATOLOGIST.
Coverage Duration	INITIAL: SSC-ILD: 6 MOS. IPF, PF-ILD: 12 MOS. RENEWAL (ALL INDICATIONS): 12 MOS.
Other Criteria	INITIAL: IPF: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS), AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: ESBRIET (PIRFENIDONE). SSC-ILD: 1) DOES NOT HAVE OTHER

Y0135\_PA25\_C

Formulary ID: 25261

Last Updated: 11/26/2025

Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., HEART FAILURE/FLUID OVERLOAD, DRUG-INDUCED LUNG TOXICITY, RECURRENT ASPIRATION), AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: ACTEMRA SUBQ. PF-ILD: LUNG FUNCTION AND RESPIRATORY SYMPTOMS OR CHEST IMAGING HAVE WORSENERD/PROGRESSED DESPITE TREATMENT WITH MEDICATIONS USED IN CLINICAL PRACTICE FOR ILD (NOT ATTRIBUTABLE TO COMORBIDITIES SUCH AS INFECTION, HEART FAILURE). RENEWAL: IPF, SSC-ILD, PF-ILD: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated:11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## NIRAPARIB

---

**Products Affected**

- ZEJULA ORAL CAPSULE
- ZEJULA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER: 1) ZEJULA WILL BE USED AS MONOTHERAPY, AND 2) ZEJULA IS STARTED NO LATER THAN 8 WEEKS AFTER THE MOST RECENT PLATINUM-CONTAINING REGIMEN.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## NIRAPARIB-ABIRATERONE

### Products Affected

- AKEEGA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **NIROGACESTAT**

---

**Products Affected**

- OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## NITISINONE

### Products Affected

- *nitisinone*
- ORFADIN ORAL SUSPENSION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HEREDITARY TYROSINEMIA TYPE 1 (HT-1): INITIAL: DIAGNOSIS CONFIRMED BY ELEVATED URINARY OR PLASMA SUCCINYLACETONE LEVELS OR A MUTATION IN THE FUMARYLACETOACETATE HYDROLASE GENE. RENEWAL: URINARY OR PLASMA SUCCINYLACETONE LEVELS HAVE DECREASED FROM BASELINE WHILE ON TREATMENT WITH NITISINONE.
Age Restrictions	
Prescriber Restrictions	HT-1: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PRESCRIBER SPECIALIZING IN INHERITED METABOLIC DISEASES.
Coverage Duration	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
Other Criteria	HT-1: INITIAL: ORFADIN SUSPENSION: TRIAL OF OR CONTRAINDICATION TO PREFERRED NITISINONE TABLETS OR CAPSULES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## NIVOLUMAB

**Products Affected**

- OPDIVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	UNRESECTABLE OR METASTATIC MELANOMA: NO CONCURRENT USE WITH TARGETED THERAPY (I.E., BRAF INHIBITORS, MEK INHIBITORS, AND NTRK INHIBITORS).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **NIVOLUMAB-HYALURONIDASE-NVHY**

---

**Products Affected**

- OPDIVO QVANTIG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **NIVOLUMAB-RELATLIMAB-RMBW**

---

**Products Affected**

- OPDUALAG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **NOGAPENDEKIN ALFA**

---

**Products Affected**

- ANKTIVA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	40 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **OCRELIZUMAB**

---

**Products Affected**

- OCREVUS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	RELAPSING FORM OF MULTIPLE SCLEROSIS (MS): TRIAL OF TWO AGENTS INDICATED FOR THE TREATMENT OF RELAPSING FORMS OF MS. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **OCRELIZUMAB-HYALURONIDASE-OCSQ**

---

**Products Affected**

- OCREVUS ZUNOVO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	RELAPSING FORM OF MULTIPLE SCLEROSIS (MS): TRIAL OF TWO AGENTS INDICATED FOR THE TREATMENT OF RELAPSING FORMS OF MS. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## OFATUMUMAB-SQ

---

**Products Affected**

- KESIMPTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **OLANZAPINE/SAMIDORPHAN**

### **Products Affected**

- LYBALVI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	SCHIZOPHRENIA, BIPOLAR I: PRESCRIBED BY OR IN CONSULTATION WITH A PSYCHIATRIST
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	SCHIZOPHRENIA: 1) AT HIGH RISK FOR WEIGHT GAIN, AND 2) TRIAL OF OR CONTRAINDICATION TO A FORMULARY VERSION OF LURASIDONE OR ONE OF THE FOLLOWING ORAL ANTIPSYCHOTICS: RISPERIDONE, CLOZAPINE TABLET, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE. BIPOLAR I: 1) AT HIGH RISK FOR WEIGHT GAIN, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING ORAL ANTIPSYCHOTICS: RISPERIDONE, OLANZAPINE, IMMEDIATE RELEASE QUETIAPINE FUMARATE, ZIPRASIDONE, ARIPIPRAZOLE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## OLAPARIB

### Products Affected

- LYNPARZA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER: MEDICATION WILL BE USED AS MONOTHERAPY. METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. ALL OTHER FDA APPROVED INDICATIONS ARE COVERED WITHOUT ADDITIONAL CRITERIA, EXCEPT THOSE CRITERIA IN THE FDA APPROVED LABEL.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **OLUTASIDENIB**

---

**Products Affected**

- REZLIDHIA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## OMACETAXINE

---

**Products Affected**

- SYNRIBO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## OMALIZUMAB

### Products Affected

- XOLAIR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: ASTHMA: POSITIVE SKIN PRICK OR BLOOD TEST (E.G., ELISA, FEIA) TO A PERENNIAL AEROALLERGEN AND A BASELINE IGE SERUM LEVEL OF AT LEAST 30 IU/ML. FOOD ALLERGY: 1) IGE SERUM LEVEL OF AT LEAST 30 IU/ML, AND 2) ALLERGEN SPECIFIC IGE SERUM LEVEL OF AT LEAST 6 KUA/L TO AT LEAST ONE FOOD, OR POSITIVE SKIN PRICK TEST TO AT LEAST ONE FOOD, OR POSITIVE MEDICALLY MONITORED FOOD CHALLENGE TO AT LEAST ONE FOOD.
Age Restrictions	
Prescriber Restrictions	INITIAL/RENEWAL: CHRONIC SPONTANEOUS URTICARIA (CSU): PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, DERMATOLOGIST, OR IMMUNOLOGIST. INITIAL: CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE. FOOD ALLERGY: PRESCRIBED BY OR IN CONSULTATION WITH ALLERGIST OR IMMUNOLOGIST.
Coverage Duration	INITIAL/RENEWAL: ASTHMA 12 MO/12 MO, CSU 6 MO/12 MO, CRSWNP 6 MO/12 MO, FOOD ALLERGY 12 MO/24 MO
Other Criteria	INITIAL: CSU: 1) TRIAL OF AND MAINTAINED ON, OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE AND 2) STILL EXPERIENCES HIVES OR ANGIOEDEMA ON MOST DAYS OF THE WEEK FOR AT LEAST 6 WEEKS. CRSWNP: 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL

Y0135\_PA25\_C

Formulary ID: 25261

Last Updated: 11/26/2025

Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	<p>CORTICOSTEROID, 2) TRIAL OF OR CONTRAINDICATION TO ONE PREFERRED AGENT: NUCALA, DUPIXENT, AND 3) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, 2) ONE OF THE FOLLOWING: (A) AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA, AND 3) NO CONCURRENT USE WITH DUPIXENT, TEZSPIRE, OR ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. FOOD ALLERGY: 1) CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION, AND 2) NO CONCURRENT USE WITH PEANUT-SPECIFIC IMMUNOTHERAPY. RENEWAL: CSU: MAINTAINED ON OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE. CRSWNP: 1) CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR AN AUTOIMMUNE INDICATION. ASTHMA: 1) NO CONCURRENT USE WITH DUPIXENT, TEZSPIRE, OR ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA, 2) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY ONE OF THE FOLLOWING: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-</p>

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. FOOD ALLERGY: 1) PERSISTENT IGE-MEDIATED FOOD ALLERGY, 2) CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION, AND 3) NO CONCURRENT USE WITH PEANUT-SPECIFIC IMMUNOTHERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated:11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## OSIMERTINIB

---

**Products Affected**

- TAGRISSO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## OXANDROLONE

### Products Affected

- oxandrolone oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	PROTEIN CATABOLISM, BONE PAIN: 1) MONITORED FOR PELIOSIS HEPATIS, LIVER CELL TUMORS, AND BLOOD LIPID CHANGES, 2) DOES NOT HAVE KNOWN OR SUSPECTED: CARCINOMA OF THE PROSTATE OR BREAST IN MALE PATIENTS, CARCINOMA OF THE BREAST IN FEMALES WITH HYPERCALCEMIA, NEPHROSIS (THE NEPHROTIC PHASE OF NEPHRITIS), OR HYPERCALCEMIA, AND 3) DOES NOT HAVE SEVERE HEPATIC DYSFUNCTION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **PACRITINIB**

---

**Products Affected**

- VONJO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	MYELOFIBROSIS: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **PALBOCICLIB**

---

**Products Affected**

- IBRANCE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## PARATHYROID HORMONE

---

**Products Affected**

- NATPARA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HYPOCALCEMIA SECONDARY TO HYPOPARATHYROIDISM: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	HYPOCALCEMIA SECONDARY TO HYPOPARATHYROIDISM: 1) TRIAL OF OR CONTRAINDICATION TO CALCITRIOL, 2) HYPOPARATHYROIDISM IS NOT DUE TO A CALCIUM SENSING RECEPTOR (CSR) MUTATION, AND 3) HYPOPARATHYROIDISM IS NOT CONSIDERED ACUTE POST-SURGICAL HYPOPARATHYROIDISM.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **PASIREOTIDE DIASPARTATE**

---

**Products Affected**

- SIGNIFOR

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CUSHINGS DISEASE (CD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	CD: RENEWAL: 1) CONTINUED IMPROVEMENT OF CUSHINGS DISEASE, AND 2) MAINTAINED TOLERABILITY TO SIGNIFOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## PAZOPANIB

### Products Affected

- *pazopanib hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADVANCED SOFT TISSUE SARCOMA (STS): NOT USED FOR ADIPOCYTIC STS OR GASTROINTESTINAL STROMAL TUMORS (GIST)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **PEGFILGRASTIM - APGF**

---

**Products Affected**

- NYVEPRIA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **PEGFILGRASTIM-NEULASTA ONPRO**

---

**Products Affected**

- NEULASTA ONPRO SUBCUTANEOUS  
SOLUTION PREFILLED SYRINGE

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## PEGINTERFERON ALFA-2A

### Products Affected

- PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML
- PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HEPATITIS B: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, OR PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (E.G., HEPATOLOGIST).
Coverage Duration	HEP B/HEP C: 48 WEEKS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## PEGVISOMANT

---

**Products Affected**

- SOMAVERT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **PEMBROLIZUMAB**

---

**Products Affected**

- KEYTRUDA INTRAVENOUS SOLUTION

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	UNRESECTABLE OR METASTATIC MELANOMA: NO CONCURRENT USE WITH TARGETED THERAPY (I.E., BRAF INHIBITORS, MEK INHIBITORS, AND NTRK INHIBITORS).
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **PEMBROLIZUMAB-BERAHYALURONIDASE ALFA-PMPH**

---

**Products Affected**

- KEYTRUDA QLEX

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## PEMIGATINIB

### Products Affected

- PEMAZYRE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	CHOLANGIOCARCINOMA, MYELOID/LYMPHOID NEOPLASMS: COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), WILL BE COMPLETED PRIOR TO INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## PENICILLAMINE TABLET

### Products Affected

- *penicillamine oral tablet*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: CYSTINURIA: HAS NEPHROLITHIASIS AND ONE OF THE FOLLOWING: 1) STONE ANALYSIS SHOWING PRESENCE OF CYSTINE, 2) PRESENCE OF PATHOGNOMONIC HEXAGONAL CYSTINE CRYSTALS ON URINALYSIS, OR 3) FAMILY HISTORY OF CYSTINURIA AND POSITIVE CYANIDE-NITROPRUSSIDE SCREENING.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: WILSONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST. CYSTINURIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEPHROLOGIST. RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
<b>Coverage Duration</b>	INITIAL: 12 MONTHS, RENEWAL: LIFETIME.
<b>Other Criteria</b>	INITIAL: WILSONS DISEASE: 1) LEIPZIG SCORE OF 4 OR GREATER. RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, AND 2) TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. RENEWAL: RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, AND 2) EXPERIENCED OR MAINTAINED IMPROVEMENT IN TENDER JOINT COUNT OR SWOLLEN JOINT COUNT COMPARED TO BASELINE. WILSONS

Y0135\_PA25\_C

Formulary ID: 25261

Last Updated: 11/26/2025

Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	DISEASE, CYSTINURIA: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## PEXIDARTINIB

---

**Products Affected**

- TURALIO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## PIMAVANSERIN

**Products Affected**

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	PSYCHOSIS IN PARKINSONS DISEASE (PD): INITIAL: 18 YEARS OR OLDER
Prescriber Restrictions	PSYCHOSIS IN PD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, GERIATRICIAN, OR A BEHAVIORAL HEALTH SPECIALIST (E.G., PSYCHIATRIST).
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	PSYCHOSIS IN PD: RENEWAL: IMPROVEMENT IN PSYCHOSIS SYMPTOMS FROM BASELINE AND DEMONSTRATES A CONTINUED NEED FOR TREATMENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## PIRFENIDONE

### Products Affected

- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 534 mg, 801 mg*

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	IDIOPATHIC PULMONARY FIBROSIS (IPF): INITIAL: 1) A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT, AND 2) PREDICTED FORCED VITAL CAPACITY (FVC) OF AT LEAST 50% AT BASELINE.
<b>Age Restrictions</b>	IPF: INITIAL: 18 YEARS OR OLDER.
<b>Prescriber Restrictions</b>	IPF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	IPF: INITIAL: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS, SYSTEMIC SCLEROSIS, RHEUMATOID ARTHRITIS, RADIATION, SARCOIDOSIS, BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION, VIRAL HEPATITIS, OR CANCER). RENEWAL: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **PIRTOBRUTINIB**

---

**Products Affected**

- JAYPIRCA ORAL TABLET 100 MG, 50 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **POMALIDOMIDE**

---

**Products Affected**

- POMALYST

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## PONATINIB

### Products Affected

- ICLUSIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	CHRONIC MYELOID LEUKEMIA (CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND ICLUSIG IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **POSACONAZOLE TABLET**

---

**Products Affected**

- *posaconazole oral tablet delayed release*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE, PROPHYLAXIS: 6 MONTHS. TREATMENT: 12 WEEKS.
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **PRALSETINIB**

---

**Products Affected**

- GAVRETO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## PYRIMETHAMINE

### Products Affected

- *pyrimethamine oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	TOXOPLASMOSIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN INFECTIOUS DISEASE SPECIALIST.
Coverage Duration	TOXOPLASMOSIS: INITIAL: 8 WEEKS, RENEWAL: 6 MOS.
Other Criteria	TOXOPLASMOSIS: RENEWAL: ONE OF THE FOLLOWING: (1) PERSISTENT CLINICAL DISEASE (HEADACHE, NEUROLOGICAL SYMPTOMS, OR FEVER) AND PERSISTENT RADIOGRAPHIC DISEASE (ONE OR MORE MASS LESIONS ON BRAIN IMAGING), OR (2) CD4 COUNT LESS THAN 200 CELLS/MM3 AND CURRENTLY TAKING AN ANTI-RETROVIRAL THERAPY IF HIV POSITIVE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## QUININE

---

**Products Affected**

- *quinine sulfate oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## QUIZARTINIB

---

**Products Affected**

- VANFLYTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## REGORAFENIB

---

**Products Affected**

- STIVARGA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## RELUGOLIX

---

**Products Affected**

- ORGOVYX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **REPOTRECTINIB**

---

**Products Affected**

- AUGTYRO ORAL CAPSULE 160 MG,  
40 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## RESLIZUMAB

### Products Affected

- CINQAIR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	ASTHMA: INITIAL: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.
Age Restrictions	
Prescriber Restrictions	ASTHMA: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	ASTHMA: INITIAL: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING 3 OR MORE DAYS WITHIN THE PAST 12 MONTHS, OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA, 3) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: FASENRA, NUCALA, DUPIXENT, AND 4)

Y0135\_PA25\_C

Formulary ID: 25261

Last Updated: 11/26/2025

Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA. RENEWAL: 1) NO CONCURRENT USE WITH XOLAIR, DUPIXENT, TEZSPIRE, OR OTHER ANTI-IL5 BIOLOGICS WHEN USED FOR ASTHMA, 2) CONTINUED USE OF ICS AND ONE OTHER MAINTENANCE MEDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## RETIFANLIMAB-DLWR

---

**Products Affected**

- ZYNYZ

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## REVUMENIB

---

**Products Affected**

- REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **RIBOCICLIB**

---

**Products Affected**

- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **RIBOCICLIB-LETROZOLE**

---

**Products Affected**

- KISQALI FEMARA (200 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **RIFAXIMIN**

---

**Products Affected**

- XIFAXAN ORAL TABLET 200 MG, 550 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	TRAVELERS DIARRHEA, HEPATIC ENCEPHALOPATHY (HE): 12 MOS. IBS-D: 8 WKS.
<b>Other Criteria</b>	HE: TRIAL OF OR CONTRAINDICATION TO LACTULOSE OR CONCURRENT LACTULOSE THERAPY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## RILONACEPT

### Products Affected

- ARCALYST

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	<p>CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE NLRP3 GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR, SERUM AMYLOID A PROTEIN (SAA) OR S100 PROTEINS), AND 2) TWO OF THE FOLLOWING: URTICARIAL-LIKE RASH (NEUTROPHILIC DERMATITIS), COLD-TRIGGERED EPISODES, SENSORINEURAL HEARING LOSS, MUSCULOSKELETAL SYMPTOMS, CHRONIC ASEPTIC MENINGITIS, SKELETAL ABNORMALITIES.</p> <p>DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE IL1RN GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR), AND 2) ONE OF THE FOLLOWING: PUSTULAR PSORIASIS-LIKE RASHES, OSTEOMYELITIS, ABSENCE OF BACTERIAL OSTEOMYELITIS, ONYCHOMADESIS. RECURRENT PERICARDITIS (RP): TWO OF THE FOLLOWING: CHEST PAIN CONSISTENT WITH PERICARDITIS, PERICARDIAL FRICTION RUB, ECG SHOWING DIFFUSE ST-SEGMENT ELEVATION OR PR-SEGMENT DEPRESSION, NEW OR WORSENING PERICARDIAL EFFUSION.</p>
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CAPS, DIRA: LIFETIME. RP: 12 MONTHS.

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Other Criteria</b>	CAPS: NO CONCURRENT USE WITH OTHER IL-1 INHIBITORS. DIRA: 1) NO CONCURRENT USE WITH OTHER IL-1 INHIBITORS, AND 2) TRIAL OF THE PREFERRED AGENT: KINERET. RP: 1) HAD AN EPISODE OF ACUTE PERICARDITIS, 2) SYMPTOM-FREE FOR 4 TO 6 WEEKS, AND 3) NO CONCURRENT USE WITH OTHER IL-1 INHIBITORS.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **RILUZOLE**

---

**Products Affected**

- TIGLUTIK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	18 YEARS OR OLDER
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	AMYOTROPHIC LATERAL SCLEROSIS (ALS): (1) TRIAL OF RILUZOLE TABLETS, AND (2) PATIENT IS UNABLE TO TAKE TABLET FORMULATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## RIMEGEPANT

### Products Affected

- NURTEC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	ACUTE MIGRAINE TREATMENT: INITIAL: TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN). INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT. RENEWAL: 1) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR 2) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS. EPISODIC MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **RIOCIGUAT**

### **Products Affected**

- ADEMPAS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PULMONARY ARTERIAL HYPERTENSION (PAH): DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) (WHO GROUP 4): WHO FUNCTIONAL CLASS II-IV SYMPTOMS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PAH, CTEPH: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: PAH: NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PHOSPHODIESTERASE (PDE) INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS. CTEPH: 1) NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PDE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS, AND 2) NOT A CANDIDATE FOR SURGERY OR HAS INOPERABLE CTEPH OR HAS PERSISTENT OR RECURRENT DISEASE AFTER SURGICAL TREATMENT. RENEWAL: PAH, CTEPH: NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PDE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS.
<b>Indications</b>	All FDA-approved Indications.

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **RIPRETINIB**

---

**Products Affected**

- QINLOCK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **RISANKIZUMAB-RZAA**

### **Products Affected**

- SKYRIZI
- SKYRIZI (150 MG DOSE)
- SKYRIZI PEN

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: PLAQUE PSORIASIS (PSO): PLAQUE PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSO. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. CD:

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## RITUXIMAB AND HYALURONIDASE HUMAN-SQ

**Products Affected**

- RITUXAN HYCELA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	FOLLICULAR LYMPHOMA (FL), DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): HAS RECEIVED OR WILL RECEIVE AT LEAST ONE FULL DOSE OF A RITUXIMAB PRODUCT BY INTRAVENOUS INFUSION PRIOR TO INITIATION OF RITUXIMAB AND HYALURONIDASE. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## RITUXIMAB-ABBS

### Products Affected

- TRUXIMA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NON-HODGKINS LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST.
Coverage Duration	RA: INITIAL: 6 MO, RENEWAL: 12 MO. NHL, GPA, MPA, PV: 12 MO. CLL: 6 MO.
Other Criteria	RA: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## RITUXIMAB-ARRX

### Products Affected

- RIABNI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	RHEUMATOID ARTHRITIS (RA): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NON-HODGKINS LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST.
Coverage Duration	RA: INITIAL: 6 MO, RENEWAL: 12 MO. NHL, GPA, MPA, PV: 12 MO. CLL: 6 MO.
Other Criteria	RA: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## RITUXIMAB-PVVR

### Products Affected

- RUXIENCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	RA: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NON-HODGKINS LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST.
Coverage Duration	RA: INITIAL: 6 MO, RENEWAL: 12 MO. NHL, GPA, MPA, PV: 12 MO. CLL: 6 MO.
Other Criteria	RA: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **ROPEGINTERFERON ALFA-2B-NJFT**

---

**Products Affected**

- BESREMI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## RUCAPARIB

---

**Products Affected**

- RUBRACA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: ONE OF THE FOLLOWING: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **RUXOLITINIB**

### **Products Affected**

- JAKAFI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	MYELOFIBROSIS: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. POLYCYTHEMIA VERA, GVHD: 12 MONTHS.
<b>Other Criteria</b>	MYELOFIBROSIS: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## SAPROPTERIN

**Products Affected**

- *javygtor oral tablet*
- *sapropterin dihydrochloride oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 2 MONTHS, RENEWAL 12 MONTHS.
Other Criteria	HYPERPHENYLALANINEMIA (HPA): INITIAL: NO CONCURRENT USE WITH PALYNZIQ. RENEWAL: 1) CONTINUES TO BENEFIT FROM TREATMENT, AND 2) NO CONCURRENT USE WITH PALYNZIQ.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## SECUKINUMAB IV

### Products Affected

- COSENTYX INTRAVENOUS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR A DERMATOLOGIST. ANKYLOSING SPONDYLITIS (AS), NR-AXSPA: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. RENEWAL: PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## SECUKINUMAB SQ

### Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)
- COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML
- COSENTYX UNOREADY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP, OR FACE. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
Age Restrictions	
Prescriber Restrictions	INITIAL: PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR A DERMATOLOGIST. ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, ENTHESITIS-RELATED ARTHRITIS (ERA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	INITIAL: HS: 12 MONTHS, ALL OTHER INDICATIONS: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	<p>PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSO. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. ERA: TRIAL OF OR CONTRAINDICATION TO ONE NSAID, SULFASALAZINE, OR METHOTREXATE. HS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR HS. RENEWAL: PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. ERA, HS: CONTINUES TO BENEFIT FROM THE MEDICATION.</p>
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## SELEXIPAG

### Products Affected

- UPTRAVI INTRAVENOUS
- UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG
- UPTRAVI TITRATION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
Age Restrictions	
Prescriber Restrictions	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	PAH: INITIAL: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING AGENTS FROM DIFFERENT DRUG CLASSES: 1) FORMULARY VERSION OF AN ORAL ENDOTHELIN RECEPTOR ANTAGONIST, 2) FORMULARY VERSION OF AN ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR FOR PAH, 3) FORMULARY VERSION OF AN ORAL CGMP STIMULATOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## SELINEXOR

### Products Affected

- XPOVIO (100 MG ONCE WEEKLY)  
ORAL TABLET THERAPY PACK 50  
MG
- XPOVIO (40 MG ONCE WEEKLY)  
ORAL TABLET THERAPY PACK 10  
MG, 40 MG
- XPOVIO (40 MG TWICE WEEKLY)  
ORAL TABLET THERAPY PACK 40  
MG
- XPOVIO (60 MG ONCE WEEKLY)  
ORAL TABLET THERAPY PACK 60  
MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY)  
ORAL TABLET THERAPY PACK 40  
MG
- XPOVIO (80 MG TWICE WEEKLY)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **SELPERCATINIB**

---

**Products Affected**

- RETEVMO ORAL CAPSULE 40 MG, 80 MG
- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **SELUMETINIB**

---

**Products Affected**

- KOSELUGO ORAL CAPSULE 10 MG, 25 MG
- KOSELUGO ORAL CAPSULE SPRINKLE 5 MG, 7.5 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## SILDENAFIL TABLET

### Products Affected

- sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: AGES 18 YEARS OR OLDER: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. AGES 1 TO 17 YEARS: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PAP GREATER THAN 20 MMHG, 2) PCWP OF 15 MMHG OR LESS, AND 3) PVR OF 3 WOOD UNITS OR GREATER.
Age Restrictions	
Prescriber Restrictions	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	PAH: INITIAL/RENEWAL: 1) NOT CONCURRENTLY OR INTERMITTENTLY TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA) OR ANY ORGANIC NITRATES IN ANY FORM AND 2) NO CONCURRENT USE WITH GUANYLATE CYCLASE STIMULATORS.
Indications	All Medically-accepted Indications.
Off Label Uses	

Y0135\_PA25\_C

Formulary ID: 25261

Last Updated: 11/26/2025

Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **SIPONIMOD**

### **Products Affected**

- MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG
- MAYZENT STARTER PACK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **SIROLIMUS PROTEIN-BOUND**

---

**Products Affected**

- FYARRO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **SODIUM OXYBATE-XYREM**

### **Products Affected**

- *sodium oxybate*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: CATAPLEXY IN NARCOLEPSY, EXCESSIVE DAYTIME SLEEPINESS (EDS) IN NARCOLEPSY: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR SPECIALIST IN SLEEP MEDICINE
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
<b>Other Criteria</b>	INITIAL: EDS IN NARCOLEPSY: 1) NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT, 2) AGES 18 YEARS OR OLDER: TRIAL, FAILURE OF, OR CONTRAINDICATION TO A FORMULARY VERSION OF MODAFINIL, ARMODAFINIL, OR SUNOSI AND ONE GENERIC STIMULANT INDICATED FOR EDS IN NARCOLEPSY, AND 3) AGES 7 TO 17 YEARS: TRIAL, FAILURE OF, OR CONTRAINDICATION TO ONE GENERIC STIMULANT INDICATED FOR EDS IN NARCOLEPSY. CATAPLEXY IN NARCOLEPSY: NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT. RENEWAL: CATAPLEXY IN NARCOLEPSY, EDS IN NARCOLEPSY: 1) SUSTAINED IMPROVEMENT OF SYMPTOMS COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## SOFOSBUVIR/VELPATASVIR

### Products Affected

- EPCLUSA ORAL PACKET 150-37.5 MG, 200-50 MG
- EPCLUSA ORAL TABLET
- *sofosbuvir-velpatasvir*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
Other Criteria	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, HIV REGIMEN THAT CONTAINS EFAVIRENZ, ROSUVASTATIN AT DOSES ABOVE 10MG, TIPRANA VIR/RITONAVIR, TOPOTECAN, SOVALDI (AS A SINGLE AGENT), HARVONI, ZEPATIER, MAVYRET, OR VOSEVI, AND 3) PATIENTS WITH DECOMPENSATED CIRRHOSIS REQUIRE CONCURRENT RIBAVIRIN UNLESS RIBAVIRIN INELIGIBLE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR

**Products Affected**

- VOSEVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
Other Criteria	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, CYCLOSPORINE, PITAVASTATIN, PRAVASTATIN (DOSES ABOVE 40MG), ROSUVASTATIN, METHOTREXATE, MITOXANTRONE, IMATINIB, IRINOTECAN, LAPATINIB, SULFASALAZINE, TOPOTECAN, OR HIV REGIMEN THAT CONTAINS EFAVIRENZ, ATAZANAVIR, LOPINAVIR, TIPRANAVIR/RITONAVIR, SOVALDI (AS A SINGLE AGENT), EPCLUSA, HARVONI, ZEPATIER, OR MAVYRET, AND 3) DOES NOT HAVE MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD-PUGH B OR C).
Indications	All FDA-approved Indications.
Off Label Uses	

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## SOMATROPIN - NORDITROPIN

### Products Affected

- NORDITROPIN FLEXPRO  
SUBCUTANEOUS SOLUTION PEN-  
INJECTOR

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES.
<b>Required Medical Information</b>	INITIAL: PEDIATRIC GROWTH HORMONE DEFICIENCY (GHD), IDIOPATHIC SHORT STATURE (ISS), SMALL FOR GESTATIONAL AGE (SGA), TURNER SYNDROME (TS), NOONAN SYNDROME: HEIGHT AT LEAST 2 STANDARD DEVIATIONS BELOW THE MEAN HEIGHT FOR CHILDREN OF THE SAME AGE AND GENDER. PRADER WILLI SYNDROME (PWS): CONFIRMED GENETIC DIAGNOSIS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL/RENEWAL: ALL INDICATIONS: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: ADULT GHD: GHD ALONE OR ASSOCIATED WITH MULTIPLE HORMONE DEFICIENCIES (HYPOPITUITARISM), AS A RESULT OF PITUITARY DISEASE, HYPOTHALAMIC DISEASE, SURGERY, RADIATION THERAPY, OR TRAUMA, OR FOR CONTINUATION OF THERAPY FROM CHILDHOOD ONSET GHD. PEDIATRIC GHD, ISS, SGA, TS, NOONAN SYNDROME: OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND. RENEWAL: PEDIATRIC GHD: 1) IMPROVEMENT WHILE ON THERAPY (I.E., INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND OR HAS NOT COMPLETED PREPUBERTAL GROWTH. ISS, SGA, TS, NOONAN

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	SYNDROME: 1) IMPROVEMENT WHILE ON THERAPY (I.E., INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND. PWS: IMPROVEMENT IN BODY COMPOSITION.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## SOMATROPIN - SEROSTIM

### Products Affected

- SEROSTIM SUBCUTANEOUS  
 SOLUTION RECONSTITUTED 4 MG, 5  
 MG, 6 MG

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES
<b>Required Medical Information</b>	INITIAL: HIV/WASTING: ONE OF THE FOLLOWING FOR WEIGHT LOSS: 1) 10% UNINTENTIONAL WEIGHT LOSS OVER 12 MONTHS, 2) 7.5% UNINTENTIONAL WEIGHT LOSS OVER 6 MONTHS, 3) 5% BODY CELL MASS (BCM) LOSS WITHIN 6 MONTHS, 4) BCM LESS THAN 35% (MEN) OF TOTAL BODY WEIGHT AND BODY MASS INDEX (BMI) LESS THAN 27 KG PER METER SQUARED, 5) BCM LESS THAN 23% (WOMEN) OF TOTAL BODY WEIGHT AND BMI LESS THAN 27 KG PER METER SQUARED, OR 6) BMI LESS THAN 18.5 KG PER METER SQUARED.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HIV/WASTING: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, NUTRITIONAL SUPPORT SPECIALIST, OR INFECTIOUS DISEASE SPECIALIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 3 MONTHS.
<b>Other Criteria</b>	HIV/WASTING: INITIAL: 1) INADEQUATE RESPONSE TO ONE PREVIOUS THERAPY (E.G., MEGACE, APPETITE STIMULANTS, ANABOLIC STEROIDS). RENEWAL: 1) CLINICAL BENEFIT IN MUSCLE MASS AND WEIGHT.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	

Y0135\_PA25\_C

Formulary ID: 25261

Last Updated: 11/26/2025

Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **SONIDEGIB**

---

**Products Affected**

- ODOMZO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	LOCALLY ADVANCED BASAL CELL CARCINOMA (BCC): BASELINE SERUM CREATINE KINASE (CK) AND SERUM CREATININE LEVELS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **SORAFENIB**

---

**Products Affected**

- *sorafenib tosylate*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## SOTATERCEPT-CSRK

### Products Affected

- WINREVAIR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
Age Restrictions	
Prescriber Restrictions	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	PAH: INITIAL: 1) ON BACKGROUND PAH THERAPY (FOR AT LEAST 3 MONTHS) WITH AT LEAST TWO OF THE FOLLOWING AGENTS FROM DIFFERENT DRUG CLASSES: A) ORAL ENDOTHELIN RECEPTOR ANTAGONIST, B) ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR FOR PAH, C) ORAL CGMP STIMULATOR, D) IV/SQ PROSTACYCLIN, OR 2) ON ONE AGENT FROM ONE OF THE ABOVE DRUG CLASSES, AND HAS A CONTRAINDICATION OR INTOLERANCE TO ALL OF THE OTHER DRUG CLASSES.
Indications	All FDA-approved Indications.
Off Label Uses	

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **SOTORASIB**

---

**Products Affected**

- LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## STIRIPENTOL

---

**Products Affected**

- DIACOMIT ORAL CAPSULE 250 MG, 500 MG
- DIACOMIT ORAL PACKET 250 MG, 500 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	DRAVET SYNDROME: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## SUNITINIB

---

**Products Affected**

- *sunitinib malate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	GASTROINTESTINAL STROMAL TUMORS (GIST): TRIAL OF OR CONTRAINDICATION TO IMATINIB (GLEEVEC).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **TADALAFIL - ADCIRCA, ALYQ**

### **Products Affected**

- *alyq*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
<b>Coverage Duration</b>	INITIAL/RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	PAH: INITIAL/RENEWAL: 1) NOT CONCURRENTLY OR INTERMITTENTLY TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA) OR ANY ORGANIC NITRATES IN ANY FORM, AND 2) NO CONCURRENT USE WITH GUANYLATE CYCLASE STIMULATORS.
<b>Indications</b>	All Medically-accepted Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **TADALAFIL-CIALIS**

---

**Products Affected**

- *tadalafil oral tablet 2.5 mg, 5 mg*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	ERECTILE DYSFUNCTION WITHOUT DIAGNOSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH).
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	BPH: 1) TRIAL OF ONE ALPHA BLOCKER (E.G., DOXAZOSIN, TERAZOSIN, TAMSULOSIN, ALFUZOSIN), AND 2) TRIAL OF ONE 5-ALPHA-REDUCTASE INHIBITOR (E.G., FINASTERIDE, DUTASTERIDE). APPLIES TO 2.5MG AND 5MG STRENGTHS ONLY.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TALAZOPARIB

### Products Affected

- TALZENNA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADVANCED OR METASTATIC BREAST CANCER: 1) HAS BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND 2) IF HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER, RECEIVED PRIOR TREATMENT WITH ENDOCRINE THERAPY OR IS CONSIDERED INAPPROPRIATE FOR ENDOCRINE THERAPY. METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TALETRECTINIB

---

**Products Affected**

- IBTROZI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## TALQUETAMAB-TGVS

---

**Products Affected**

- TALVEY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **TARLATAMAB-DLLE**

---

**Products Affected**

- IMDELLTRA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TAZEMETOSTAT

---

**Products Affected**

- TAZVERIK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **TEBENTAFUSP-TEBN**

---

**Products Affected**

- KIMMTRAK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **TECLISTAMAB-CQYV**

---

**Products Affected**

- TECVAYLI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **TELISOTUZUMAB VEDOTIN-TLLV**

---

**Products Affected**

- EMRELIS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## TELOTRISTAT

---

**Products Affected**

- XERMELO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CARCINOID SYNDROME DIARRHEA: PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST OR GASTROENTEROLOGIST
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TEPOTINIB

---

**Products Affected**

- TEPMETKO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **TERIPARATIDE**

---

**Products Affected**

- TERIPARATIDE SUBCUTANEOUS  
SOLUTION PEN-INJECTOR 560  
MCG/2.24ML

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	24 MONTHS
<b>Other Criteria</b>	OSTEOPOROSIS: HAS NOT RECEIVED A TOTAL OF 24 MONTHS CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY, UNLESS REMAINS AT OR HAS RETURNED TO HAVING A HIGH RISK FOR FRACTURE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TESTOSTERONE

### Products Affected

- testosterone gel 1.62 % transdermal
- testosterone transdermal gel 12.5 mg/act (1%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 50 mg/5gm (1%)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	MALE HYPOGONADISM: INITIAL: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TESTOSTERONE CYPIONATE

### Products Affected

- testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	MALE HYPOGONADISM: INITIAL: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TESTOSTERONE ENANTHATE

### Products Affected

- *testosterone enanthate intramuscular solution*
- XYOSTED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL: MALE DELAYED PUBERTY: 6MO, MALE HYPOGONADISM: 12 MO. OTHER INDICATIONS: 12 MO.
Other Criteria	INITIAL: MALE HYPOGONADISM: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: MALE HYPOGONADISM: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT. MALE DELAYED PUBERTY: HAS NOT RECEIVED MORE THAN TWO 6-MONTH COURSES OF TESTOSTERONE REPLACEMENT THERAPY
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **TETRABENAZINE**

---

**Products Affected**

- *tetrabenazine*

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	HUNTINGTONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **THALIDOMIDE**

---

**Products Affected**

- THALOMID

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **TISLELIZUMAB-JSGR**

---

**Products Affected**

- TEVIMBRA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **TISOTUMAB VEDOTIN-TFTV**

---

**Products Affected**

- TIVDAK

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **TIVOZANIB**

---

**Products Affected**

- FOTIVDA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TOCILIZUMAB IV

### Products Affected

- ACTEMRA

PA Criteria	Criteria Details
Exclusion Criteria	CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
Coverage Duration	INITIAL: RA, PJIA, SJIA, GCA: 6 MONTHS. CRS: 1 MONTH. RENEWAL: RA, PJIA, SJIA, GCA: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PJIA: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, RINVOQ, ORENCIA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. SJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	TARGETED SMALL MOLECULES FOR PJIA. SJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated:11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TOCILIZUMAB SQ

### Products Affected

- ACTEMRA
- ACTEMRA ACTPEN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST. SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR RHEUMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PJIA: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, RINVOQ, ORENCIA, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. SJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA. SSC-ILD: DOES NOT

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS). RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. SJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA. SSC-ILD: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TOCILIZUMAB-AAZG

### Products Affected

- TYENNE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PJIA: 1) TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, ORENCIA, RINVOQ, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PJIA. SJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	TARGETED SMALL MOLECULES FOR PJIA. SJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SJIA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated:11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TOCILIZUMAB-AAZG IV

### Products Affected

- TYENNE

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
<b>Coverage Duration</b>	INITIAL: RA, PJIA, SJIA, GCA: 6 MOS. CRS: 1 MO. RENEWAL: RA, PJIA, SJIA, GCA: 12 MOS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ, RINVOQ, ORENCIA. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: ENBREL, HUMIRA/CYLTEZO/YUFLYMA, XELJANZ IR, ORENCIA, RINVOQ. CYTOKINE RELEASE SYNDROME (CRS): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR CRS. INITIAL/RENEWAL FOR PJIA, SJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR SAME INDICATION. RENEWAL FOR RA, PJIA, SJIA: CONTINUES TO BENEFIT FROM MEDICATION.
<b>Indications</b>	All FDA-approved Indications.

Y0135\_PA25\_C

Formulary ID: 25261

Last Updated: 11/26/2025

Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TOFACITINIB

### Products Affected

- XELJANZ
- XELJANZ XR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PCJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PCJIA. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	TARGETED SMALL MOLECULES FOR AS. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. PCJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PCJIA. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TOLVAPTAN

### Products Affected

- *tolvaptan oral tablet*
- *tolvaptan oral tablet therapy pack*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): INITIAL: CONFIRMED POLYCYSTIC KIDNEY DISEASE VIA CT, MRI, OR ULTRASOUND.
Age Restrictions	
Prescriber Restrictions	ADPKD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEPHROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	ADPKD: INITIAL: DOES NOT HAVE ESRD (I.E., RECEIVING DIALYSIS). RENEWAL: HAS NOT PROGRESSED TO ESRD/DIALYSIS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TOPICAL TRETINOIN

---

**Products Affected**

- ALTRENO
- *tretinoin external cream*

PA Criteria	Criteria Details
Exclusion Criteria	COSMETIC INDICATIONS SUCH AS WRINKLES, PHOTOAGING, MELASMA.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ACNE VULGARIS: BRAND TOPICAL TRETINOIN REQUIRES TRIAL OF OR CONTRAINDICATION TO A GENERIC TOPICAL TRETINOIN PRODUCT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **TORIPALIMAB-TPZI**

---

**Products Affected**

- LOQTORZI

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	NASOPHARYNGEAL CARCINOMA (NPC): FIRST LINE TREATMENT: 24 MOS, PREVIOUSLY TREATED: LIFETIME.
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TOVORAFENIB

---

**Products Affected**

- OJEMDA ORAL SUSPENSION                      • OJEMDA ORAL TABLET
- RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TRAMADOL

### Products Affected

- TRAMADOL HCL ORAL SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	PAIN: 1) TRIAL OF OR CONTRAINDICATION TO GENERIC TRAMADOL IMMEDIATE RELEASE TABLET OR GENERIC TRAMADOL/ACETAMINOPHEN COMBINATION PRODUCT, AND 2) UNABLE TO TAKE ORAL SOLID FORMULATIONS OF TRAMADOL OR TRAMADOL/ACETAMINOPHEN COMBINATION PRODUCT (E.G., DIFFICULTY SWALLOWING).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TRAMETINIB SOLUTION

### Products Affected

- MEKINIST ORAL SOLUTION  
RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	UNRESECTABLE OR METASTATIC MELANOMA, MELANOMA, METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC), UNRESECTABLE OR METASTATIC SOLID TUMOR, LOW-GRADE GLIOMA (LGG); UNABLE TO SWALLOW MEKINIST TABLETS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## TRAMETINIB TABLET

---

**Products Affected**

- MEKINIST ORAL TABLET 0.5 MG, 2 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## TRASTUZUMAB-DKST

---

**Products Affected**

- OGIVRI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TRASTUZUMAB-DTTB

---

**Products Affected**

- ONTRUZANT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **TRASTUZUMAB-HYALURONIDASE-OYSK**

---

**Products Affected**

- HERCEPTIN HYLECTA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	ADJUVANT BREAST CANCER, METASTATIC BREAST CANCER: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: HERZUMA, OGIVRI, ONTRUZANT, TRAZIMERA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TRASTUZUMAB-PKRB

---

**Products Affected**

- HERZUMA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## TRASTUZUMAB-QYYP

---

**Products Affected**

- TRAZIMERA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## TRAZODONE

---

**Products Affected**

- RALDESY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	MAJOR DEPRESSIVE DISORDER (MDD): CONTRAINDICATION TO OR UNABLE TO SWALLOW TRAZODONE TABLETS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **TREMELIMUMAB-ACTL**

### **Products Affected**

- IMJUDO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	UHCC: 30 DAYS. METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): 5 MONTHS.
<b>Other Criteria</b>	UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC): HAS NOT RECEIVED PRIOR TREATMENT WITH IMJUDO. NSCLC: HAS NOT RECEIVED A TOTAL OF 5 DOSES OF IMJUDO.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## TRIENTINE CAPSULE

### Products Affected

- trientine hcl oral capsule 250 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	WILSONS DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 12 MONTHS, RENEWAL: LIFETIME.
Other Criteria	WILSONS DISEASE: INITIAL: 1) LEIPZIG SCORE OF 4 OR GREATER, AND 2) TRIAL OF OR CONTRAINDICATION TO FORMULARY VERSION OF PENICILLAMINE TABLET. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## TRIFLURIDINE/TIPIRACIL

---

**Products Affected**

- LONSURF ORAL TABLET 15-6.14 MG,  
20-8.19 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **TRIPTORELIN-TRELSTAR**

---

**Products Affected**

- TRELSTAR MIXJECT

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS.
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## TUCATINIB

---

**Products Affected**

- TUKYSA ORAL TABLET 150 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## UBROGEPANT

### Products Affected

- UBRELVY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	ACUTE MIGRAINE TREATMENT: INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN), AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT. RENEWAL: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT, AND 2) ONE OF THE FOLLOWING: (A) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR (B) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## UPADACITINIB

**Products Affected**

- RINVOQ
- RINVOQ LQ

PA Criteria	Criteria Details
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	INITIAL: NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI). ATOPIC DERMATITIS (AD): ATOPIC DERMATITIS COVERING AT LEAST 10 PERCENT OF BODY SURFACE AREA OR ATOPIC DERMATITIS AFFECTING THE FACE, HEAD, NECK, HANDS, FEET, GROIN, OR INTERTRIGINOUS AREAS
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. AD: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST, ALLERGIST, OR IMMUNOLOGIST. ULCERATIVE COLITIS (UC), CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
<b>Other Criteria</b>	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	<p>DOSE IS REQUIRED. PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PJIA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. AD: 1) INTRACTABLE PRURITUS OR CRACKING/OOZING/BLEEDING OF AFFECTED SKIN, 2) TRIAL OF OR CONTRAINDICATION TO A TOPICAL CORTICOSTEROID, TOPICAL CALCINEURIN INHIBITOR, TOPICAL PDE4 INHIBITOR, OR TOPICAL JAK INHIBITOR, AND 3) NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGICS FOR ATOPIC DERMATITIS OR OTHER JAK INHIBITORS FOR ANY INDICATION. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. AS: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID (NON-STEROIDAL ANTI-INFLAMMATORY DRUG), AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1) TRIAL OF OR CONTRAINDICATION TO AN NSAID, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. GIANT CELL ARTERITIS (GCA): HAS COMPLETED, STARTED, OR WILL SOON START A TAPERING COURSE OF GLUCOCORTICOID. RENEWAL: RA: CONTINUES TO BENEFIT FROM THE MEDICATION. AD: 1) IMPROVEMENT WHILE ON THERAPY, AND 2) NO CONCURRENT USE WITH OTHER SYSTEMIC BIOLOGICS FOR ATOPIC DERMATITIS OR OTHER JAK INHIBITOR FOR ANY INDICATION. PSA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. AS: 1) CONTINUES TO BENEFIT MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR AS. NR-AXSPA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR NR-AXSPA. PJIA: 1) CONTINUES TO BENEFIT FROM MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER</p>

**Y0135\_PA25\_C**

**Formulary ID: 25261**

**Last Updated: 11/26/2025**

**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PJIA. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## USTEKINUMAB

### Products Affected

- STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## USTEKINUMAB IV

### Products Affected

- STELARA INTRAVENOUS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	2 MONTHS
Other Criteria	CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## USTEKINUMAB-AEKN IV

### Products Affected

- SELARSDI INTRAVENOUS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO

Y0135\_PA25\_C

Formulary ID: 25261

Last Updated: 11/26/2025

Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## USTEKINUMAB-AEKN SQ

### Products Affected

- SELARSDI SUBCUTANEOUS  
SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

<b>PA Criteria</b>	<b>Criteria Details</b>
	TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## USTEKINUMAB-KFCE IV

### Products Affected

- YESINTEK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO

Y0135\_PA25\_C

Formulary ID: 25261

Last Updated: 11/26/2025

Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## USTEKINUMAB-KFCE SQ

### Products Affected

- YESINTEK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR PSA. PSO: 1) ONE OF THE FOLLOWING: (A) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY) FOR THE TREATMENT OF PSO, (B) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA FOR THE TREATMENT OF PSO, OR (C) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO

Y0135\_PA25\_C

Formulary ID: 25261

Last Updated: 11/26/2025

Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

PA Criteria	Criteria Details
	CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC. RENEWAL: PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSA. PSO: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR PSO. CD: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR CD. UC: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR UC.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## VALBENAZINE

**Products Affected**

- INGREZZA ORAL CAPSULE
- INGREZZA ORAL CAPSULE SPRINKLE
- INGREZZA ORAL CAPSULE THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	TARDIVE DYSKINESIA (TD): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST. CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST.
Coverage Duration	12 MONTHS
Other Criteria	TD: HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **VANDETANIB**

---

**Products Affected**

- CAPRELSA ORAL TABLET 100 MG,  
300 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	CURRENTLY STABLE ON CAPRELSA REQUIRES NO EXTRA CRITERIA.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **VANZACAFTOR-TEZACAFTOR- DEUTIVACAFTOR**

---

**Products Affected**

- ALYFTREK ORAL TABLET 10-50-125  
MG, 4-20-50 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	CF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT.
<b>Coverage Duration</b>	INITIAL: 6 MONTHS. RENEWAL: LIFETIME.
<b>Other Criteria</b>	CF: INITIAL: NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## VEMURAFENIB

---

**Products Affected**

- ZELBORAF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	MELANOMA: ZELBORAF WILL BE USED ALONE OR IN COMBINATION WITH COTELLIC
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## VENETOCLAX

---

**Products Affected**

- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## VERICIGUAT

### Products Affected

- VERQUVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL:12 MONTHS.
Other Criteria	HEART FAILURE (HF): INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO ONE PREFERRED SGLT-2 INHIBITOR, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE AGENT FROM ANY OF THE FOLLOWING STANDARD OF CARE CLASSES: (A) ACE INHIBITOR, ARB, OR ARNI, (B) BETA BLOCKER (BISOPROLOL, CARVEDILOL, METOPROLOL SUCCINATE), OR (C) ALDOSTERONE ANTAGONIST (SPIRONOLACTONE, EPLERENONE). INITIAL/RENEWAL: NO CONCURRENT USE WITH RIOCIGUAT OR PDE-5 INHIBITORS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated:11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## VIGABATRIN

**Products Affected**

- *vigabatrin*
- *vigadrone*
- *vigpoder*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	REFRACTORY COMPLEX PARTIAL SEIZURES (CPS), INFANTILE SPASMS: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	CPS: TRIAL OF OR CONTRAINDICATION TO TWO ANTIEPILEPTIC AGENTS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## VIMSELTINIB

---

**Products Affected**

- ROMVIMZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## VISMODEGIB

---

**Products Affected**

- ERIVEDGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **VORASIDENIB**

---

**Products Affected**

- VORANIGO

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## VORICONAZOLE SUSPENSION

### Products Affected

- *voriconazole oral suspension reconstituted*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CANDIDA INFECTIONS: 3 MOS. CONTINUATION OF THERAPY, ALL OTHER INDICATIONS: 6 MOS.
Other Criteria	CANDIDA INFECTIONS: 1) TRIAL OF OR CONTRAINDICATION TO FLUCONAZOLE, AND 2) UNABLE TO SWALLOW TABLETS. ALL INDICATIONS EXCEPT ESOPHAGEAL CANDIDIASIS: UNABLE TO SWALLOW TABLETS. CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE REQUIRES NO EXTRA CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **ZANIDATAMAB-HRII**

---

**Products Affected**

- ZIIHERA

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **ZANUBRUTINIB**

---

**Products Affected**

- BRUKINSA ORAL CAPSULE
- BRUKINSA ORAL TABLET

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## ZENOCUTUZUMAB-ZBCO

### Products Affected

- BIZENGRI (750 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	THIS DRUG ALSO REQUIRES PAYMENT DETERMINATION AND MAY BE COVERED UNDER MEDICARE PART B OR D.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

Y0135\_PA25\_C  
Formulary ID: 25261  
Last Updated: 11/26/2025  
Effective: 12/01/2025



**Provider Partners Health Plan**  
**2025 Formulary – Prior Authorization Criteria**

## **ZOLBETUXIMAB-CLZB**

---

**Products Affected**

- VYLOY

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **ZONGERTINIB**

---

**Products Affected**

- HERNEXEOS

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	12 MONTHS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

**Provider Partners Health Plan  
2025 Formulary – Prior Authorization Criteria**

## **ZURANOLONE**

---

**Products Affected**

- ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

<b>PA Criteria</b>	<b>Criteria Details</b>
<b>Exclusion Criteria</b>	
<b>Required Medical Information</b>	
<b>Age Restrictions</b>	
<b>Prescriber Restrictions</b>	
<b>Coverage Duration</b>	14 DAYS
<b>Other Criteria</b>	
<b>Indications</b>	All FDA-approved Indications.
<b>Off Label Uses</b>	
<b>Part B Prerequisite</b>	No

**Y0135\_PA25\_C**  
**Formulary ID: 25261**  
**Last Updated: 11/26/2025**  
**Effective: 12/01/2025**

# Provider Partners Health Plan

## 2025 Formulary – Prior Authorization Criteria

### INDEX

#### A

abiraterone acetate ..... 7  
 abirtega..... 7  
 ABOUTTIME PEN NEEDLE 30G X 8 MM  
 ..... 167, 187, 188  
 ABOUTTIME PEN NEEDLE 31G X 5 MM  
 ..... 167, 187, 188  
 ABOUTTIME PEN NEEDLE 31G X 8 MM  
 ..... 167, 187, 188  
 ABOUTTIME PEN NEEDLE 32G X 4 MM  
 ..... 167, 187, 188  
 ACTEMRA ..... 368, 369, 370, 371  
 ACTEMRA ACTPEN ..... 370, 371  
 ACTHAR ..... 76, 77  
 ACTHAR GEL SUBCUTANEOUS PEN-  
 INJECTOR 40 UNIT/0.5ML, 80  
 UNIT/ML ..... 76, 77  
 ACTIMMUNE..... 192  
 ADEMPAS ..... 306, 307  
 ADVOCATE INSULIN PEN NEEDLE 32G  
 X 4 MM..... 167, 187, 188  
 ADVOCATE INSULIN PEN NEEDLES  
 29G X 12.7MM..... 167, 187, 188  
 ADVOCATE INSULIN PEN NEEDLES  
 31G X 5 MM..... 167, 187, 188  
 ADVOCATE INSULIN PEN NEEDLES  
 31G X 8 MM..... 167, 187, 188  
 ADVOCATE INSULIN PEN NEEDLES  
 33G X 4 MM..... 167, 187, 188  
 ADVOCATE INSULIN SYRINGE 29G X  
 1/2 ..... 167, 187, 188  
 ADVOCATE INSULIN SYRINGE 30G X  
 5/16 ..... 167, 187, 188  
 ADVOCATE INSULIN SYRINGE 31G X  
 5/16 ..... 167, 187, 188  
 AIMOVIG..... 123  
 AJOVY ..... 139  
 AKEEGA ..... 246  
 ALCOHOL PREP PAD..... 167, 187, 188  
 ALCOHOL PREP PAD 70 %. 167, 187, 188  
 ALCOHOL PREP PADS PAD 70 % .... 167,  
 187, 188  
 ALCOHOL SWABS PAD..... 167, 187, 188

ALCOHOL SWABS PAD 70 % ... 167, 187,  
 188  
 ALECENSA..... 21  
 ALTRENO..... 379  
 ALUNBRIG ORAL TABLET 180 MG, 30  
 MG, 90 MG..... 61  
 ALUNBRIG ORAL TABLET THERAPY  
 PACK..... 61  
 ALVAIZ..... 110  
 ALYFTREK ORAL TABLET 10-50-125  
 MG, 4-20-50 MG ..... 413  
 alyq..... 347  
 ANKTIVA ..... 252  
 AQ INSULIN SYRINGE 31G X 5/16... 167,  
 187, 188  
 AQINJECT PEN NEEDLE 31G X 5 MM  
 ..... 167, 187, 188  
 AQINJECT PEN NEEDLE 32G X 4 MM  
 ..... 167, 187, 188  
 ARCALYST ..... 301, 302  
 ARIKAYCE..... 23  
 armodafinil..... 238  
 ASSURE ID DUO PRO PEN NEEDLES  
 31G X 5 MM..... 167, 187, 188  
 ASSURE ID INSULIN SAFETY SYR 29G  
 X 1/2..... 167, 187, 188  
 ASSURE ID INSULIN SAFETY SYR 31G  
 X 15/64..... 167, 187, 188  
 ASSURE ID PRO PEN NEEDLES 30G X 5  
 MM ..... 167, 187, 188  
 AUGTYRO ORAL CAPSULE 160 MG, 40  
 MG ..... 293  
 AUM ALCOHOL PREP PADS PAD 70 %  
 ..... 167, 187, 188  
 AUM INSULIN SAFETY PEN NEEDLE  
 31G X 4 MM..... 167, 187, 188  
 AUM INSULIN SAFETY PEN NEEDLE  
 31G X 5 MM..... 167, 187, 188  
 AUM MINI INSULIN PEN NEEDLE 32G  
 X 4 MM..... 167, 187, 188  
 AUM MINI INSULIN PEN NEEDLE 32G  
 X 5 MM..... 167, 187, 188

## Provider Partners Health Plan

### 2025 Formulary – Prior Authorization Criteria

AUM MINI INSULIN PEN NEEDLE 32G X 6 MM..... 167, 187, 188

AUM MINI INSULIN PEN NEEDLE 32G X 8 MM..... 167, 187, 188

AUM MINI INSULIN PEN NEEDLE 33G X 4 MM..... 168, 187, 188

AUM MINI INSULIN PEN NEEDLE 33G X 5 MM..... 168, 187, 188

AUM MINI INSULIN PEN NEEDLE 33G X 6 MM..... 168, 187, 188

AUM PEN NEEDLE 32G X 4 MM ..... 168, 187, 188

AUM PEN NEEDLE 32G X 5 MM ..... 168, 187, 188

AUM PEN NEEDLE 32G X 6 MM ..... 168, 187, 188

AUM PEN NEEDLE 33G X 4 MM ..... 168, 187, 188

AUM PEN NEEDLE 33G X 5 MM ..... 168, 187, 188

AUM PEN NEEDLE 33G X 6 MM ..... 168, 187, 188

AUM READYGARD DUO PEN NEEDLE 32G X 4 MM..... 168, 187, 188

AUM SAFETY PEN NEEDLE 31G X 4 MM ..... 168, 187, 188

AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG ..... 92

AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG ..... 92

AUSTEDO XR PATIENT TITRATION . 92

AVMAPKI FAKZYNJA CO-PACK..... 40

AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT..... 189

AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT..... 189

AYVAKIT ..... 39

**B**

BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG..... 122

BD AUTOSHIELD DUO 30G X 5 MM 168, 187, 188

BD ECLIPSE SYRINGE 30G X 1/2 ..... 168, 187, 188

BD INSULIN SYR ULTRAFINE II 31G X 5/16 ..... 168, 187, 188

BD INSULIN SYRINGE 25G X 1 168, 187, 188

BD INSULIN SYRINGE 25G X 5/8..... 168, 187, 188

BD INSULIN SYRINGE 26G X 1/2..... 168, 187, 188

BD INSULIN SYRINGE 27.5G X 5/8.. 168, 187, 188

BD INSULIN SYRINGE 27G X 1/2..... 168, 187, 188

BD INSULIN SYRINGE 29G X 1/2..... 168, 187, 188

BD INSULIN SYRINGE HALF-UNIT 31G X 5/16..... 168, 187, 188

BD INSULIN SYRINGE MICROFINE 27G X 5/8..... 168, 187, 188

BD INSULIN SYRINGE MICROFINE 28G X 1/2..... 168, 187, 188

BD INSULIN SYRINGE U-100 1 ML . 168, 187, 188

BD INSULIN SYRINGE ULTRAFINE 29G X 1/2..... 168, 187, 188

BD INSULIN SYRINGE ULTRAFINE 30G X 1/2..... 168, 187, 188

BD PEN NEEDLE MICRO ULTRAFINE 32G X 6 MM..... 168, 187, 188

BD PEN NEEDLE MINI U/F 31G X 5 MM ..... 168, 187, 188

BD PEN NEEDLE MINI ULTRAFINE 31G X 5 MM..... 168, 187, 188

BD PEN NEEDLE NANO 2ND GEN 32G X 4 MM..... 168, 187, 188

BD PEN NEEDLE NANO ULTRAFINE 32G X 4 MM..... 168, 187, 188

BD PEN NEEDLE ORIG ULTRAFINE 29G X 12.7MM..... 168, 187, 188

BD PEN NEEDLE SHORT ULTRAFINE 31G X 8 MM..... 168, 187, 188

BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2..... 168, 187, 188

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

BD SAFETYGLIDE INSULIN SYRINGE 30G X 5/16.....	168, 187, 188	CAPRELSA ORAL TABLET 100 MG, 300 MG .....	412
BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64.....	168, 169, 187, 188	CAREFINE PEN NEEDLES 29G X 12MM .....	169, 187, 188
BD SAFETYGLIDE INSULIN SYRINGE 31G X 5/16.....	169, 187, 188	CAREFINE PEN NEEDLES 30G X 8 MM .....	169, 187, 188
BD SAFETYGLIDE SYRINGE/NEEDLE 27G X 5/8.....	169, 187, 188	CAREFINE PEN NEEDLES 31G X 6 MM .....	169, 187, 188
BD SWAB SINGLE USE REGULAR PAD .....	169, 187, 188	CAREFINE PEN NEEDLES 31G X 8 MM .....	169, 187, 188
BD SWABS SINGLE USE BUTTERFLY PAD.....	169, 187, 188	CAREFINE PEN NEEDLES 32G X 4 MM .....	169, 187, 188
BD VEO INSULIN SYR U/F 1/2UNIT 31G X 15/64.....	169, 187, 188	CAREFINE PEN NEEDLES 32G X 5 MM .....	169, 187, 188
BD VEO INSULIN SYR ULTRAFINE 31G X 15/64.....	169, 187, 188	CAREFINE PEN NEEDLES 32G X 6 MM .....	169, 187, 188
BD VEO INSULIN SYRINGE U/F 31G X 15/64 .....	169, 187, 188	CAREONE INSULIN SYRINGE 30G X 1/2 .....	169, 187, 188
BENDAMUSTINE HCL INTRAVENOUS SOLUTION.....	49	CAREONE INSULIN SYRINGE 31G X 5/16 .....	169, 187, 188
bendamustine hcl intravenous solution reconstituted.....	49	CARETOUCH ALCOHOL PREP PAD 70 % .....	169, 187, 188
BENDEKA .....	49	CARETOUCH INSULIN SYRINGE 28G X 5/16 .....	169, 187, 188
BENLYSTA SUBCUTANEOUS.....	46	CARETOUCH INSULIN SYRINGE 29G X 5/16 .....	169, 187, 188
BESREMI .....	315	CARETOUCH INSULIN SYRINGE 30G X 5/16 .....	169, 187, 188
betaine .....	52	CARETOUCH INSULIN SYRINGE 31G X 5/16 .....	169, 187, 188
BETASERON SUBCUTANEOUS KIT	190	CARETOUCH PEN NEEDLES 29G X 12MM .....	169, 187, 188
bexarotene .....	56	CARETOUCH PEN NEEDLES 31G X 5 MM .....	169, 187, 188
BIZENGRI (750 MG DOSE) .....	424	CARETOUCH PEN NEEDLES 31G X 6 MM .....	169, 187, 188
bortezomib injection .....	58	CARETOUCH PEN NEEDLES 31G X 8 MM .....	169, 187, 188
BORUZU .....	58	CARETOUCH PEN NEEDLES 32G X 4 MM .....	169, 187, 188
bosentan oral tablet .....	59	CARETOUCH PEN NEEDLES 32G X 5 MM .....	169, 187, 188
BOSULIF ORAL CAPSULE 100 MG, 50 MG .....	60	CARETOUCH PEN NEEDLES 33G X 4 MM .....	170, 187, 188
BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG.....	60	carglumic acid oral tablet soluble .....	68
BRAFTOVI ORAL CAPSULE 75 MG .	114		
BRUKINSA ORAL CAPSULE .....	423		
BRUKINSA ORAL TABLET.....	423		
<b>C</b>			
CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG.....	64		
CALQUENCE .....	9		
CAMZYOS .....	225		

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

CAYSTON.....	44	COMFORT EZ PEN NEEDLES 32G X 6	
CIMZIA (2 SYRINGE) .....	70, 71	MM .....	170, 187, 188
CIMZIA SUBCUTANEOUS KIT 2 X 200		COMFORT EZ PEN NEEDLES 32G X 8	
MG .....	70, 71	MM .....	170, 187, 188
CINQAIR.....	294, 295	COMFORT EZ PEN NEEDLES 33G X 4	
CLEVER CHOICE COMFORT EZ 29G X		MM .....	170, 187, 188
12MM .....	170, 187, 188	COMFORT EZ PEN NEEDLES 33G X 5	
CLEVER CHOICE COMFORT EZ 33G X		MM .....	170, 187, 188
4 MM .....	170, 187, 188	COMFORT EZ PEN NEEDLES 33G X 6	
CLICKFINE PEN NEEDLES 31G X 8 MM		MM .....	170, 187, 188
.....	170, 187, 188	COMFORT EZ PEN NEEDLES 33G X 8	
CLICKFINE PEN NEEDLES 32G X 4 MM		MM .....	170, 187, 188
.....	170, 187, 188	COMFORT EZ PRO PEN NEEDLES 30G	
COMETRIQ (100 MG DAILY DOSE)		X 8 MM.....	170, 187, 188
ORAL KIT 80 & 20 MG .....	63	COMFORT EZ PRO PEN NEEDLES 31G	
COMETRIQ (140 MG DAILY DOSE)		X 4 MM.....	170, 187, 188
ORAL KIT 3 X 20 MG & 80 MG .....	63	COMFORT EZ PRO PEN NEEDLES 31G	
COMETRIQ (60 MG DAILY DOSE).....	63	X 5 MM.....	170, 187, 188
COMFORT ASSIST INSULIN SYRINGE		COMFORT TOUCH INSULIN PEN NEED	
29G X 1/2.....	170, 187, 188	31G X 4 MM.....	170, 187, 188
COMFORT ASSIST INSULIN SYRINGE		COMFORT TOUCH INSULIN PEN NEED	
31G X 5/16.....	170, 187, 188	31G X 5 MM.....	170, 187, 188
COMFORT EZ INSULIN SYRINGE 28G		COMFORT TOUCH INSULIN PEN NEED	
X 1/2.....	170, 187, 188	31G X 6 MM.....	171, 187, 188
COMFORT EZ INSULIN SYRINGE 29G		COMFORT TOUCH INSULIN PEN NEED	
X 1/2.....	170, 187, 188	31G X 8 MM.....	171, 187, 188
COMFORT EZ INSULIN SYRINGE 30G		COMFORT TOUCH INSULIN PEN NEED	
X 1/2.....	170, 187, 188	32G X 4 MM.....	171, 187, 188
COMFORT EZ INSULIN SYRINGE 30G		COMFORT TOUCH INSULIN PEN NEED	
X 5/16.....	170, 187, 188	32G X 5 MM.....	171, 187, 188
COMFORT EZ INSULIN SYRINGE 31G		COMFORT TOUCH INSULIN PEN NEED	
X 15/64.....	170, 187, 188	32G X 6 MM.....	171, 187, 188
COMFORT EZ INSULIN SYRINGE 31G		COMFORT TOUCH INSULIN PEN NEED	
X 5/16.....	170, 187, 188	32G X 8 MM.....	171, 187, 188
COMFORT EZ PEN NEEDLES 31G X 5		COPIKTRA.....	104
MM .....	170, 187, 188	CORTROPHIN .....	76, 77
COMFORT EZ PEN NEEDLES 31G X 6		COSENTYX (300 MG DOSE).....	321, 322
MM .....	170, 187, 188	COSENTYX INTRAVENOUS.....	319, 320
COMFORT EZ PEN NEEDLES 31G X 8		COSENTYX SENSOREADY (300 MG)	
MM .....	170, 187, 188	.....	321, 322
COMFORT EZ PEN NEEDLES 32G X 4		COSENTYX SUBCUTANEOUS	
MM .....	170, 187, 188	SOLUTION PREFILLED SYRINGE 75	
COMFORT EZ PEN NEEDLES 32G X 5		MG/0.5ML .....	321, 322
MM .....	170, 187, 188	COSENTYX UNOREADY .....	321, 322
		COTELLIC .....	75

## Provider Partners Health Plan

### 2025 Formulary – Prior Authorization Criteria

CRESEMBA ORAL ..... 194  
 CURITY ALCOHOL PREPS PAD 70 %  
 ..... 171, 187, 188  
 CURITY ALL PURPOSE SPONGES PAD  
 2..... 171, 187, 188  
 CURITY GAUZE PAD 2 ..... 171, 187, 188  
 CURITY GAUZE SPONGE PAD 2..... 171,  
 187, 188  
 CURITY SPONGES PAD 2... 171, 187, 188  
 CVS GAUZE PAD 2 ..... 171, 187, 188  
 CVS GAUZE STERILE PAD 2 .... 171, 187,  
 188  
 CVS ISOPROPYL ALCOHOL WIPES 171,  
 187, 188  
 CYLTEZO (2 PEN) ..... 17, 19  
 CYLTEZO (2 SYRINGE) ..... 17, 19  
 CYLTEZO-CD/UC/HS STARTER.... 17, 19  
 CYLTEZO-PSORIASIS/UV STARTER 17,  
 19

#### **D**

dalfampridine er ..... 83  
 DANYELZA ..... 239  
 DANZITEN ..... 242  
 dasatinib oral tablet 100 mg, 140 mg, 20 mg,  
 50 mg, 70 mg, 80 mg ..... 85  
 DATROWAY ..... 86  
 DAURISMO ORAL TABLET 100 MG, 25  
 MG ..... 146  
 deferasirox granules ..... 88, 89  
 deferasirox oral tablet ..... 88, 89  
 DERMACEA GAUZE SPONGE PAD 2  
 ..... 171, 187, 188  
 DERMACEA IV DRAIN SPONGES PAD  
 2..... 171, 187, 188  
 DERMACEA NON-WOVEN SPONGES  
 PAD 2..... 171, 187, 188  
 DERMACEA TYPE VII GAUZE PAD 2  
 ..... 171, 187, 188  
 DIACOMIT ORAL CAPSULE 250 MG,  
 500 MG ..... 345  
 DIACOMIT ORAL PACKET 250 MG, 500  
 MG ..... 345  
 DIATHRIVE PEN NEEDLE 31G X 5 MM  
 ..... 171, 187, 188

DIATHRIVE PEN NEEDLE 31G X 6 MM  
 ..... 171, 187, 188  
 DIATHRIVE PEN NEEDLE 31G X 8 MM  
 ..... 171, 187, 188  
 DIATHRIVE PEN NEEDLE 32G X 4 MM  
 ..... 171, 187, 188  
 diclofenac epolamine external ..... 94  
 diclofenac sodium external solution 2 %.. 93  
 dimethyl fumarate oral capsule delayed  
 release 120 mg, 240 mg ..... 95  
 dimethyl fumarate starter pack oral capsule  
 delayed release therapy pack ..... 95  
 dronabinol ..... 99  
 DROPLET INSULIN SYRINGE 29G X 1/2  
 ..... 171, 187, 188  
 DROPLET INSULIN SYRINGE 30G X 1/2  
 ..... 171, 187, 188  
 DROPLET INSULIN SYRINGE 30G X  
 15/64 ..... 171, 187, 188  
 DROPLET INSULIN SYRINGE 30G X  
 5/16 ..... 171, 187, 188  
 DROPLET INSULIN SYRINGE 31G X  
 15/64 ..... 171, 187, 188  
 DROPLET INSULIN SYRINGE 31G X  
 5/16 ..... 171, 187, 188  
 DROPLET MICRON 34G X 3.5 MM... 171,  
 187, 188  
 DROPLET PEN NEEDLES 29G X 10MM  
 ..... 171, 187, 188  
 DROPLET PEN NEEDLES 29G X 12MM  
 ..... 171, 187, 188  
 DROPLET PEN NEEDLES 30G X 8 MM  
 ..... 171, 187, 188  
 DROPLET PEN NEEDLES 31G X 5 MM  
 ..... 171, 187, 188  
 DROPLET PEN NEEDLES 31G X 6 MM  
 ..... 171, 187, 188  
 DROPLET PEN NEEDLES 31G X 8 MM  
 ..... 171, 187, 188  
 DROPLET PEN NEEDLES 32G X 4 MM  
 ..... 172, 187, 188  
 DROPLET PEN NEEDLES 32G X 5 MM  
 ..... 172, 187, 188  
 DROPLET PEN NEEDLES 32G X 6 MM  
 ..... 172, 187, 188



## Provider Partners Health Plan

### 2025 Formulary – Prior Authorization Criteria

DROPLET PEN NEEDLES 32G X 8 MM  
 ..... 172, 187, 188

DROPSAFE ALCOHOL PREP PAD 70 %  
 ..... 172, 187, 188

DROPSAFE SAFETY PEN NEEDLES 31G  
 X 5 MM..... 172, 187, 188

DROPSAFE SAFETY PEN NEEDLES 31G  
 X 6 MM..... 172, 187, 188

DROPSAFE SAFETY PEN NEEDLES 31G  
 X 8 MM..... 172, 187, 188

DROPSAFE SAFETY SYRINGE/NEEDLE  
 29G X 1/2..... 172, 187, 188

DROPSAFE SAFETY SYRINGE/NEEDLE  
 31G X 15/64..... 172, 187, 188

DROPSAFE SAFETY SYRINGE/NEEDLE  
 31G X 5/16..... 172, 187, 188

droxidopa ..... 100

DRUG MART ULTRA COMFORT SYR  
 29G X 1/2..... 172, 187, 188

DRUG MART ULTRA COMFORT SYR  
 30G X 5/16..... 172, 187, 188

DRUG MART UNIFINE PENTIPS 31G X  
 5 MM ..... 172, 187, 188

DUPIXENT SUBCUTANEOUS  
 SOLUTION AUTO-INJECTOR 101, 103

DUPIXENT SUBCUTANEOUS  
 SOLUTION PREFILLED SYRINGE 101,  
 103

**E**

EASY COMFORT ALCOHOL PADS PAD  
 ..... 172, 187, 188

EASY COMFORT INSULIN SYRINGE  
 29G X 5/16..... 172, 187, 188

EASY COMFORT INSULIN SYRINGE  
 30G X 1/2..... 172, 187, 188

EASY COMFORT INSULIN SYRINGE  
 30G X 5/16..... 172, 187, 188

EASY COMFORT INSULIN SYRINGE  
 31G X 1/2..... 172, 187, 188

EASY COMFORT INSULIN SYRINGE  
 31G X 5/16..... 172, 187, 188

EASY COMFORT INSULIN SYRINGE  
 32G X 5/16..... 172, 187, 188

EASY COMFORT PEN NEEDLES 29G X  
 4MM ..... 172, 187, 188

EASY COMFORT PEN NEEDLES 29G X  
 5MM ..... 172, 187, 188

EASY COMFORT PEN NEEDLES 31G X  
 5 MM ..... 172, 187, 188

EASY COMFORT PEN NEEDLES 31G X  
 6 MM ..... 172, 187, 188

EASY COMFORT PEN NEEDLES 31G X  
 8 MM ..... 172, 187, 188

EASY COMFORT PEN NEEDLES 32G X  
 4 MM ..... 172, 187, 188

EASY COMFORT PEN NEEDLES 33G X  
 4 MM ..... 172, 187, 188

EASY COMFORT PEN NEEDLES 33G X  
 5 MM ..... 172, 187, 188

EASY COMFORT PEN NEEDLES 33G X  
 6 MM ..... 173, 187, 188

EASY GLIDE PEN NEEDLES 33G X 4  
 MM ..... 173, 187, 188

EASY TOUCH ALCOHOL PREP  
 MEDIUM PAD 70 %..... 173, 187, 188

EASY TOUCH FLIPLOCK INSULIN SY  
 29G X 1/2..... 173, 187, 188

EASY TOUCH FLIPLOCK INSULIN SY  
 30G X 1/2..... 173, 187, 188

EASY TOUCH FLIPLOCK INSULIN SY  
 30G X 5/16..... 173, 187, 188

EASY TOUCH FLIPLOCK INSULIN SY  
 31G X 5/16..... 173, 187, 188

EASY TOUCH FLIPLOCK SAFETY SYR  
 27G X 1/2..... 173, 187, 188

EASY TOUCH INSULIN BARRELS U-  
 100 1 ML..... 173, 187, 188

EASY TOUCH INSULIN SAFETY SYR  
 29G X 1/2..... 173, 187, 188

EASY TOUCH INSULIN SAFETY SYR  
 30G X 1/2..... 173, 187, 188

EASY TOUCH INSULIN SAFETY SYR  
 30G X 5/16..... 173, 187, 188

EASY TOUCH INSULIN SYRINGE 27G  
 X 1/2..... 173, 187, 188

EASY TOUCH INSULIN SYRINGE 27G  
 X 5/8..... 173, 187, 188

EASY TOUCH INSULIN SYRINGE 28G  
 X 1/2..... 173, 187, 188

## Provider Partners Health Plan

### 2025 Formulary – Prior Authorization Criteria

EASY TOUCH INSULIN SYRINGE 29G X 1/2.....	173, 187, 188
EASY TOUCH INSULIN SYRINGE 30G X 1/2.....	173, 187, 188
EASY TOUCH INSULIN SYRINGE 30G X 5/16.....	173, 187, 188
EASY TOUCH INSULIN SYRINGE 31G X 5/16.....	173, 187, 188
EASY TOUCH PEN NEEDLES 29G X 12MM .....	173, 187, 188
EASY TOUCH PEN NEEDLES 30G X 5 MM .....	173, 187, 188
EASY TOUCH PEN NEEDLES 30G X 6 MM .....	173, 187, 188
EASY TOUCH PEN NEEDLES 30G X 8 MM .....	173, 187, 188
EASY TOUCH PEN NEEDLES 31G X 5 MM .....	173, 187, 188
EASY TOUCH PEN NEEDLES 31G X 6 MM .....	173, 187, 188
EASY TOUCH PEN NEEDLES 31G X 8 MM .....	173, 187, 188
EASY TOUCH PEN NEEDLES 32G X 4 MM .....	173, 187, 188
EASY TOUCH PEN NEEDLES 32G X 5 MM .....	173, 187, 188
EASY TOUCH PEN NEEDLES 32G X 6 MM .....	173, 187, 188
EASY TOUCH SAFETY PEN NEEDLES 29G X 5MM.....	173, 187, 188
EASY TOUCH SAFETY PEN NEEDLES 29G X 8MM.....	174, 187, 188
EASY TOUCH SAFETY PEN NEEDLES 30G X 8 MM.....	174, 187, 188
EASY TOUCH SHEATHLOCK SYRINGE 29G X 1/2.....	174, 187, 188
EASY TOUCH SHEATHLOCK SYRINGE 30G X 1/2.....	174, 187, 188
EASY TOUCH SHEATHLOCK SYRINGE 30G X 5/16.....	174, 187, 188
EASY TOUCH SHEATHLOCK SYRINGE 31G X 5/16.....	174, 187, 188
ELAHERE .....	235
ELIGARD .....	208
ELREXFIO SUBCUTANEOUS SOLUTION 44 MG/1.1ML, 76 MG/1.9ML .....	109
eltrombopag olamine oral packet 12.5 mg, 25 mg .....	111, 112
eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg .....	111, 112
EMBECTA AUTOSHIELD DUO 30G X 5 MM .....	174, 187, 188
EMBECTA INS SYR U/F 1/2 UNIT 31G X 15/64 .....	174, 187, 188
EMBECTA INS SYR U/F 1/2 UNIT 31G X 5/16 .....	174, 187, 188
EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2.....	174, 187, 188
EMBECTA INSULIN SYR ULTRAFINE 31G X 15/64.....	174, 187, 188
EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16.....	174, 187, 188
EMBECTA INSULIN SYRINGE 28G X 1/2 .....	174, 187, 188
EMBECTA INSULIN SYRINGE U-100 27G X 5/8.....	174, 187, 188
EMBECTA INSULIN SYRINGE U-100 28G X 1/2.....	174, 187, 188
EMBECTA INSULIN SYRINGE U-500 .....	174, 187, 188
EMBECTA PEN NEEDLE NANO 2 GEN 32G X 4 MM.....	174, 187, 188
EMBECTA PEN NEEDLE NANO 32G X 4 MM .....	174, 187, 188
EMBECTA PEN NEEDLE ULTRAFINE 29G X 12.7MM.....	174, 187, 188
EMBECTA PEN NEEDLE ULTRAFINE 31G X 5 MM.....	174, 187, 188
EMBECTA PEN NEEDLE ULTRAFINE 31G X 8 MM.....	174, 187, 188
EMBECTA PEN NEEDLE ULTRAFINE 32G X 6 MM.....	174, 187, 188
EMBRACE PEN NEEDLES 29G X 12MM .....	174, 187, 188
EMBRACE PEN NEEDLES 30G X 5 MM .....	174, 187, 188
EMBRACE PEN NEEDLES 30G X 8 MM .....	174, 187, 188

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

EMBRACE PEN NEEDLES 31G X 5 MM  
..... 174, 187, 188

EMBRACE PEN NEEDLES 31G X 6 MM  
..... 174, 187, 188

EMBRACE PEN NEEDLES 31G X 8 MM  
..... 174, 187, 188

EMBRACE PEN NEEDLES 32G X 4 MM  
..... 174, 187, 188

EMGALITY..... 142

EMGALITY (300 MG DOSE)..... 142

EMRELIS ..... 356

ENBREL MINI..... 126, 127

ENBREL SUBCUTANEOUS SOLUTION  
25 MG/0.5ML..... 126, 127

ENBREL SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE ..... 126, 127

ENBREL SUBCUTANEOUS SOLUTION  
RECONSTITUTED..... 126, 127

ENBREL SURECLICK SUBCUTANEOUS  
SOLUTION AUTO-INJECTOR 126, 127

EPCLUSA ORAL PACKET 150-37.5 MG,  
200-50 MG..... 333

EPCLUSA ORAL TABLET..... 333

EPIDIOLEX..... 65

EPKINLY ..... 119

EQL ALCOHOL SWABS PAD 70 %... 174,  
187, 188

EQL GAUZE PAD 2 ..... 174, 187, 188

EQL INSULIN SYRINGE 29G X 1/2... 174,  
187, 188

EQL INSULIN SYRINGE 30G X 5/16. 174,  
187, 188

ERBITUX ..... 72

ERIVEDGE..... 419

ERLEADA ORAL TABLET 240 MG, 60  
MG ..... 27, 28

erlotinib hcl oral tablet 100 mg, 150 mg, 25  
mg ..... 124

everolimus oral tablet 10 mg, 2.5 mg, 5 mg,  
7.5 mg ..... 128

everolimus oral tablet soluble ..... 129

EXEL COMFORT POINT INSULIN SYR  
29G X 1/2..... 174, 187, 188

EXEL COMFORT POINT INSULIN SYR  
30G X 5/16..... 174, 187, 188

EXEL COMFORT POINT PEN NEEDLE  
29G X 12MM..... 174, 187, 188

**F**

FASENRA ..... 50, 51

FASENRA PEN..... 50, 51

fentanyl citrate buccal lozenge on a handle  
..... 133

fingolimod hcl..... 137

FINTEPLA..... 132

FOTIVDA..... 367

FREESTYLE PRECISION INS SYR 30G X  
5/16 ..... 174, 175, 187, 188

FREESTYLE PRECISION INS SYR 31G X  
5/16 ..... 175, 187, 188

FRUZAQLA ORAL CAPSULE 1 MG, 5  
MG ..... 140

FYARRO ..... 330

**G**

GAUZE PADS PAD 2..... 175, 187, 188

GAUZE TYPE VII MEDI-PAK PAD 2 175,  
187, 188

GAVRETO ..... 287

gefitinib ..... 144

GILOTRIF ..... 20

glatiramer acetate subcutaneous solution  
prefilled syringe 20 mg/ml, 40 mg/ml 147

glatopa subcutaneous solution prefilled  
syringe 20 mg/ml, 40 mg/ml ..... 147

GLOBAL ALCOHOL PREP EASE..... 175,  
187, 188

GLOBAL EASE INJECT PEN NEEDLES  
29G X 12MM..... 175, 187, 188

GLOBAL EASE INJECT PEN NEEDLES  
31G X 5 MM..... 175, 187, 188

GLOBAL EASE INJECT PEN NEEDLES  
31G X 8 MM..... 175, 187, 188

GLOBAL EASE INJECT PEN NEEDLES  
32G X 4 MM..... 175, 187, 188

GLOBAL EASY GLIDE INSULIN SYR  
31G X 15/64..... 175, 187, 188

GLOBAL INJECT EASE INSULIN SYR  
30G X 1/2..... 175, 187, 188

GLUCOPRO INSULIN SYRINGE 30G X  
1/2 ..... 175, 187, 188

## Provider Partners Health Plan

### 2025 Formulary – Prior Authorization Criteria

GLUCOPRO INSULIN SYRINGE 30G X 5/16 ..... 175, 187, 188

GLUCOPRO INSULIN SYRINGE 31G X 5/16 ..... 175, 187, 188

GNP ALCOHOL SWABS PAD.... 175, 187, 188

GNP CLICKFINE PEN NEEDLES 31G X 6 MM ..... 175, 187, 188

GNP CLICKFINE PEN NEEDLES 31G X 8 MM ..... 175, 187, 188

GNP INSULIN SYRINGE 28G X 1/2 .. 175, 187, 188

GNP INSULIN SYRINGE 29G X 1/2 .. 175, 187, 188

GNP INSULIN SYRINGE 30G X 5/16 175, 187, 188

GNP INSULIN SYRINGES 29GX1/2 .. 175, 187, 188

GNP INSULIN SYRINGES 30G X 5/16 ..... 175, 187, 188

GNP INSULIN SYRINGES 30GX5/16 175, 187, 188

GNP INSULIN SYRINGES 31GX5/16 175, 187, 188

GNP PEN NEEDLES 32G X 4 MM ..... 175, 187, 188

GNP STERILE GAUZE PAD 2 .... 175, 187, 188

GNP ULTRA COM INSULIN SYRINGE 29G X 1/2..... 175, 187, 188

GNP ULTRA COM INSULIN SYRINGE 30G X 5/16..... 175, 187, 188

GOMEKLI ORAL CAPSULE 1 MG, 2 MG ..... 234

GOMEKLI ORAL TABLET SOLUBLE234

GOODSENSE ALCOHOL SWABS PAD 70 % ..... 175, 187, 188

GOODSENSE CLICKFINE PEN NEEDLE 31G X 5 MM..... 175, 187, 188

GOODSENSE PEN NEEDLE PENFINE 31G X 5 MM..... 175, 187, 188

GOODSENSE PEN NEEDLE PENFINE 31G X 8 MM..... 175, 187, 188

GOODSENSE PEN NEEDLE PENFINE 32G X 4 MM..... 176, 187, 188

GOODSENSE PEN NEEDLE PENFINE 32G X 6 MM..... 176, 187, 188

**H**

HAEGARDA SUBCUTANEOUS SOLUTION RECONSTITUTED 2000 UNIT, 3000 UNIT ..... 62

HARVONI ORAL PACKET 33.75-150 MG, 45-200 MG ..... 202

HARVONI ORAL TABLET ..... 202

HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16..... 176, 187, 188

HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16..... 176, 187, 188

HEALTHWISE MICRON PEN NEEDLES 32G X 4 MM..... 176, 187, 188

HEALTHWISE SHORT PEN NEEDLES 31G X 5 MM..... 176, 187, 188

HEALTHWISE SHORT PEN NEEDLES 31G X 8 MM..... 176, 187, 188

HEALTHY ACCENTS UNIFINE PENTIP 29G X 12MM..... 176, 187, 188

HEALTHY ACCENTS UNIFINE PENTIP 31G X 5 MM..... 176, 187, 188

HEALTHY ACCENTS UNIFINE PENTIP 31G X 6 MM..... 176, 187, 188

HEALTHY ACCENTS UNIFINE PENTIP 31G X 8 MM..... 176, 187, 188

HEALTHY ACCENTS UNIFINE PENTIP 32G X 4 MM..... 176, 187, 188

H-E-B INCONTROL ALCOHOL PAD 176, 187, 188

H-E-B INCONTROL PEN NEEDLES 29G X 12MM..... 176, 187, 188

H-E-B INCONTROL PEN NEEDLES 31G X 5 MM..... 176, 187, 188

H-E-B INCONTROL PEN NEEDLES 31G X 6 MM..... 176, 187, 188

H-E-B INCONTROL PEN NEEDLES 31G X 8 MM..... 176, 187, 188

H-E-B INCONTROL PEN NEEDLES 32G X 4 MM..... 176, 187, 188

HERCEPTIN HYLECTA..... 387

HERNEXEOS..... 426

HERZUMA..... 388

## Provider Partners Health Plan

### 2025 Formulary – Prior Authorization Criteria

HM STERILE ALCOHOL PREP PAD 176, 187, 188

HM STERILE PADS PAD 2.. 176, 187, 188

HM ULTICARE INSULIN SYRINGE 30G X 1/2..... 176, 187, 188

HM ULTICARE INSULIN SYRINGE 31G X 5/16..... 176, 187, 188

HM ULTICARE SHORT PEN NEEDLES 31G X 8 MM..... 176, 187, 188

HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT..... 11, 12, 13

HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML ..... 11, 12, 13

HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT ..... 11, 12, 13

HUMIRA-PED<40KG CROHNS STARTER..... 11, 12, 13

HUMIRA-PED>=40KG CROHNS START ..... 11, 12, 13

HUMIRA-PED>=40KG UC STARTER SUBCUTANEOUS AUTO-INJECTOR KIT ..... 11, 12, 13

HUMIRA-PS/UV/ADOL HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT ..... 11, 12, 13

HUMIRA-PSORIASIS/UEIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT ..... 11, 12, 13

**I**

IBRANCE ..... 266

IBTROZI..... 350

icatibant acetate..... 157

ICLUSIG..... 285

IDHIFA ..... 113

imatinib mesylate oral tablet 100 mg, 400 mg ..... 159

IMBRUVICA ORAL CAPSULE 140 MG, 70 MG ..... 156

IMBRUVICA ORAL SUSPENSION..... 156

IMBRUVICA ORAL TABLET ..... 156

IMDELLTRA ..... 352

IMJUDO ..... 391

IMKELDI..... 160

IMPAVIDO..... 233

INCONTROL ULTICARE PEN NEEDLES 31G X 6 MM..... 176, 187, 188

INCONTROL ULTICARE PEN NEEDLES 31G X 8 MM..... 176, 187, 188

INCONTROL ULTICARE PEN NEEDLES 32G X 4 MM..... 176, 187, 188

INCRELEX..... 226

infliximab..... 164, 165, 166

INGREZZA ORAL CAPSULE..... 411

INGREZZA ORAL CAPSULE SPRINKLE ..... 411

INGREZZA ORAL CAPSULE THERAPY PACK..... 411

INLURIYO ..... 162

INLYTA ORAL TABLET 1 MG, 5 MG.. 42

INQOVI ..... 87

INREBIC..... 131

INSULIN SYRINGE 29G X 1/2 ... 176, 187, 188

INSULIN SYRINGE 30G X 5/16 . 176, 187, 188

INSULIN SYRINGE 31G X 5/16 . 176, 187, 188

INSULIN SYRINGE/NEEDLE 27G X 1/2 ..... 177, 187, 188

INSULIN SYRINGE/NEEDLE 28G X 1/2 ..... 177, 187, 188

INSULIN SYRINGE-NEEDLE U-100 27G X 1/2..... 176, 187, 188

INSULIN SYRINGE-NEEDLE U-100 28G X 1/2..... 176, 187, 188

INSULIN SYRINGE-NEEDLE U-100 30G X 5/16..... 176, 187, 188

INSULIN SYRINGE-NEEDLE U-100 31G X 1/4..... 176, 187, 188

INSULIN SYRINGE-NEEDLE U-100 31G X 5/16..... 176, 187, 188

INSUPEN PEN NEEDLES 31G X 5 MM ..... 177, 187, 188

INSUPEN PEN NEEDLES 31G X 8 MM ..... 177, 187, 188

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

INSUPEN PEN NEEDLES 32G X 4 MM  
..... 177, 187, 188

INSUPEN PEN NEEDLES 33G X 4 MM  
..... 177, 187, 188

INSUPEN SENSITIVE 32G X 6 MM... 177,  
187, 188

INSUPEN SENSITIVE 32G X 8 MM... 177,  
187, 188

INSUPEN ULTRAFIN 29G X 12MM.. 177,  
187, 188

INSUPEN ULTRAFIN 30G X 8 MM... 177,  
187, 188

INSUPEN ULTRAFIN 31G X 6 MM... 177,  
187, 188

INSUPEN ULTRAFIN 31G X 8 MM... 177,  
187, 188

INSUPEN32G EXTR3ME 32G X 6 MM  
..... 177, 187, 188

ITOVEBI ORAL TABLET 3 MG, 9 MG  
..... 163

IWILFIN ..... 105

**J**

J & J GAUZE PAD 2..... 177, 187, 188

JAKAFI..... 317

javygtor oral tablet..... 318

JAYPIRCA ORAL TABLET 100 MG, 50  
MG ..... 283

JEMPERLI..... 98

**K**

KALYDECO..... 195

KENDALL HYDROPHILIC FOAM  
DRESS PAD 2 ..... 177, 187, 188

KENDALL HYDROPHILIC FOAM PLUS  
PAD 2..... 177, 187, 188

KERENDIA ..... 136

KESIMPTA..... 255

KEYTRUDA INTRAVENOUS  
SOLUTION..... 274

KEYTRUDA QLEX..... 275

KIMMTRAK ..... 354

KINERET SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE ..... 25, 26

KINRAY INSULIN SYRINGE 29G X 1/2  
..... 177, 187, 188

KISQALI (200 MG DOSE)..... 298

KISQALI (400 MG DOSE)..... 298

KISQALI (600 MG DOSE)..... 298

KISQALI FEMARA (200 MG DOSE) .. 299

KISQALI FEMARA (400 MG DOSE) .. 299

KISQALI FEMARA (600 MG DOSE) .. 299

KMART VALU INSULIN SYRINGE 29G  
U-100 1 ML ..... 177, 187, 188

KMART VALU INSULIN SYRINGE 30G  
U-100 0.3 ML ..... 177, 187, 188

KMART VALU INSULIN SYRINGE 30G  
U-100 1 ML ..... 177, 187, 188

KOSELUGO ORAL CAPSULE 10 MG, 25  
MG ..... 326

KOSELUGO ORAL CAPSULE  
SPRINKLE 5 MG, 7.5 MG..... 326

KRAZATI..... 10

KROGER INSULIN SYRINGE 30G X 5/16  
..... 177, 187, 188

KROGER PEN NEEDLES 29G X 12MM  
..... 177, 187, 188

KROGER PEN NEEDLES 31G X 6 MM  
..... 177, 187, 188

KYNMOBI ..... 30

KYNMOBI TITRATION KIT ..... 30

**L**

LANREOTIDE ACETATE ..... 198

lapatinib ditosylate ..... 199

LAZCLUZE ORAL TABLET 240 MG, 80  
MG ..... 201

LEADER INSULIN SYRINGE 28G X 1/2  
..... 177, 187, 188

LEADER UNIFINE PENTIPS 31G X 5  
MM ..... 177, 187, 188

LEADER UNIFINE PENTIPS 32G X 4  
MM ..... 177, 187, 188

LEADER UNIFINE PENTIPS PLUS 31G  
X 5 MM..... 177, 187, 188

LEADER UNIFINE PENTIPS PLUS 31G  
X 8 MM..... 177, 187, 188

ledipasvir-sofosbuvir..... 202

lenalidomide..... 203

LENVIMA (10 MG DAILY DOSE) ..... 204

LENVIMA (12 MG DAILY DOSE) ..... 204

LENVIMA (14 MG DAILY DOSE) ..... 204

LENVIMA (18 MG DAILY DOSE) ..... 204

## Provider Partners Health Plan

### 2025 Formulary – Prior Authorization Criteria

LENVIMA (20 MG DAILY DOSE) .....	204	LUPRON DEPOT-PED (6-MONTH) ...	211,
LENVIMA (24 MG DAILY DOSE) .....	204	212	
LENVIMA (4 MG DAILY DOSE) .....	204	LUTRATE DEPOT .....	207
LENVIMA (8 MG DAILY DOSE) .....	204	LYBALVI .....	256
LEUPROLIDE ACETATE (3 MONTH)	207	LYNOZYFIC INTRAVENOUS	
leuprolide acetate injection .....	206	SOLUTION 200 MG/10ML, 5	
l-glutamine oral packet .....	213	MG/2.5ML .....	217
lidocaine external ointment 5 % .....	214	LYNPARZA ORAL TABLET .....	257
lidocaine external patch 5 % .....	215	LYTGOBI (12 MG DAILY DOSE) .....	141
lidocaine-prilocaine external cream .....	216	LYTGOBI (16 MG DAILY DOSE) .....	141
lidocan .....	215	LYTGOBI (20 MG DAILY DOSE) .....	141
LITETOUCH INSULIN SYRINGE 28G X		<b>M</b>	
1/2 .....	177, 187, 188	MAGELLAN INSULIN SAFETY SYR	
LITETOUCH INSULIN SYRINGE 29G X		29G X 1/2 .....	177, 178, 187, 188
1/2 .....	177, 187, 188	MAGELLAN INSULIN SAFETY SYR	
LITETOUCH INSULIN SYRINGE 30G X		30G X 5/16 .....	178, 187, 188
5/16 .....	177, 187, 188	MARGENZA .....	223
LITETOUCH INSULIN SYRINGE 31G X		MAVENCLAD (10 TABS) .....	73
5/16 .....	177, 187, 188	MAVENCLAD (4 TABS) .....	73
LITETOUCH PEN NEEDLES 29G X		MAVENCLAD (5 TABS) .....	73
12.7MM .....	177, 187, 188	MAVENCLAD (6 TABS) .....	73
LITETOUCH PEN NEEDLES 31G X 5		MAVENCLAD (7 TABS) .....	73
MM .....	177, 187, 188	MAVENCLAD (8 TABS) .....	73
LITETOUCH PEN NEEDLES 31G X 6		MAVENCLAD (9 TABS) .....	73
MM .....	177, 187, 188	MAVYRET ORAL TABLET .....	148, 149
LITETOUCH PEN NEEDLES 31G X 8		MAXICOMFORT II PEN NEEDLE 31G X	
MM .....	177, 187, 188	6 MM .....	178, 187, 188
LITETOUCH PEN NEEDLES 32G X 4		MAXI-COMFORT INSULIN SYRINGE	
MM .....	177, 187, 188	28G X 1/2 .....	178, 187, 188
LIVTENCITY .....	224	MAXI-COMFORT SAFETY PEN	
LONSURF ORAL TABLET 15-6.14 MG,		NEEDLE 29G X 5MM .....	178, 187, 188
20-8.19 MG .....	393	MAXI-COMFORT SAFETY PEN	
LOQTORZI .....	380	NEEDLE 29G X 8MM .....	178, 187, 188
LORBRENA ORAL TABLET 100 MG, 25		MAXICOMFORT SYR 27G X 1/2	178, 187,
MG .....	219	188	
LUMAKRAS ORAL TABLET 120 MG,		MAYZENT ORAL TABLET 0.25 MG, 1	
240 MG, 320 MG .....	344	MG, 2 MG .....	329
LUNSUMIO .....	237	MAYZENT STARTER PACK .....	329
LUPRON DEPOT (1-MONTH) .....	209, 210	MEDIC INSULIN SYRINGE 30G X 5/16	
LUPRON DEPOT (3-MONTH) .....	209, 210	.....	178, 187, 188
LUPRON DEPOT (4-MONTH) .....	209, 210	MEDICINE SHOPPE PEN NEEDLES 29G	
LUPRON DEPOT (6-MONTH) .....	209, 210	X 12MM .....	178, 187, 188
LUPRON DEPOT-PED (3-MONTH) ...	211,	MEDICINE SHOPPE PEN NEEDLES 31G	
212		X 8 MM .....	178, 187, 188

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

MEDPURA ALCOHOL PADS 70 % EXTERNAL ..... 178, 187, 188	MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2 ..... 178, 187, 188
MEIJER ALCOHOL SWABS PAD 70 % ..... 178, 187, 188	MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2 . 178, 179, 187, 188
MEIJER PEN NEEDLES 29G X 12MM ..... 178, 187, 188	MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16 ..... 179, 187, 188
MEIJER PEN NEEDLES 31G X 6 MM 178, 187, 188	MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR ..... 152
MEIJER PEN NEEDLES 31G X 8 MM 178, 187, 188	MS INSULIN SYRINGE 30G X 5/16... 179, 187, 188
MEKINIST ORAL SOLUTION RECONSTITUTED ..... 383	MS INSULIN SYRINGE 31G X 5/16... 179, 187, 188
MEKINIST ORAL TABLET 0.5 MG, 2 MG ..... 384	MVASI..... 54
MEKTOVI ..... 57	N
MICRODOT PEN NEEDLE 31G X 6 MM ..... 178, 187, 188	NATPARA..... 267
MICRODOT PEN NEEDLE 32G X 4 MM ..... 178, 187, 188	NERLYNX ..... 240
MICRODOT PEN NEEDLE 33G X 4 MM ..... 178, 187, 188	NEULASTA ONPRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 271
mifepristone oral tablet 300 mg ..... 232	NIKTIMVO ..... 41
MIPLYFFA..... 33	NINLARO..... 197
MIRASORB SPONGES 2..... 178, 187, 188	nitisinone..... 248
MM PEN NEEDLES 31G X 6 MM ..... 178, 187, 188	NIVESTYM..... 135
MM PEN NEEDLES 32G X 4 MM ..... 178, 187, 188	NORDITROPIN FLEXPRO SUBCUTANEOUS SOLUTION PEN- INJECTOR..... 336, 337
modafinil oral tablet 100 mg, 200 mg..... 238	NOVOFINE AUTOCOVER 30G X 8 MM ..... 179, 187, 188
MODEYSO..... 97	NOVOFINE PEN NEEDLE 32G X 6 MM ..... 179, 187, 188
MONOJECT INSULIN SYRINGE 25G X 5/8 ..... 178, 187, 188	NOVOFINE PLUS PEN NEEDLE 32G X 4 MM ..... 179, 187, 188
MONOJECT INSULIN SYRINGE 27G X 1/2 ..... 178, 187, 188	NOVOTWIST PEN NEEDLE 32G X 5 MM ..... 179, 187, 188
MONOJECT INSULIN SYRINGE 28G X 1/2 ..... 178, 187, 188	NUBEQA..... 84
MONOJECT INSULIN SYRINGE 29G X 1/2 ..... 178, 187, 188	NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR ..... 228, 229, 230
MONOJECT INSULIN SYRINGE 30G X 5/16 ..... 178, 187, 188	NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 40 MG/0.4ML ..... 228, 229, 230
MONOJECT INSULIN SYRINGE 31G X 5/16 ..... 178, 187, 188	NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED ..... 228, 229, 230
MONOJECT INSULIN SYRINGE U-100 1 ML..... 178, 187, 188	NUPLAZID ORAL CAPSULE..... 280
	NUPLAZID ORAL TABLET 10 MG.... 280
	NURTEC..... 304, 305
	NYVEPRIA ..... 270



## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

### O

OCREVUS.....	253
OCREVUS ZUNOVO.....	254
ODOMZO.....	340
OFEV.....	243, 244
OGIVRI.....	385
OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG.....	247
OJEMDA ORAL SUSPENSION RECONSTITUTED.....	381
OJEMDA ORAL TABLET.....	381
OJJAARA.....	236
ONAPGO.....	29
ONTRUZANT.....	386
ONUREG.....	43
OPDIVO.....	249
OPDIVO QVANTIG.....	250
OPDUALAG.....	251
OPSUMIT.....	222
ORENCIA CLICKJECT.....	4, 5
ORENCIA INTRAVENOUS.....	2, 3
ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	4, 5
ORFADIN ORAL SUSPENSION.....	248
ORGOVYX.....	292
ORILISSA ORAL TABLET 150 MG, 200 MG.....	107, 108
ORKAMBI ORAL TABLET.....	221
ORSERDU ORAL TABLET 345 MG, 86 MG.....	106
OSENVELT.....	90
OTEZLA.....	31, 32
OTEZLA XR.....	31, 32
oxandrolone oral.....	264
OZEMPIC (0.25 OR 0.5 MG/DOSE).....	151
OZEMPIC (1 MG/DOSE).....	151
OZEMPIC (2 MG/DOSE).....	151

### P

pazopanib hcl.....	269
PC UNIFINE PENTIPS 31G X 5 MM..	179, 187, 188
PC UNIFINE PENTIPS 31G X 6 MM..	179, 187, 188
PC UNIFINE PENTIPS 31G X 8 MM..	179, 187, 188

PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML.....	272
PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	272
PEMAZYRE.....	276
PEN NEEDLE/5-BEVEL TIP 31G X 8 MM .....	179, 187, 188
PEN NEEDLE/5-BEVEL TIP 32G X 4 MM .....	179, 187, 188
PEN NEEDLES 30G X 5 MM (OTC)...	179, 187, 188
PEN NEEDLES 30G X 8 MM	179, 187, 188
PEN NEEDLES 32G X 5 MM	179, 187, 188
penicillamine oral tablet.....	277, 278
PENTIPS 29G X 12MM (RX)	179, 187, 188
PENTIPS 31G X 5 MM (RX).	179, 187, 188
PENTIPS 31G X 8 MM (RX).	179, 187, 188
PENTIPS 32G X 4 MM (RX).	179, 187, 188
PENTIPS GENERIC PEN NEEDLES 29G X 12MM.....	179, 187, 188
PENTIPS GENERIC PEN NEEDLES 31G X 6 MM.....	179, 187, 188
PENTIPS GENERIC PEN NEEDLES 32G X 6 MM.....	179, 187, 188
PIP PEN NEEDLES 31G X 5MM 31G X 5 MM.....	179, 187, 188
PIP PEN NEEDLES 32G X 4MM 32G X 4 MM.....	179, 187, 188
PIQRAY (200 MG DAILY DOSE).....	22
PIQRAY (250 MG DAILY DOSE).....	22
PIQRAY (300 MG DAILY DOSE).....	22
pirfenidone oral capsule.....	281, 282
pirfenidone oral tablet 267 mg, 534 mg, 801 mg.....	281, 282
PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION AUTO- INJECTOR.....	191
PLEGRIDY STARTER PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE.....	191
PLEGRIDY SUBCUTANEOUS SOLUTION AUTO-INJECTOR.....	191
PLEGRIDY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	191
POMALYST.....	284

## Provider Partners Health Plan

### 2025 Formulary – Prior Authorization Criteria

posaconazole oral tablet delayed release 286  
PRECISION SUREDOSE PLUS SYR 29G  
X 1/2..... 179, 187, 188  
PRECISION SURE-DOSE SYRINGE 28G  
X 1/2..... 179, 187, 188  
PRECISION SURE-DOSE SYRINGE 29G  
X 1/2..... 179, 187, 188  
PRECISION SURE-DOSE SYRINGE 30G  
X 3/8..... 179, 187, 188  
PRECISION SURE-DOSE SYRINGE 30G  
X 5/16..... 179, 187, 188  
PREFERRED PLUS INSULIN SYRINGE  
28G X 1/2..... 179, 187, 188  
PREFERRED PLUS INSULIN SYRINGE  
29G X 1/2..... 179, 187, 188  
PREFERRED PLUS INSULIN SYRINGE  
30G X 5/16..... 179, 187, 188  
PREFERRED PLUS UNIFINE PENTIPS  
29G X 12MM..... 179, 187, 188  
PREVENT DROPSAFE PEN NEEDLES  
31G X 6 MM..... 179, 187, 188  
PREVENT DROPSAFE PEN NEEDLES  
31G X 8 MM..... 179, 187, 188  
PREVENT SAFETY PEN NEEDLES 31G  
X 6 MM..... 179, 187, 188  
PREVENT SAFETY PEN NEEDLES 31G  
X 8 MM..... 179, 187, 188  
PREVYMIS ORAL TABLET ..... 205  
PRO COMFORT ALCOHOL PAD 70 %  
..... 179, 187, 188  
PRO COMFORT INSULIN SYRINGE 30G  
X 1/2..... 179, 180, 187, 188  
PRO COMFORT INSULIN SYRINGE 30G  
X 5/16..... 180, 187, 188  
PRO COMFORT INSULIN SYRINGE 31G  
X 5/16..... 180, 187, 188  
PRO COMFORT PEN NEEDLES 32G X 4  
MM ..... 180, 187, 188  
PRO COMFORT PEN NEEDLES 32G X 5  
MM ..... 180, 187, 188  
PRO COMFORT PEN NEEDLES 32G X 6  
MM ..... 180, 187, 188  
PRO COMFORT PEN NEEDLES 32G X 8  
MM ..... 180, 187, 188

PRODIGY INSULIN SYRINGE 28G X 1/2  
..... 180, 187, 188  
PRODIGY INSULIN SYRINGE 31G X  
5/16 ..... 180, 187, 188  
PURE COMFORT ALCOHOL PREP PAD  
..... 180, 187, 188  
PURE COMFORT PEN NEEDLE 32G X 4  
MM ..... 180, 187, 188  
PURE COMFORT PEN NEEDLE 32G X 5  
MM ..... 180, 187, 188  
PURE COMFORT PEN NEEDLE 32G X 6  
MM ..... 180, 187, 188  
PURE COMFORT PEN NEEDLE 32G X 8  
MM ..... 180, 187, 188  
PURE COMFORT SAFETY PEN NEEDLE  
31G X 5 MM..... 180, 187, 188  
PURE COMFORT SAFETY PEN NEEDLE  
31G X 6 MM..... 180, 187, 188  
PURE COMFORT SAFETY PEN NEEDLE  
32G X 4 MM..... 180, 187, 188  
PX SHORTLENGTH PEN NEEDLES 31G  
X 8 MM..... 180, 187, 188  
pyrimethamine oral ..... 288  
**Q**  
QC ALCOHOL ..... 180, 187, 188  
QC ALCOHOL SWABS PAD 70 %..... 180,  
187, 188  
QC BORDER ISLAND GAUZE PAD 2  
..... 180, 187, 188  
QINLOCK..... 308  
QUICK TOUCH INSULIN PEN NEEDLE  
29G X 12.7MM..... 180, 187, 188  
QUICK TOUCH INSULIN PEN NEEDLE  
31G X 4 MM..... 180, 187, 188  
QUICK TOUCH INSULIN PEN NEEDLE  
31G X 5 MM..... 180, 187, 188  
QUICK TOUCH INSULIN PEN NEEDLE  
31G X 6 MM..... 180, 187, 188  
QUICK TOUCH INSULIN PEN NEEDLE  
31G X 8 MM..... 180, 187, 188  
QUICK TOUCH INSULIN PEN NEEDLE  
32G X 4 MM..... 180, 187, 188  
QUICK TOUCH INSULIN PEN NEEDLE  
32G X 5 MM..... 180, 187, 188

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

QUICK TOUCH INSULIN PEN NEEDLE  
32G X 6 MM..... 180, 187, 188

QUICK TOUCH INSULIN PEN NEEDLE  
32G X 8 MM..... 180, 187, 188

QUICK TOUCH INSULIN PEN NEEDLE  
33G X 4 MM..... 180, 187, 188

QUICK TOUCH INSULIN PEN NEEDLE  
33G X 5 MM..... 180, 187, 188

QUICK TOUCH INSULIN PEN NEEDLE  
33G X 6 MM..... 180, 187, 188

QUICK TOUCH INSULIN PEN NEEDLE  
33G X 8 MM..... 180, 187, 188

quinine sulfate oral..... 289

QULIPTA ..... 37

**R**

RA ALCOHOL SWABS PAD 70 %..... 180,  
187, 188

RA INSULIN SYRINGE 29G X 1/2..... 180,  
187, 188

RA INSULIN SYRINGE 30G X 5/16... 180,  
187, 188

ra isopropyl alcohol wipes ..... 181, 187, 188

RA PEN NEEDLES 31G X 5 MM 181, 187,  
188

RA PEN NEEDLES 31G X 8 MM 181, 187,  
188

RA STERILE PAD 2 ..... 181, 187, 188

RALDESY ..... 390

RAYA SURE PEN NEEDLE 29G X 12MM  
..... 181, 187, 188

RAYA SURE PEN NEEDLE 31G X 4 MM  
..... 181, 187, 188

RAYA SURE PEN NEEDLE 31G X 5 MM  
..... 181, 187, 188

RAYA SURE PEN NEEDLE 31G X 6 MM  
..... 181, 187, 188

REALITY INSULIN SYRINGE 28G X 1/2  
..... 181, 187, 188

REALITY INSULIN SYRINGE 29G X 1/2  
..... 181, 187, 188

REALITY SWABS PAD..... 181, 187, 188

RELION ALCOHOL SWABS PAD..... 181,  
187, 188

RELI-ON INSULIN SYRINGE 29G 0.3  
ML..... 181, 187, 188

RELI-ON INSULIN SYRINGE 29G X 1/2  
..... 181, 187, 188

RELION INSULIN SYRINGE 31G X 15/64  
..... 181, 187, 188

RELION MINI PEN NEEDLES 31G X 6  
MM ..... 181, 187, 188

RELION PEN NEEDLES 29G X 12MM  
..... 181, 187, 188

RELION PEN NEEDLES 31G X 6 MM181,  
187, 188

RELION PEN NEEDLES 31G X 8 MM181,  
187, 188

RESTORE CONTACT LAYER PAD 2 181,  
187, 188

RETACRIT INJECTION SOLUTION  
10000 UNIT/ML, 10000  
UNIT/ML(1ML), 2000 UNIT/ML, 20000  
UNIT/ML, 3000 UNIT/ML, 4000  
UNIT/ML, 40000 UNIT/ML ..... 120, 121

RETEVMO ORAL CAPSULE 40 MG, 80  
MG ..... 325

RETEVMO ORAL TABLET 120 MG, 160  
MG, 40 MG, 80 MG ..... 325

REVUFORJ ORAL TABLET 110 MG, 160  
MG, 25 MG..... 297

REZLIDHIA ..... 258

REZUROCK..... 47

RIABNI..... 313

RINVOQ ..... 397, 399

RINVOQ LQ..... 397, 399

RITUXAN HYCELA ..... 311

ROMVIMZA ..... 418

ROZLYTREK ORAL CAPSULE 100 MG,  
200 MG ..... 115

ROZLYTREK ORAL PACKET ..... 116

RUBRACA ..... 316

RUXIENCE ..... 314

RYBELSUS ..... 151

RYBELSUS (FORMULATION R2)..... 151

RYBREVANT ..... 24

RYDAPT..... 231

RYTELO..... 161

**S**

SAFETY INSULIN SYRINGES 29G X 1/2  
..... 181, 187, 188

## Provider Partners Health Plan

### 2025 Formulary – Prior Authorization Criteria

SAFETY INSULIN SYRINGES 30G X 1/2 ..... 181, 187, 188	SOMATULINE DEPOT SUBCUTANEOUS SOLUTION 60 MG/0.2ML, 90 MG/0.3ML ..... 198
SAFETY INSULIN SYRINGES 30G X 5/16 ..... 181, 187, 188	SOMAVERT..... 273
SAFETY PEN NEEDLES 30G X 5 MM ..... 181, 187, 188	sorafenib tosylate ..... 341
SAFETY PEN NEEDLES 30G X 8 MM ..... 181, 187, 188	SPRAVATO (56 MG DOSE)..... 125
sapropterin dihydrochloride oral tablet... 318	SPRAVATO (84 MG DOSE)..... 125
SB ALCOHOL PREP PAD 70 %.. 181, 187, 188	STELARA INTRAVENOUS ..... 402
SB INSULIN SYRINGE 29G X 1/2 ..... 181, 187, 188	STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML ..... 400, 401
SB INSULIN SYRINGE 30G X 5/16 ... 181, 187, 188	STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 400, 401
SB INSULIN SYRINGE 31G X 5/16 ... 181, 187, 188	STERILE GAUZE PAD 2 ..... 181, 187, 188
SCSEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG..... 34	STERILE PAD 2..... 181, 187, 188
SECURESAFE INSULIN SYRINGE 29G X 1/2..... 181, 187, 188	STIVARGA ..... 291
SECURESAFE SAFETY PEN NEEDLES 30G X 8 MM..... 181, 187, 188	STRENSIQ ..... 35, 36
SELARSDI INTRAVENOUS ..... 403, 404	sunitinib malate..... 346
SELARSDI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 405, 406	SURE COMFORT ALCOHOL PREP PAD 70 % ..... 181, 187, 188
SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG..... 338, 339	SURE COMFORT INSULIN SYRINGE 28G X 1/2..... 181, 187, 188
SIGNIFOR ..... 268	SURE COMFORT INSULIN SYRINGE 29G X 1/2..... 181, 182, 187, 188
sildenafil citrate oral tablet 20 mg .. 327, 328	SURE COMFORT INSULIN SYRINGE 30G X 1/2..... 182, 187, 188
SIRTURO ..... 45	SURE COMFORT INSULIN SYRINGE 30G X 5/16..... 182, 187, 188
SKYRIZI..... 309, 310	SURE COMFORT INSULIN SYRINGE 31G X 1/4..... 182, 187, 188
SKYRIZI (150 MG DOSE) ..... 309, 310	SURE COMFORT INSULIN SYRINGE 31G X 5/16..... 182, 187, 188
SKYRIZI PEN ..... 309, 310	SURE COMFORT PEN NEEDLES 29G X 12.7MM ..... 182, 187, 188
SM ALCOHOL PREP PAD ... 181, 187, 188	SURE COMFORT PEN NEEDLES 30G X 8 MM ..... 182, 187, 188
SM ALCOHOL PREP PAD 6-70 % EXTERNAL ..... 181, 187, 188	SURE COMFORT PEN NEEDLES 31G X 5 MM ..... 182, 187, 188
SM ALCOHOL PREP PAD 70 %. 181, 187, 188	SURE COMFORT PEN NEEDLES 31G X 6 MM ..... 182, 187, 188
SM GAUZE PAD 2 ..... 181, 187, 188	SURE COMFORT PEN NEEDLES 31G X 8 MM ..... 182, 187, 188
sodium oxybate ..... 331, 332	SURE COMFORT PEN NEEDLES 32G X 4 MM (OTC)..... 182, 187, 188
sofosbuvir-velpatasvir ..... 333	

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

SURE COMFORT PEN NEEDLES 32G X  
4 MM (RX) ..... 182, 187, 188  
SURE COMFORT PEN NEEDLES 32G X  
6 MM ..... 182, 187, 188  
SURE-JECT INSULIN SYRINGE 31G X  
5/16 ..... 182, 187, 188  
SURE-PREP ALCOHOL PREP PAD 70 %  
..... 182, 187, 188  
SURGICAL GAUZE SPONGE PAD 2 182,  
187, 188  
SYMPAZAN..... 74  
SYNRIBO ..... 259

### T

TABRECTA ..... 67  
tadalafil oral tablet 2.5 mg, 5 mg ..... 348  
TAFINLAR ORAL CAPSULE ..... 80  
TAFINLAR ORAL TABLET SOLUBLE 81  
TAGRISSO ..... 263  
TALVEY..... 351  
TALZENNA ..... 349  
TASIGNA ORAL CAPSULE 150 MG, 200  
MG, 50 MG..... 241  
TAVNEOS..... 38  
TAZVERIK..... 353  
TECHLITE INSULIN SYRINGE 29G X  
1/2 ..... 182, 187, 188  
TECHLITE PEN NEEDLES 32G X 4 MM  
..... 182, 187, 188  
TECVAYLI..... 355  
TEPMETKO ..... 358  
TERIPARATIDE SUBCUTANEOUS  
SOLUTION PEN-INJECTOR 560  
MCG/2.24ML ..... 359  
testosterone cypionate intramuscular  
solution 100 mg/ml, 200 mg/ml, 200  
mg/ml (1 ml) ..... 361  
testosterone enanthate intramuscular  
solution..... 362  
testosterone gel 1.62 % transdermal ..... 360  
testosterone transdermal gel 12.5 mg/act  
(1%), 20.25 mg/act (1.62%), 25  
mg/2.5gm (1%), 50 mg/5gm (1%)..... 360  
tetrabenazine ..... 363  
TEVIMBRA..... 365  
THALOMID ..... 364

THERAGAUZE PAD 2..... 182, 187, 188  
TIBSOVO ..... 196  
TIGLUTIK..... 303  
TIVDAK ..... 366  
TODAYS HEALTH PEN NEEDLES 29G  
X 12MM..... 182, 187, 188  
TODAYS HEALTH SHORT PEN  
NEEDLE 31G X 8 MM ..... 182, 187, 188  
tolvaptan oral tablet..... 378  
tolvaptan oral tablet therapy pack ..... 378  
TOPCARE CLICKFINE PEN NEEDLES  
31G X 6 MM..... 182, 187, 188  
TOPCARE CLICKFINE PEN NEEDLES  
31G X 8 MM..... 182, 187, 188  
TOPCARE ULTRA COMFORT INS SYR  
29G X 1/2..... 182, 187, 188  
TOPCARE ULTRA COMFORT INS SYR  
30G X 5/16..... 182, 187, 188  
TOPCARE ULTRA COMFORT INS SYR  
31G X 5/16..... 182, 183, 187, 188  
torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5  
mg ..... 128  
TRAMADOL HCL ORAL SOLUTION 382  
TRAZIMERA ..... 389  
TRELSTAR MIXJECT ..... 394  
TREMIFYA CROHNS INDUCTION .... 154,  
155  
TREMIFYA INTRAVENOUS ..... 154, 155  
TREMIFYA ONE-PRESS SOLUTION  
PEN-INJECTOR 100 MG/ML  
SUBCUTANEOUS..... 154, 155  
TREMIFYA ONE-PRESS  
SUBCUTANEOUS SOLUTION AUTO-  
INJECTOR..... 154, 155  
TREMIFYA PEN SUBCUTANEOUS  
SOLUTION AUTO-INJECTOR 200  
MG/2ML ..... 154, 155  
TREMIFYA SUBCUTANEOUS  
SOLUTION PREFILLED SYRINGE 154,  
155  
TREMIFYA-CD/UC INDUCTION  
SOLUTION AUTO-INJECTOR 200  
MG/2ML SUBCUTANEOUS .... 154, 155  
tretinoin external cream ..... 379  
trientine hcl oral capsule 250 mg ..... 392

## Provider Partners Health Plan

### 2025 Formulary – Prior Authorization Criteria

TRUE COMFORT ALCOHOL PREP		TRUEPLUS 5-BEVEL PEN NEEDLES	
PADS PAD 70 %.....	183, 187, 188	29G X 12.7MM.....	183, 187, 188
TRUE COMFORT INSULIN SYRINGE		TRUEPLUS 5-BEVEL PEN NEEDLES	
30G X 1/2.....	183, 187, 188	31G X 5 MM.....	183, 187, 188
TRUE COMFORT INSULIN SYRINGE		TRUEPLUS 5-BEVEL PEN NEEDLES	
30G X 5/16.....	183, 187, 188	31G X 6 MM.....	183, 187, 188
TRUE COMFORT INSULIN SYRINGE		TRUEPLUS 5-BEVEL PEN NEEDLES	
31G X 5/16.....	183, 187, 188	31G X 8 MM.....	183, 187, 188
TRUE COMFORT INSULIN SYRINGE		TRUEPLUS 5-BEVEL PEN NEEDLES	
32G X 5/16.....	183, 187, 188	32G X 4 MM.....	183, 187, 188
TRUE COMFORT PEN NEEDLES 31G X		TRUEPLUS INSULIN SYRINGE 28G X	
5 MM .....	183, 187, 188	1/2 .....	183, 187, 188
TRUE COMFORT PEN NEEDLES 31G X		TRUEPLUS INSULIN SYRINGE 29G X	
6 MM .....	183, 187, 188	1/2 .....	183, 184, 187, 188
TRUE COMFORT PEN NEEDLES 32G X		TRUEPLUS INSULIN SYRINGE 30G X	
4 MM .....	183, 187, 188	5/16 .....	184, 187, 188
TRUE COMFORT PRO ALCOHOL PREP		TRUEPLUS INSULIN SYRINGE 31G X	
PAD 70 % .....	183, 187, 188	5/16 .....	184, 187, 188
TRUE COMFORT PRO INSULIN SYR		TRUEPLUS PEN NEEDLES 29G X 12MM	
30G X 1/2.....	183, 187, 188	.....	184, 187, 188
TRUE COMFORT PRO INSULIN SYR		TRUEPLUS PEN NEEDLES 31G X 5 MM	
30G X 5/16.....	183, 187, 188	.....	184, 187, 188
TRUE COMFORT PRO INSULIN SYR		TRUEPLUS PEN NEEDLES 31G X 6 MM	
31G X 5/16.....	183, 187, 188	.....	184, 187, 188
TRUE COMFORT PRO INSULIN SYR		TRUEPLUS PEN NEEDLES 31G X 8 MM	
32G X 5/16.....	183, 187, 188	.....	184, 187, 188
TRUE COMFORT PRO PEN NEEDLES		TRUEPLUS PEN NEEDLES 32G X 4 MM	
31G X 5 MM.....	183, 187, 188	.....	184, 187, 188
TRUE COMFORT PRO PEN NEEDLES		TRULICITY SUBCUTANEOUS	
31G X 6 MM.....	183, 187, 188	SOLUTION AUTO-INJECTOR .....	150
TRUE COMFORT PRO PEN NEEDLES		TRUQAP ORAL TABLET .....	66
31G X 8 MM.....	183, 187, 188	TRUQAP TABLET THERAPY PACK 160	
TRUE COMFORT PRO PEN NEEDLES		MG ORAL .....	66
32G X 4 MM.....	183, 187, 188	TRUXIMA.....	312
TRUE COMFORT PRO PEN NEEDLES		TUKYSA ORAL TABLET 150 MG, 50	
32G X 5 MM.....	183, 187, 188	MG .....	395
TRUE COMFORT PRO PEN NEEDLES		TURALIO .....	279
32G X 6 MM.....	183, 187, 188	TYENNE.....	372, 373, 374, 375
TRUE COMFORT PRO PEN NEEDLES		TYMLOS .....	1
33G X 4 MM.....	183, 187, 188	U	
TRUE COMFORT PRO PEN NEEDLES		UBRELVY.....	396
33G X 5 MM.....	183, 187, 188	ULTICARE INSULIN SAFETY SYR 29G	
TRUE COMFORT PRO PEN NEEDLES		X 1/2.....	184, 187, 188
33G X 6 MM.....	183, 187, 188	ULTICARE INSULIN SYRINGE 28G X	
		1/2 .....	184, 187, 188

## Provider Partners Health Plan

### 2025 Formulary – Prior Authorization Criteria

ULTICARE INSULIN SYRINGE 29G X  
 1/2 ..... 184, 187, 188  
 ULTICARE INSULIN SYRINGE 30G X  
 1/2 ..... 184, 187, 188  
 ULTICARE INSULIN SYRINGE 30G X  
 5/16 ..... 184, 187, 188  
 ULTICARE INSULIN SYRINGE 31G X  
 1/4 ..... 184, 187, 188  
 ULTICARE INSULIN SYRINGE 31G X  
 5/16 ..... 184, 187, 188  
 ULTICARE MICRO PEN NEEDLES 32G  
 X 4 MM..... 184, 187, 188  
 ULTICARE MINI PEN NEEDLES 30G X 5  
 MM ..... 184, 187, 188  
 ULTICARE MINI PEN NEEDLES 31G X 6  
 MM ..... 184, 187, 188  
 ULTICARE MINI PEN NEEDLES 32G X 6  
 MM ..... 184, 187, 188  
 ULTICARE PEN NEEDLES 29G X  
 12.7MM (OTC)..... 184, 187, 188  
 ULTICARE PEN NEEDLES 29G X  
 12.7MM (RX) ..... 184, 187, 188  
 ULTICARE PEN NEEDLES 31G X 5 MM  
 ..... 185, 187, 188  
 ULTICARE SHORT PEN NEEDLES 30G  
 X 8 MM..... 185, 187, 188  
 ULTICARE SHORT PEN NEEDLES 31G  
 X 8 MM (OTC)..... 185, 187, 188  
 ULTICARE SHORT PEN NEEDLES 31G  
 X 8 MM (RX) ..... 185, 187, 188  
 ULTIGUARD SAFEPACK PEN NEEDLE  
 29G X 12.7MM..... 185, 187, 188  
 ULTIGUARD SAFEPACK PEN NEEDLE  
 31G X 5 MM..... 185, 187, 188  
 ULTIGUARD SAFEPACK PEN NEEDLE  
 31G X 6 MM..... 185, 187, 188  
 ULTIGUARD SAFEPACK PEN NEEDLE  
 31G X 8 MM..... 185, 187, 188  
 ULTIGUARD SAFEPACK PEN NEEDLE  
 32G X 4 MM..... 185, 187, 188  
 ULTIGUARD SAFEPACK PEN NEEDLE  
 32G X 6 MM..... 185, 187, 188  
 ULTIGUARD SAFEPACK SYR/NEEDLE  
 30G X 1/2..... 185, 187, 188

ULTIGUARD SAFEPACK SYR/NEEDLE  
 31G X 5/16..... 185, 187, 188  
 ULTILET ALCOHOL SWABS PAD ... 185,  
 187, 188  
 ULTILET PEN NEEDLE 29G X 12.7MM  
 ..... 185, 187, 188  
 ULTILET PEN NEEDLE 31G X 5 MM 185,  
 187, 188  
 ULTILET PEN NEEDLE 31G X 8 MM 185,  
 187, 188  
 ULTILET PEN NEEDLE 32G X 4 MM 185,  
 187, 188  
 ULTRA COMFORT INSULIN SYRINGE  
 30G X 5/16..... 185, 187, 188  
 ULTRA FLO INSULIN PEN NEEDLES  
 29G X 12MM..... 185, 187, 188  
 ULTRA FLO INSULIN PEN NEEDLES  
 31G X 8 MM..... 185, 187, 188  
 ULTRA FLO INSULIN PEN NEEDLES  
 32G X 4 MM..... 185, 187, 188  
 ULTRA FLO INSULIN PEN NEEDLES  
 33G X 4 MM..... 185, 187, 188  
 ULTRA FLO INSULIN SYR 1/2 UNIT  
 30G X 1/2..... 185, 187, 188  
 ULTRA FLO INSULIN SYR 1/2 UNIT  
 30G X 5/16..... 185, 187, 188  
 ULTRA FLO INSULIN SYR 1/2 UNIT  
 31G X 5/16..... 185, 187, 188  
 ULTRA FLO INSULIN SYRINGE 29G X  
 1/2 ..... 185, 187, 188  
 ULTRA FLO INSULIN SYRINGE 30G X  
 1/2 ..... 185, 187, 188  
 ULTRA FLO INSULIN SYRINGE 30G X  
 5/16 ..... 185, 187, 188  
 ULTRA FLO INSULIN SYRINGE 31G X  
 5/16 ..... 185, 187, 188  
 ULTRA THIN PEN NEEDLES 32G X 4  
 MM ..... 185, 187, 188  
 ULTRACARE INSULIN SYRINGE 30G X  
 1/2 ..... 186, 187, 188  
 ULTRACARE INSULIN SYRINGE 30G X  
 5/16 ..... 186, 187, 188  
 ULTRACARE INSULIN SYRINGE 31G X  
 5/16 ..... 186, 187, 188

## Provider Partners Health Plan 2025 Formulary – Prior Authorization Criteria

ULTRACARE PEN NEEDLES 31G X 5 MM .....	186, 187, 188	UNIFINE PENTIPS PLUS 31G X 6 MM .....	186, 187, 188
ULTRACARE PEN NEEDLES 31G X 6 MM .....	186, 187, 188	UNIFINE PENTIPS PLUS 32G X 4 MM .....	186, 187, 188
ULTRACARE PEN NEEDLES 31G X 8 MM .....	186, 187, 188	UNIFINE PROTECT PEN NEEDLE 30G X 5 MM .....	186, 187, 188
ULTRACARE PEN NEEDLES 32G X 4 MM .....	186, 187, 188	UNIFINE PROTECT PEN NEEDLE 30G X 8 MM .....	186, 187, 188
ULTRACARE PEN NEEDLES 32G X 5 MM .....	186, 187, 188	UNIFINE PROTECT PEN NEEDLE 32G X 4 MM .....	186, 187, 188
ULTRACARE PEN NEEDLES 32G X 6 MM .....	186, 187, 188	UNIFINE SAFECONTROL PEN NEEDLE 30G X 5 MM.....	186, 187, 188
ULTRACARE PEN NEEDLES 33G X 4 MM .....	186, 187, 188	UNIFINE SAFECONTROL PEN NEEDLE 30G X 8 MM.....	186, 187, 188
ULTRA-COMFORT INSULIN SYRINGE 29G X 1/2.....	185, 187, 188	UNIFINE SAFECONTROL PEN NEEDLE 31G X 5 MM.....	186, 187, 188
ULTRA-THIN II INS SYR SHORT 30G X 5/16 .....	186, 187, 188	UNIFINE SAFECONTROL PEN NEEDLE 31G X 6 MM.....	186, 187, 188
ULTRA-THIN II INS SYR SHORT 31G X 5/16 .....	186, 187, 188	UNIFINE SAFECONTROL PEN NEEDLE 31G X 8 MM.....	186, 187, 188
ULTRA-THIN II INSULIN SYRINGE 29G X 1/2.....	186, 187, 188	UNIFINE SAFECONTROL PEN NEEDLE 32G X 4 MM.....	187, 188
ULTRA-THIN II MINI PEN NEEDLE 31G X 5 MM.....	186, 187, 188	UNIFINE ULTRA PEN NEEDLE 31G X 5 MM .....	187, 188
ULTRA-THIN II PEN NEEDLE SHORT 31G X 8 MM.....	186, 187, 188	UNIFINE ULTRA PEN NEEDLE 31G X 6 MM .....	187, 188
ULTRA-THIN II PEN NEEDLES 29G X 12.7MM .....	186, 187, 188	UNIFINE ULTRA PEN NEEDLE 31G X 8 MM .....	187, 188
UNIFINE OTC PEN NEEDLES 31G X 5 MM .....	186, 187, 188	UNIFINE ULTRA PEN NEEDLE 32G X 4 MM .....	187, 188
UNIFINE OTC PEN NEEDLES 32G X 4 MM .....	186, 187, 188	UPTRAVI INTRAVENOUS.....	323
UNIFINE PEN NEEDLES 32G X 4 MM .....	186, 187, 188	UPTRAVI ORAL TABLET 1000 MCG, 1200 MCG, 1400 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG .....	323
UNIFINE PENTIPS 29G X 12MM.....	186, 187, 188	UPTRAVI TITRATION.....	323
UNIFINE PENTIPS 31G X 6 MM .....	186, 187, 188	<b>V</b>	
UNIFINE PENTIPS 31G X 8 MM .....	186, 187, 188	VALCHLOR.....	227
UNIFINE PENTIPS 32G X 4 MM .....	186, 187, 188	VALUE HEALTH INSULIN SYRINGE 29G X 1/2.....	187, 188
UNIFINE PENTIPS PLUS 29G X 12MM .....	186, 187, 188	VANFLYTA .....	290
		VANISHPOINT INSULIN SYRINGE 29G X 5/16.....	187, 188
		VANISHPOINT INSULIN SYRINGE 30G X 3/16.....	187, 188



## Provider Partners Health Plan

### 2025 Formulary – Prior Authorization Criteria

VANISHPOINT INSULIN SYRINGE 30G X 5/16.....	187, 188	VP INSULIN SYRINGE 29G X 1/2 .....	187, 188
VEGZELMA.....	53	VUMERITY .....	96
VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG.....	415	VYALEV SUBCUTANEOUS SOLUTION 12-240 MG/ML.....	138
VENCLEXTA STARTING PACK .....	415	VYLOY.....	425
VEOZAH .....	134	<b>W</b>	
VERIFINE INSULIN PEN NEEDLE 29G X 12MM.....	187, 188	WEBCOL ALCOHOL PREP LARGE PAD 70 % .....	187, 188
VERIFINE INSULIN PEN NEEDLE 31G X 5 MM.....	187, 188	WEGMANS UNIFINE PENTIPS PLUS 31G X 8 MM.....	187, 188
VERIFINE INSULIN PEN NEEDLE 32G X 6 MM.....	187, 188	WELIREG.....	48
VERIFINE INSULIN SYRINGE 28G X 1/2 .....	187, 188	WINREVAIR.....	342, 343
VERIFINE INSULIN SYRINGE 29G X 1/2 .....	187, 188	<b>X</b>	
VERIFINE INSULIN SYRINGE 30G X 1/2 .....	187, 188	XALKORI ORAL CAPSULE.....	78
VERIFINE INSULIN SYRINGE 30G X 5/16 .....	187, 188	XALKORI ORAL CAPSULE SPRINKLE 150 MG, 20 MG, 50 MG .....	79
VERIFINE INSULIN SYRINGE 31G X 5/16 .....	187, 188	XDEMVY .....	220
VERIFINE PLUS PEN NEEDLE 31G X 5 MM .....	187, 188	XELJANZ .....	376, 377
VERIFINE PLUS PEN NEEDLE 31G X 8 MM .....	187, 188	XELJANZ XR .....	376, 377
VERIFINE PLUS PEN NEEDLE 32G X 4 MM .....	187, 188	XERMELO .....	357
VERQUVO .....	416	XGEVA.....	91
VERZENIO.....	6	XIFAXAN ORAL TABLET 200 MG, 550 MG .....	300
vigabatrin .....	417	XOLAIR .....	260, 262
vigadrone.....	417	XOSPATA .....	145
vigpoder .....	417	XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG .....	324
VITRAKVI ORAL CAPSULE 100 MG, 25 MG .....	200	XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 10 MG, 40 MG .....	324
VITRAKVI ORAL SOLUTION .....	200	XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG .....	324
VIVIMUSTA .....	49	XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG..	324
VIZIMPRO .....	82	XPOVIO (60 MG TWICE WEEKLY)...	324
VONJO .....	265	XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG..	324
VORANIGO .....	420	XPOVIO (80 MG TWICE WEEKLY)...	324
voriconazole oral suspension reconstituted .....	421	XTANDI ORAL CAPSULE.....	117, 118
VOSEVI.....	334, 335	XTANDI ORAL TABLET 40 MG, 80 MG .....	117, 118
VOWST .....	130	XYOSTED .....	362

# **Provider Partners Health Plan** **2025 Formulary – Prior Authorization Criteria**

## **Y**

YERVOY .....	193
YESINTEK .....	407, 408, 409, 410
YONSA .....	8
YUFLYMA (1 PEN).....	14, 16
YUFLYMA (2 SYRINGE).....	14, 16
YUFLYMA-CD/UC/HS STARTER ..	14, 16

## **Z**

ZEJULA ORAL CAPSULE .....	245
ZEJULA ORAL TABLET.....	245
ZELBORAF .....	414
ZEVRX STERILE ALCOHOL PREP PAD PAD 70 % .....	187, 188

ZIIHERA.....	422
ZIRABEV .....	55
ZOLADEX.....	153
ZTALMY .....	143
ZTLIDO .....	215
ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG.....	427
ZYDELIG .....	158
ZYKADIA ORAL TABLET .....	69
ZYNLONTA.....	218
ZYNYZ .....	296